

**PHARMACOLOGY BIOCHEMISTRY
&
BEHAVIOR**

Index to

VOLUME 17

CONTENTS

Evidence that agents increasing water consumption do not necessarily generate "false positives" in conflict procedures using water as a reinforcer. CARLI, M. and R. SAMANIN	1
Failure of amphetamine isomers to decrease hyperactivity in developing rats. CONCANNON, J. T. and M. D. SCHECHTER	5
Apomorphine and glycoprotein synthesis during consolidation. JORK, R., G. GRECKSCH and H. MATTHIES	11
The interaction between β -[Tyr ⁹]melanotropin-(9-18), haloperidol and amphetamine in different behavior tests of rats. TELEGDY, G., L. VÉCSEI, A. V. SCHALLY and D. H. COY	15
Pulmonary vagal afferent stimulants in the conscious rat: Opioids and phenyldiguanide. WILLETTE, R. N., P. GATTI, S. B. GERTNER and H. N. SAPRU	19
Effects of fluphenazine decanoate (a long-acting phenothiazine) on serum prolactin and amphetamine-induced behavioural changes. MERALI, Z. and G. TOTH	25
Dopamine involvement in ACTH-induced grooming behavior. GUILD, A. L. and A. J. DUNN	31
Regional glucose metabolism in mouse brain following ACTH peptides and naloxone. DUNN, A. J. and R. W. HURD	37
Benzodiazepine effects upon Geller-Seifter conflict test in rats: Analysis of individual variability. BABBINI, M., M. GAIARDI and M. BARTOLETTI	43
Effect of valproic acid on brain serotonin metabolism in isolated and grouped rats. KEMPF, E., G. MACK, C. SCHLEEF and P. MANDEL	49
Phencyclidine: Behavioral and biochemical evidence against the anticholinergic hypothesis. JOHNSON, K. M.	53
Effects of apomorphine and diazepam on a quickly learned conditioned suppression in rats. KAMEYAMA, T. and M. NAGASAKA	59
Aqueous extract of valerian root (<i>Valeriana officinalis</i> L.) improves sleep quality in man. LEATHWOOD, P. D., F. CHAUFFARD, E. HECK and R. MUNOZ-BOX	65
Cellular dehydration and hypovolemia: Effect of acetylsalicylic on drinking. KENNEY, N. J. and K. E. MOE	73
A10 lesion and passive avoidance latency: Correlation with limbic tyrosine-hydroxylase-activity. RAAB, A. and G. KOJER	77
Effects of anticholinergic drugs on DRL performance of rhesus monkeys. McDONOUGH, J. H., JR.	85
Seizure susceptibility of the pregnant mouse. SMOLEN, A., T. N. SMOLEN and A. C. COLLINS	91
Effects of γ -vinyl GABA on food intakes of rats. HUOT, S. and M. G. PALFREYMAN	99

Opiate effects on plasma corticosteroids: Relationship to dysphoria and self-administration. LAHTI, R. A. and R. J. COLLINS	107
Oral ethanol intake and levels of blood alcohol in the squirrel monkey. KAPLAN, J. N., M. B. HENNESSY and R. A. HOWD	111
Conditioned and unconditioned influences on body temperature and ethanol hypothermia in laboratory rats. YORK, J. L. and S. G. REGAN	119
Effects of alcohol consumption during pregnancy on subsequent maternal behaviour in rats. HILL, L. G. J. and L. W. MEANS	125
Enhancement of avoidance-suppressing effect after repeated administration of haloperidol and serum haloperidol in rats. HAYASHI, T., S. TADOKORO, H. HASHIMOTO and M. NAKASHIMA	131
Chronic exposure to caffeine during early development modifies spatial behavior in juvenile jewel fish schools. BURGESS, J. W.	137
Alcohol-chlordiazepoxide interaction. CHAN, A. W. K., H. B. GREIZERSTEIN and W. STRAUSS	141
Anti-aggressive effect of a new phenylpiperazine compound (DU27716) on hypothalamically induced behavioural activities. VAN DER POEL, A. M., B. OLIVIER, J. MOS, M. R. KRUK, W. MEELIS and J. H. M. VAN AKEN	147
Differential control of puff duration and interpuff interval in cigarette smokers. CHAIT, L. D. and R. R. GRIFFITHS	155
Human brain receptor alterations in suicidal victims. MEYERSON, L. R., L. P. WENNOGLE, M. S. ABEL, J. COUPET, A. S. LIPPA, C. E. RAUH and B. BEER	159
Diazepam and learning: Assessment of acquisition deficits. HINRICHS, J. V., S. P. MEWALDT, M. M. GHONEIM and J. L. BERIE	165
 <i>BRIEF COMMUNICATION</i>	
Postmortem plasma luteinizing hormone levels and antemortem violence. MENDELSON, J. H., P. E. DIETZ and J. ELLINGBOE	171
 <i>ANNOUNCEMENTS</i>	175

CONTENTS

Dose related facilitation and inhibition of passive avoidance behavior by the ACTH 4-9 analog (ORG 2766). FEKETE, M. and D. DE WIED	177
A new subcutaneously-implantable reservoir for sustained release of nicotine in the rat. ERICKSON, C. K., S. A. STAVCHANSKY, K. I. KOCH and J. W. MCGINITY	183
Effects of cycloheximide, a protein synthesis inhibitor, on mouse brain catecholamine biochemistry. FREEDMAN, L. S., M. E. JUDGE and D. QUARTERMAIN	187
Time course of certain behavioral changes after hippocampal damage and their alteration by dopaminergic intervention into nucleus accumbens. REINSTEIN, D. K., J. H. HANNIGAN, JR. and R. L. ISAACSON	193
Mechanisms of dopamine induced changes in hippocampal glycoprotein metabolism. JORK, R., S. SCHMIDT, S. SCHULZECK, B. LÖSSNER, N. POPOV and H. MATTHIES	203
Influence of hashish extract on the social behaviour of encountering male baboons (<i>Papio c. anubis</i>). SIEBER, B.	209
Enkephalin analogue effects in the amygdala central nucleus on conditioned heart rate. GALLAGHER, M., B. S. KAPP and J. P. PASCOE	217
Acute tolerance to the discriminative stimulus properties of morphine. WITKIN, J. M., L. A. DYKSTRA and R. B. CARTER	223
Prior hot plate exposure enhances morphine analgesia in tolerant and drug-naive rats. SHERMAN, J. E., C. PROCTOR and H. STRUB	229
Actions of drugs of abuse on brain reward systems: A reconsideration with specific attention to alcohol. AMIT, Z. and Z. W. BROWN	233
Action of drugs of abuse on brain reward systems: An update with specific attention to opiates. WISE, R. A. and M. A. BOZARTH	239
Effects of pentobarbital in mice selected for differential sensitivity to ethanol. O'CONNOR, M. F., T. C. HOWERTON and A. C. COLLINS	245
Intracranial injection of thyrotropin releasing hormone (TRH) suppresses starvation-induced feeding and drinking in rats. SUZUKI, T., H. KOHNO, T. SAKURADA, T. TADANO and K. KISARA	249
Microstructural analysis of the involvement of beta-receptors in amphetamine anorexia. WILLNER, P. and A. TOWELL	255
Stimulus change influences escape performance: Deficits induced by uncontrollable stress and by haloperidol. ANISMAN, H. and R. M. ZACHARKO	263
Amphetamine anorexia and hypothalamic catecholamines in genetically obese mice (<i>obob</i>). KUPRYS, R. and G. A. OLTMANS	271

Locomotor hypokinesia in the reserpine-treated rat: Drug effects from the corpus striatum and nucleus accumbens. JOHNELS, B.	283
Discriminative stimulus properties of ketamine stereoisomers in phencyclidine-trained rats. BRADY, K. T. and R. L. BALSTER	291
Intraseptally injected opiate agents: Effects on morphine-induced behaviour of cats. MEGENS, A. A. P. H. and A. R. COOLS	297
Dexamethasone: A potent blocker for radiation-induced taste aversion in rats. CAIRNIE, A. B. and K. E. LEACH	305
Memory and postsynaptic cholinergic receptors in aging mice. KUBANIS, P., S. F. ZORNETZER and G. FREUND	313
Reproductive state modulates ethanol intake in rats: Effects of ovariectomy, ethanol concentration, estrous cycle and pregnancy. FORGER, N. G. and L. P. MORIN	323
Ethanol reinforced responding in the rat: A concurrent analysis using sucrose as the alternate choice. SAMSON, H. H., T. A. ROEHRS and G. A. TOLLIVER	333
Rapid acquisition of oral phencyclidine self-administration in food-deprived and food-satiated rhesus monkeys: Concurrent phencyclidine and water choice. CARROLL, M. E.	341
Effects of naloxone and diprenorphine on spontaneous activity in rats and mice. DEROSSETT, S. E. and S. G. HOLTZMAN	347
Phencyclidine in combination with pentobarbital: Supra-additive effects on complex operant behavior in pigeons. THOMPSON, D. M. and J. M. MOERSCHBAECHER	353
 <i>BRIEF COMMUNICATIONS</i>	
The inhibitory effect of diazepam on conditioned defensive burying is reversed by picrotoxin. TREIT, D., J. P. J. PINEL and H. C. FIBIGER	359
Schooling behavior of tadpoles: A potential indicator of ototoxicity. LUM, A. M., R. J. WASSERSUG, M. J. POTEI and S. A. LERNER	363
Tofizopam modulates the affinity of benzodiazepine receptors in the rat brain. SAANO, V. and A. URTTI	367
Effect of morphine and morphine-like drugs on carbachol-induced fighting in cats. KRSTIĆ, S. K., K. STEFANOVIĆ-DENIĆ and D. B. BELESLIN	371
Lack of behavioral evidence for dopamine autoreceptor subsensitivity after acute electroconvulsive shock. CREESE, I., R. KUCZENSKI and D. SEGAL	375
Effect of lithium upon desipramine enhanced shock-elicited fighting in rats. PRASAD, V. and M. H. SHEARD	377
 <i>ANNOUNCEMENTS</i>	379

CONTENTS

Chronic amphetamine: Effects on defensive flight in the rat. MOLLENAUER, S., M. WHITE, R. PLOTNIK and B. PIPKIN	381
Effects of chlorpromazine on continuous avoidance behavior in mice. DAVIDSON, A. B.	385
Behavioral alterations produced by chronic naloxone injections. MALIN, D. H., M. P. LAYNG, P. SWANK, M. J. BAKER and J. L. HOOD	389
Dopaminergic activity of quipazine. SCHECHTER, M. D. and J. T. CONCANNON	393
Effect of age, clonidine or propranolol on behavioral toxicity induced with digitoxin in mice. PALFAI, T. and V. H. FELLEMAN	399
Dietary ferulic acid, biochanin A, and the inhibition of reproductive behavior in Japanese quail (<i>Coturnix coturnix</i>). DE MAN, E. and H. V. S. PEEKE	405
Stress-induced facilitation of acoustic startle after d-amphetamine administration. KOKKINIDIS, L. and E. P. MACNEILL	413
Morphine enhances high-affinity choline uptake in mouse striatum. VALLANO, M. L., M. T. SPOERLEIN and C. VANDERWENDE	419
Strain differences to the effects of central acting drugs on Sidman avoidance response in Wistar and Fischer 344 rats. KURIBARA, H.	425
Dopamine mediates ipsi- and contraversive circling elicited from the substantia nigra. VACCARINO, F. J. and K. B. J. FRANKLIN	431
Effects of central and peripheral pretreatment with fluoxetine in gustatory conditioning. LORDEN, J. F. and W. B. NUNN	435
Behavioral observation and intracerebral electrochemical recording following administration of amphetamine in rats. SALAMONE, J. D., W. S. LINDSAY, D. B. NEILL and J. B. JUSTICE	445
GABAergic influences on defensive fighting in rats. RODGERS, R. J. and A. DEPAULIS ...	451
Blockade of 3-carbomethoxy- β -carboline induced seizures by diazepam and the benzodiazepine antagonists, Ro 15-1788 and CGS 8216. SCHWERI, M., M. CAIN, J. COOK, S. PAUL and P. SKOLNICK	457
Effects of acute and subacute antidepressant treatment on kindled seizures in rats. KNOBLOCH, L. C., J. M. GOLDSTEIN and J. B. MALICK	461
Environmental determinants of parachloroamphetamine toxicity in rats. GALLUS, J. A., R. G. SEWELL, JR., N. I. NEARCHOUS and F. P. GAULT	467
Maze exploration in juvenile rats treated with corticosteroids during development. GOLUB, M. S. ..	473

Caffeine-induced hypodipsia in water-deprived rats: Relationships with benzodiazepine mechanisms. COOPER, S. J.	481
Motility response of rats to chronic constant-dose treatment with narcotics. DAVIS, W. M., K. L. HEMNANI and H. B. PACE	489
A new ingestion method for long-term morphine intoxication in rat. ZEUCHNER, J., L. ROSENGREN, A. WRONSKI and L. RÖNNBÄCK	495
Effects of phencyclidine on aggressive behavior in mice. TYLER, C. B. and K. A. MICZEK ..	503
DSIP-induced changes of the daily concentrations of brain neurotransmitters and plasma proteins in rats. GRAF, M., J. B. BAUMANN, J. GIRARD, H. J. TOBLER and G. A. SCHOENENBERGER	511
Effects of clonidine and guanfacine on drinking and ambulation in spontaneously hypertensive rats. TOGASHI, H., M. MINAMI, Y. BANDO, Y. KOIKE, K. SHIMAMURA and H. SAITO	519
Schedule-induced cigarette self-administration. CHEREK, D. R.	523
Endocrine control of ethanol intake by rats or hamsters: Relative contributions of the ovaries, adrenals and steroids. MORIN, L. P. and N. G. FORGER	529
Anorexia and hyperphagia produced by five pharmacologic classes of hallucinogens. VAUPEL, D. B. and E. C. MORTON	539
Evidence that a behavioral augmentation following repeated amphetamine administration does not involve peripheral mechanisms. KUCZENSKI, R., D. S. SEGAL, S. B. WEINBERGER and R. G. BROWNE	547
Consistency in catecholamine and cortisol excretion in males and females. FORSMAN, L. and U. LUNDBERG	555
Increased intravenous drug self-administration during deprivation of other reinforcers. CARROLL, M. E. and I. N. BOE	563
Evidence for genetic correlation of hypnotic effects and cerebellar Purkinje neuron depression in response to ethanol in mice. SPUHLER, K., B. HOFFER, N. WEINER and M. PALMER ...	569
 <i>BRIEF COMMUNICATIONS</i>	
Effects of dopaminergic nucleus accumbens lesions on the acquisition of schedule induced self injection of nicotine in the rat. SINGER, G., M. WALLACE and R. HALL	579
A TRS-80-based system for the control of behavioral experiments. EMMETT-OGLESBY, M. W., D. G. SPENCER, JR. and D. E. ARNOULT	583
Lack of synergism and cross tolerance between tactile stimulus- and LSD-induced limb flicking in the cat. TRULSON, M. E. and T. CRISP	589
 <i>ANNOUNCEMENTS</i>	593

CONTENTS

Time course analysis of para-chlorophenylalanine induced suppression of self-stimulation behavior. GRATTON, A.	597
Comparison of behavioral properties of di- and tri-methoxyphenylisopropylamines. GLENNON, R. A. and R. YOUNG	603
Induction of high voluntary ethanol intake in dependent rats. MARFAING-JALLAT, P. and J. LE MAGNEN	609
Self-injurious behavior produced in rats by daily caffeine and continuous amphetamine. MUELLER, K., S. SABODA, R. PALMOUR and W. L. NYHAN	613
Rotational behavior produced by unilateral ventral noradrenergic bundle lesions: Evidence for a noradrenergic-dopaminergic interaction in the brain. PŁAZNIK, A., O. PUCIŁOWSKI, W. KOSTOWSKI, A. BIDZIŃSKI and M. HAUPTMANN	619
Selective neurotoxin lesions of the lateral septum: Changes in social and aggressive behaviours. CLARKE, A. and S. E. FILE	623
Female reproduction during chronic ethanol consumption in rats. KRUEGER, W. A., W. J. BO and P. K. RUDEEN	629
Effects of H-Phe-Ile-Tyr-His-Ser-Tyr-Lys-OH on passive and active avoidance behavior and on open-field activity of rats. VÉCSEI, L., G. TELEGDY, A. V. SCHALLY and D. H. COY	633
Enhanced neophobia but normal plasma corticosterone levels in rats with dorsal noradrenergic bundle lesions. MARTIN-IVERSON, M. T., M. PISA, E. CHAN and H. C. FIBIGER	639
A sensitive and selective monkey conflict test. PATEL, J. B. and B. MIGLER	645
An <i>in vivo</i> method for testing GABAergic compounds. FUNG, Y. K., A. NOVIN-BAHERAN, T. K. BOSH and D. R. GRASSMAN	651
Clonidine suppresses methylxanthine induced quasi-morphine withdrawal syndrome. GRANT, S. J. and D. E. REDMOND, JR.	655
Effect of early pre- and postnatal acquired malnutrition on development and sexual behavior in the rat. MENENDEZ-PATTERSON, A., S. FERNANDEZ, J. FLOREZ-LOZANO and B. MARÍN	659
Establishment of secondary reinforcement in sign tracking and place preference tests following pimozide treatment. TOMBAUGH, T. N., L. J. GRANDMAISON and K. A. ZITO	665
Discriminative stimulus properties of <i>d</i> -amphetamine in pigeons. JÄRBE, T. U. C.	671
Brain cyclic AMP and memory in mice. RANDT, C. T., M. E. JUDGE, K. A. BONNET and D. QUARTERMAIN	677
Dopaminergic antagonists do not block testosterone-induced decrease in luteinizing hormone. CHAPIN, R. E., G. R. BREESE and R. A. MUELLER	681

Structural requirements for neurohypophyseal peptide maintenance of ethanol tolerance. HOFFMAN, P. L.	685
Effects of opiate antagonists on social and aggressive behavior of isolated mice. PUGLISI-ALLEGRA, S., A. OLIVERIO and P. MANDEL	691
Attenuation of pentobarbital-elicited hypothermia in rats with a history of pentobarbital-LiCl pairings. TAU KULIS, H. K.	695
Chronic phencyclidine treatment decreases phencyclidine and dopamine receptors in rat brain. QUIRION, R., M. A. BAYORH, R. L. ZERBE and C. B. PERT	699
Similarities of the cataleptic state induced by β -endorphin and morphine. RONDEAU, D. B., M. TURCOTTE, L. YOUNG and D. HEBERT	703
Generalization between benzodiazepine- and triazolopyridazine-elicited discriminative cues. McELROY, J. F. and R. S. FELDMAN	709
On the possible role of excitatory amino acids in the striatum in mediating morphine-induced muscular rigidity. TURSKI, L., U. HAVEMANN and K. KUSCHINSKY	715
Prenatal stress: Effects on brain biogenic amine and plasma corticosterone levels. PETERS, D. A. V.	721
Bethanechol-induced water intake in rats: Possible mechanisms of induction. FREGLY, M. J., D. C. KIKTA and J. E. GREENLEAF	727
Interaction between nicotine and endogenous opioid mechanisms in the unanesthetized dog. KAMERLING, S. G., J. G. WETTSTEIN, J. W. SLOAN, T.-P. SU and W. R. MARTIN	733
Drinking stimulation by a new angiotensin, crinia-angiotensin II, in rats and pigeons. CANTALAMESSA, F., G. DE CARO, M. MASSI and L. G. MICOSSI	741
Morphine enhances the release of ³ H-purines from rat brain cerebral cortical prisms. WU, P. H., J. W. PHILLIS and H. YUEN	749
Similar antagonism of morphine analgesia by MIF-1 and naloxone in <i>Carassius auratus</i> . EHRENSING, R. H., G. F. MICHELL and A. J. KASTIN	757
Effects of intravenous ethanol and of 4-methylpyrazole on alcohol drinking in alcohol-preferring rats. WALLER, M. B., W. J. McBRIDE, L. LUMENG and T.-K. LI	763
Does pimozide block the reinforcing effect of brain stimulation? GALLISTEL, C. R., M. BOYTIM, Y. GOMITA and L. KLEBANOFF	769
Pimozide blocks reinforcement but not priming from MFB stimulation in the rat. WASSERMAN, E. M., Y. GOMITA and C. R. GALLISTEL	783
Effects of the combination of tripelennamine and pentazocine at the behavioral and molecular levels. SHANNON, H. E. and T.-P. SU	789
TRH and its novel analog (DN-1417): Antipentobarbital action and involvement of cholinergic mechanisms. MIYAMOTO, M., Y. NAGAI, S. NARUMI, Y. SAJI and Y. NAGAWA ..	797
Intravenous self-administration of acetaldehyde in the rat as a function of schedule, food deprivation and photoperiod. MYERS, W. D., K. T. NG and G. SINGER	807
Ethanol and some tetrahydroisoquinolines alter the discharge of cortical and hippocampal neurons: Relationship to endogenous opioids. BERGER, T., E. D. FRENCH, G. R. SIGGINS, W. T. SHIER and F. E. BLOOM	813

PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR

A tethering system for intravenous and intragastric drug administration in the baboon. LUKAS, S. E., R. R. GRIFFITHS, L. D. BRADFORD, J. V. BRADY, L. DALEY and R. DELORENZO 823

Alcohol drinking in the rat: Increases following intracerebroventricular treatment with tetrahydro- β -carbolines. TUOMISTO, L., M. M. AIRAKSINEN, P. PEURA and C. J. P. ERIKSSON 831

BRIEF COMMUNICATIONS

Ergot drugs suppress plasma levels of prolactin (PRL) but not growth hormone (GH), luteinizing hormone (LH) or corticosterone (CORT) in parturient mice. MANN, M. A., S. D. MICHAEL and B. SVARE 837

Effects of reinforcement-blocking doses of pimozide on neural systems driven by rewarding stimulation of the MFB: A ^{14}C -2-deoxyglucose analysis. GOMITA, Y. and C. R. GALLISTEL 841

Role of serotonin in the blockade of muricidal behavior by tricyclic antidepressants. EISENSTEIN, N., L. C. IORIO and D. CLODY 847

A comparison of atropine, benztropine and diphenhydramine on the reversal of haloperidol induced suppression of self-stimulation. CAREY, R. J. 851

Biphasic dose-response effect of baclofen on haloperidol catalepsy in the rat. RICHARDSON, J. S. and A. K. RICHARDSON 855

Effects of paced coital stimulation on termination of estrus and brain indoleamine levels in female rats. ERSKINE, M. S. and M. J. BAUM 857

Effects of atropine methyl nitrate on sham feeding in the rat. WEINGARTEN, H. P. and S. D. WATSON 863

BOOKS RECEIVED 869

ANNOUNCEMENTS 870

CONTENTS

A quantitative analysis of stereotyped gnawing induced by apomorphine. REDGRAVE, P., P. DEAN and G. LEWIS	873
Evidence for a serotonergic mechanism of the learned helplessness phenomenon. BROWN, L., R. A. ROSELLINI, O. B. SAMUELS and E. P. RILEY	877
Selective breeding for sensitivity to DFP: Generalization of effects beyond criterion variables. RUSSELL, R. W., D. H. OVERSTREET, M. MESSENGER and S. C. HELPS	885
Memory enhancement induced in chicks by L-prolyl-L-leucyl-glycineamide. DAVIS, J. L., R. M. PICO and A. CHERKIN	893
Central and peripheral components of morphine mydriasis in mice. KORCZYN, A. D. and D. MAOR	897
Disruption of cocaine self-administration following 6-hydroxydopamine lesions of the ventral tegmental area in rats. ROBERTS, D. C. S. and G. F. KOOB	901
Naloxone and play fighting in juvenile rats. BEATTY, W. W. and K. B. COSTELLO	905
Effects of sodium barbitone on learning and memory-storage of an appetitive and an aversive task. TOMAZ, C. A. B., D. F. VENTURA and J. R. LEITE	909
Effects of nicotine on the visual evoked response. WOODSON, P. P., K. BAETTIG, M. W. ETKIN, W. M. KALLMAN, G. J. HARRY, M. J. KALLMAN and J. A. ROSECRANS ..	915
Enhancement of osmotic- and hypovolemic-induced drinking by chlordiazepoxide in rats is blocked by naltrexone. COOPER, S. J.	921
Effects of prenatal and postnatal exposure of rats to alcohol: Changes in (Na⁺-K⁺) ATPase. GUERRI, C. and S. GRISOLÍA	927
Lesions of cholinergic forebrain nuclei: Changes in avoidance behavior and scopolamine actions. LO CONTE, G., L. BARTOLINI, F. CASAMENTI, I. MARCONCINI-PEPEU and G. PEPEU	933
Brain serotonergic activity and plasma amino acid levels in genetically obese Zucker rats. FINKELSTEIN, J. A., W. T. CHANCE and J. E. FISCHER	939
p-Chlorophenylalanine effects on shock-induced attack and pressing responses in rats. SEWELL, R. G., J. A. GALLUS, F. P. GAULT and J. P. CLEARY	945
Dopaminergic properties of nomifensine. GIANUTSOS, G., G. MORROW, S. LIGHT and M. J. SWEENEY	951
Failure of rats deprived of water to increase food intake during glucoprivation induced by 2-deoxy-D-glucose. WATSON, P. J. and M. D. BIDERMAN	955
Open-field emotional reactivity and alcohol intake in rats. SATINDER, K. P.	961
Analysis of the difference in the behavioral effects of apomorphine in C57BL/6 and DBA/2 mice. VETULANI, J., M. SANSONE and A. OLIVERIO	967

Intra-raphe muscimol induced hyperactivity depends on ascending serotonin projections. SAINATI, S. M. and S. A. LORENS	973
An examination of methodological refinements, clozapine and fluphenazine in the anhedonia paradigm. FAUSTMAN, W. O. and S. C. FOWLER	987
Effects of piribedil on schedule-controlled responding of the pigeon. LEANDER, J. D.	995
Effects of PAM, proPAM, and DFP on behavior, thermoregulation, and brain AChE in rats. KENLEY, R. A., R. A. HOWD and E. T. UYENO	1001
Delta sleep-inducing peptide crosses the blood-brain-barrier in dogs: Some correlations with protein binding. BANKS, W. A., A. J. KASTIN and D. H. COY	1009
Apomorphine-induced facilitation of intracranial self-stimulation following dopamine denervation of the nucleus accumbens. STRECKER, R. E., D. C. S. ROBERTS and G. F. KOOB	1015
Extent and control of shock affects naltrexone sensitivity of stress-induced analgesia and reactivity to morphine. HYSON, R. L., L. J. ASHCRAFT, R. C. DRUGAN, J. W. GRAU and S. F. MAIER	1019
Estrogen and haloperidol-induced versus handling-related catalepsy in male rats. DE RYCK, M., R. E. HRUSKA and E. K. SILBERGELD	1027
Ethanol intoxication and withdrawal among three age groups of C57BL/6NNIA mice. WOOD, W. G., H. J. ARMBRECHT and R. W. WISE	1037
Delay of cancer anorexia following the intraventricular injection of para-Chlorophenylalanine. CHANCE, W. T., M. VON MEYENFELDT and J. E. FISCHER	1043
Effects of clozapine, haloperidol and thiothixene on schedule-controlled responding and schedule-induced eating and drinking of rabbits. BARRETT, J. E.	1049
Intravenous diazepam in humans: Effects on acquisition and performance of response chains. DESJARDINS, P. J., J. M. MOERSCHBAECHER, D. M. THOMPSON and J. R. THOMAS	1055
Failure to find electrophysiological correlates of chronic neuroleptic-induced oral dyskinesias in cats: Somatosensory and substantia nigra evoked potentials, electroencephalogram, and caudate spindles. GLASSMAN, R. B., H. N. GLASSMAN and B. M. BALTRUS	1061
Cyclic AMP and cyclic GMP response to stress in brain and pituitary: Stress elevates pituitary cyclic AMP. KANT, G. J., J. L. MEYERHOFF, B. N. BUNNELL and R. H. LENOX	1067
Does tolerance develop to the activating, as well as the depressant, effects of ethanol? TABAKOFF, B. and K. KIIANMAA	1073
Sex-dependent biological changes following prenatal nicotine exposure in the rat. PETERS, D. A. V. and S. TANG	1077
Failure of naloxone or MIF-1 to reverse ischemic-induced neurologic deficits in gerbils. KASTIN, A. J., C. NISSEN and R. D. OLSON	1083
Comparative lethality of coca and cocaine. BEDFORD, J. A., C. E. TURNER and H. N. ELSOHLY	1087
Intragastric methylphenidate does have effects on the behavior of rats. FOLTIN, R. W.	1089
ANNOUNCEMENTS	1091

CONTENTS

Brain stimulation as the reinforcer in alcohol-saline discrimination. DEWITTE, PH.	1093
Reduced preference for alcohol during pregnancy and following lactation in rats. MEANS, L. W. and H. B. GOY	1097
Acute effects of ethanol and acetaldehyde on blood pressure and heart rate in disulfiram-treated and control rats. HELLSTRÖM, E. and O. TOTTMAR	1103
Bidirectional transfer of intracerebrally administered pentylenetetrazol and electrical kindling. CAIN, D. P.	1111
Dopamine receptors in the striatum and limbic system of various strains of mice: Relation to differences in responses to apomorphine. MICHALUK, J., L. ANTKIEWICZ-MICHALUK, A. ROKOSZ-PELC, M. SANSONE, A. OLIVERIO and J. VETULANI	1115
Disruption of passive avoidance memory by REM sleep deprivation: Methodological and pharmacological considerations. HARRIS, P. F., D. H. OVERSTREET and J. ORBACH	1119
Effects of DDAVP, a vasopressin analog, on delayed matching behavior in the pigeon. TEAL, J. J. and H. L. EVANS	1123
Learned taste aversion to saccharin following intraventricular or intraperitoneal administration of d,l-amphetamine. GREENSHAW, A. J. and O. BUREŠOVÁ	1129
Anorexic properties of three monoamine oxidase inhibitors. WILLIS, G. L. and G. C. SMITH	1135
Concerning the specificity of the hypothalamic opiate receptor responsible for food intake in the rat. TEPPERMAN, F. S. and M. HIRST	1141
Inhibition of acute feeding responses to systemic 2-deoxyglucose or insulin in rats pretreated with the GABA-transaminase blocker ethanolamine-O-sulfate (EOS). NOBREGA, J. and D. V. COSCINA	1145
Reduced prolactin binding to liver membranes during pheromonal emission in the rat. LEE, T. M., B. HALPERN, C. LEE and H. MOLTZ	1149
Neuropharmacological profile of R 18 503-induced wet-shake behaviour in the rat: Noradrenergic and opiate components. ASHTON, D. and A. WAUQUIER	1155
Enhanced analgesic response to morphine in adult rats exposed to morphine prenatally. KIRBY, M. L., S. E. DEROSSETT and S. G. HOLTZMAN	1161
Chlordiazepoxide-induced ataxia, muscle relaxation and sedation in the rat: Effects of muscimol, picrotoxin and naloxone. FILE, S. E.	1165
Onset and offset of the diazepam stimulus complex. HAUG, T. and K. G. GÖTESTAM	1171
Naloxazone and pain-inhibitory systems: Evidence for a collateral inhibition model. KIRCHGESSNER, A. L., R. J. BODNAR and G. W. PASTERNAK	1175

- Opiate effects on social investigatory behavior of male mice. LANDAUER, M. R. and R. L. BALSTER 1181
- Differential penetration of DSIP peptides into rat brain. KASTIN, A. J., W. A. BANKS, P. F. CASTELLANOS, C. NISSEN and D. H. COY 1187
- Characterization of binding sites for N-Tyr-MIF-1 (Tyr-Pro-Leu-Gly-NH₂) in rat brain. ZADINA, J., A. J. KASTIN, E. F. KRIEG JR. and D. H. COY 1193
- Limitations to effect of α -MSH on permeability of blood-brain barrier to IV ^{99m}Tc-pertechnetate. KASTIN, A. J. and L. A. FABRE 1199
- Opposite effects of CRF and ACTH on reserpine-induced hypothermia. KASTIN, A. J., L. C. HONOUR, J. SUEIRAS-DIAZ and D. H. COY 1203
- Self-stimulation response decrement patterns differentiate clonidine, baclofen and dopamine antagonists from drugs causing performance deficit. FENTON, H. M. and J. M. LIEBMAN 1207
- Morphine analgesia and tolerance in the tail-flick and formalin tests: Dose-response relationships. ABBOTT, F. V., R. MELZACK and B. F. LEBER 1213
- The acute effects of amitriptyline, iprindole and trazodone on blood pressure and heart rate in rats. RICHARDSON, J. S. and E. K. Y. CHIU 1221
- Prednisolone effects upon body and organ weights, water intake, and several behaviors. SEWELL, R. G., J. A. GALLUS and K. P. NANRY 1225
- Prostaglandin inhibition of apomorphine-induced circling in mice. SCHWARZ, R. D., N. J. URETSKY and J. R. BIANCHINE 1233
- Dissociation of tolerance and physical dependence after ethanol/chlordiazepoxide intake. CHAN, A. W. K., D. L. SCHANLEY, F. W. LEONG and D. CASBEER 1239
- Avoidance performance, cue and response-choice discrimination after neuroleptic treatment. ANISMAN, H., A. CORRADINI, T. N. TOMBAUGH and R. ZACHARKO 1245
- Circadian variation in methamphetamine- and apomorphine-induced increase in ambulatory activity in mice. KURIBARA, H. and S. TADOKORO 1251
- Modulation of long-term potentiation: Effects of adrenergic and neuroleptic drugs. DUNWIDDIE, T. V., N. L. ROBERSON and T. WORTH 1257
- Effect of D- and/or L-aspartic acids on feeding, drinking, urine outflow and core temperature. KOYUNCUOĞLU, H. and K. BERKMAN 1265
- Hibernation "trigger": Opioid-like inhibitory action on brain function of the monkey. OELTGEN, P. R., J. W. WALSH, S. R. HAMANN, D. C. RANDALL, W. A. SPURRIER and R. D. MYERS 1271
- Effects of opiate antagonists and putative mu- and kappa-agonists on milk intake in rat and squirrel monkey. LOCKE, K. W., D. R. BROWN and S. G. HOLTZMAN 1275
- BRIEF COMMUNICATIONS*
- Effects of apomorphine on appetitive conditioning in 6-hydroxydopamine treated rat pups. WELDON, D. A., R. S. WOOL, M. H. TEICHER, B. A. SHAYWITZ, D. J. COHEN and G. M. ANDERSON 1281
- Pharmacological responses of the microvasculature of transplanted cardiac tissue. CORNISH, K. G., W. L. JOYNER and J. P. GILMORE 1285

PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR

Effects of naloxone and its quarternary form on fluid consumption in rats. HEMMER, R. C., G. A. OLSON, A. J. KASTIN, J. H. McLEAN and R. D. OLSON	1287
Alterations in trace amine and trace acid concentrations in isolated aggressive mice. DOURISH, C. T., B. A. DAVIS, L. E. DYCK, R. S. G. JONES and A. A. BOULTON	1291
Effects of haloperidol and physostigmine on self-administration of local anesthetics. GARZA, R. DE LA and C. E. JOHANSON	1295
MIF-1 does not act like naloxone in antagonizing the cardiovascular activity of leucine-enkephalin in the conscious dog. SANDER, G. E., A. J. KASTIN and T. D. GILES	1301
Implications for multiple transmitter mediation in amphetamine-induced stereotypies. CHEAL, M. L., M. E. KURKULOS and L. SILVA	1305
Antiapomorphine and locomotor effects of neuroleptics in rhesus monkeys. PROSOLT, R. D., S. ROUX and M. JALFRE	1309
Acute effects of alcohol on photic evoked potentials of albino rats: Visual cortex and superior colliculus. HETZLER, B. E., K. E. OAKLAY, R. L. HEILBRONNER and T. VESTAL	1313
Inhibition by lithium of β-endorphin-induced psychomotor excitation in cats. BELESLIN, D. B., R. SAMARDŽIĆ and S. K. KRSTIĆ	1317
<i>INDEX TO VOLUME 17</i>	1321

Dopamine Receptors and Their Behavioral Correlates

Supplement to *PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR*

CONTENTS

Introduction. WAYNER, M. J.	v
Dopamine autoreceptor stimulation: Clinical significance. MELTZER, H. Y.	1
Structure activity relationships of presynaptic dopamine receptor agonists. BHATNAGER, R. K., S. P. ARNERIĆ, J. G. CANNON, J. FLYNN and J. P. LONG	11
Stress and its timing: Critical factors in determining the consequences of dopaminergic agents. ANTELMAN, S.	21
Dopamine and antianxiety activity. TAYLOR, D. P., L. A. RIBLET, H. C. STANTON, A. S. EISON, M. S. EISON and D. L. TEMPLE, JR.	25
Comparative neuropharmacology of antianxiety drugs. PAUL, S. M. and P. SKOLNICK	37
Nutritional iron and dopamine binding sites in the rat brain. ASHKENAZI, R., D. BENSHACHAR and M. B. H. YAUDIM	43
Subject Index	49

PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR

VOLUME 17 1982

SUBJECT INDEX

- Abstinence syndrome, 389
 chronic administration
 dependence
 endorphins
 morphine
 naloxone
 opiates
- Acetaldehyde
 Antabuse®, 1103
 blood pressure, 1103
 body weight, 807
 disulfiram, 1103
 ethanol, 1103
 food deprivation, 807
 heart rate, 1103
 photoperiod, 807
 4-methylpyrazole, 1103
 schedule-controlled responding, 807
 self-injection, 807
- Acetylcholine, 419
 analgesia
 corpus striatum
 morphine
- Acetylcholine release, 933
 avoidance behavior
 lesions, magnocellular forebrain nuclei
 scopolamine
- Acetylcholinesterase reactivation, 1001
 conditioned avoidance
 DFP
 oximes
 PAM
 proPAM
 thermoregulation
- Acetylsalicylic acid, 73
 cellular dehydration
 drinking
 hypovolemia
 indomethacin
 plasma angiotensin II
 prostaglandin E
- Acoustic startle, 413
 d-amphetamine
 schizophrenia, etiology
 sensitization
 stress
- Acquisition, 1055
 diazepam
 human studies
 scheduled responding
- Acquisition deficits, 165
 cognition
 diazepam
 free recall
 human studies
 paired-associate learning
 serial learning
 serial position effects
- ACTH
 corticotropin releasing factor (CRF), 1203
 dopamine agonists, 31
 dopamine antagonists, 31
 dopaminergic system, 31
 β -endorphin, 1203
 grooming, 31
 hypothermia, 1203
 locomotor activity, 31
 α -MSH, 1203
 naloxone, 1203
 ptosis, 1203
 reserpine, 1203
 sedation, 1203
 temperature, 1203
- ACTH₁₋₂₄, 37
 deoxyglucose uptake
 footshock
 MSH/ACTH₄₋₁₀
 naloxone
- ACTH₄₋₉ analog, 177
 active avoidance
 dose-dependent effects
 ORG-2766
 passive avoidance
- Active avoidance
 ACTH₄₋₉ analog, 177
 amphetamine, 15
 dose-dependent effects, 177
 haloperidol, 15
 β -[Tyr⁶]melanotropin-(9-18), 15
 open field, 15
 ORG-2766, 177
 passive avoidance, 177
- Acute administration, 461
 antidepressants
 kindling, amygdaloid
 seizures
 subacute administration
- Adenosine, 749
 cerebral cortical prisms
 dipyridamole
 morphine
 ³H-purines release
- Adenosine triphosphatase, 927
 ethanol
 postnatal exposure
 prenatal exposure
- Adipsia, 249
 anorexia
 drinking
 eating
 hypothalamus
 starvation
 TRH
- Adrenalectomy, 529
 corticosterone
 endocrine effects
 estradiol
 ethanol
 hamsters
 ovariectomy
- Adrenergics, 1257
 catecholamines

- hippocampus
- in vitro studies
- learning and memory
- long-term potentiation
- neuroleptics
- Affective behavior, 381
 - amphetamine psychosis
 - animal models
 - chronic administration
 - defensive flight
- Age, 1187
 - blood-brain barrier
 - delta sleep-inducing peptide (DSIP)
 - DSIP analogs
 - radioimmunoassay
- Age differences, 1037
 - ethanol
 - intoxication
 - withdrawal
- Aggregation toxicity, 467
 - catecholamines
 - p-chloroamphetamine
 - environmental effects
 - stress
- Aggression
 - anxiety, 623
 - desipramine, 377
 - electroshock, 377
 - lesions, septum, 623
 - lithium, 377
 - neurotoxins, 623
 - social interaction, 623
- Aggression inhibition, 147
 - brain stimulation, electrical
 - DU27716
 - hypothalamus
 - phenylpiperazines
- Aggression, shock-induced, 945
 - p-chlorophenylalanine
 - pressing responses
 - serotonin
- Aggressive behavior
 - hyperactivity, 503
 - isolation housing, 691
 - isolation syndrome, 1291
 - opiate antagonists, 691
 - phencyclidine, 503
 - phenylethylamine, 1291
 - social behavior, 691
 - stress, 1291
 - tyramine, 1291
- Aging mice, 313
 - benzodiazepine
 - cholinergic receptors
 - environmental enrichment
 - passive avoidance
- Albino rats, 1313
 - ethyl alcohol
 - photic evoked potentials
 - superior colliculus
 - visual cortex
- Alcohol
 - brain reward systems, 233
 - brain stimulation, 1093
 - defecation, 961
 - drug discrimination, 1093
 - drugs of abuse, 233
 - emotionality, 961
 - genetic differences, 961
 - open field reactivity, 961
 - reward, 1093
 - sex differences, 961
- Alcohol preference
 - β -carbolines, 831
 - cohabitation, 1097
 - drinking, 763, 831
 - ICV infusion, 831
 - intravenous infusion, 763
 - lactation, 1097
 - 4-methylpyrazole, 763
 - post-lactation, 1097
 - pregnancy, 1097
- Aldehyde dehydrogenase, 91
 - aldehyde oxidase
 - eclampsia
 - flurothyl
 - pregnancy, mice
 - pyridoxal kinase
 - pyridoxamine phosphate oxidase
 - seizure susceptibility
- Aldehyde oxidase, 91
 - aldehyde dehydrogenase
 - eclampsia
 - fluorothyl
 - pregnancy, mice
 - pyridoxal kinase
 - pyridoxamine phosphate oxidase
 - seizure susceptibility
- Ambulatory activity
 - apomorphine, 1251
 - circadian variation, 1251
 - clonidine, 519
 - drinking, 519
 - guanfacine, 519
 - hypertension, 519
 - methamphetamine, 1251
- Amino acids, 939
 - obesity, genetic
 - serotonin
 - tryptophan
 - Zucker rats
- Aminoglycosides, 363
 - hair cells
 - ototoxicity
 - schooling behavior
 - streptomycin
 - tadpoles
- Amitriptyline, 1221
 - blood pressure
 - cardiovascular system
 - heart rate
 - iprindole
 - trazodone
- Amnesia, 187
 - anisomycin
 - catecholamine biochemistry
 - cycloheximide
 - protein synthesis inhibitors
- Amphetamine
 - active avoidance, 15
 - anorexia, 99, 255, 271
 - antagonism, 671
 - apomorphine, 375, 1305
 - attentional deficit disorder, 5
 - behavioral augmentation, 547
 - brain catecholamine levels, 271
 - brain stimulation, 431
 - caffeine, 613
 - catecholamines, 255
 - circling behavior, 431
 - conditioned taste aversion, 1129
 - developing rats, 5
 - discriminative stimulus, 603, 671
 - dopamine, 1305
 - dopamine autoreceptors, 375
 - dopaminergic system, 431
 - eating, 99, 255
 - electroconvulsive shock, 375
 - fenfluramine, 99
 - GABA, 99

generalization, 671
 genetically obese mice, 271
 gerbils, 1305
 hallucinogens, 603
 haloperidol, 15, 613
 6-hydroxydopamine, 5, 99
 hyperactivity, 5
 hyperglycemia, 271
 hyperkinesia, 5
 hyperphagia, 271
 intracerebral electrochemistry, 445
 log survivor analysis, 255
 locomotor activity, 99, 445, 547
 metergoline, 99
 methoxyphenylisopropylamines, 603
 microstructural analysis, 255
 neurotransmitters, 1305
 nucleus accumbens, 445
 obesity, 271
 open field, 15
 phenylisopropylamines, 603
 pigeons, 671
 pimozide, 431, 613, 1305
 propranolol, 255
 repeated administration, 547
 route of administration, 1129
 saccharin, 1129
 self-biting, 613
 social behavior, 1305
 stereotypy, 547, 1305
 striatum, 445
 structure-activity relationships, 603
 substantia nigra, 431
 sympathomimetics, 547
 β -[Tyr⁹]melanotropin-(9-18)

d-Amphetamine
 acoustic startle, 413
 1-desamino-8-D-arginine, 1123
 fluphenazine decanoate, 25
 locomotor activity, 25
 matching-to-sample, 1123
 memory, short-term, 1123
 pigeons, 1123
 schizophrenia, etiology, 413
 scopolamine, 1123
 sensitivity, 25
 sensitization, 413
 serum prolactin, 25
 stress, 413
 vasopressin analogues, 1123

Amphetamine psychosis, 381
 affective behavior
 animal models
 chronic administration
 defensive flight

Amygdala central nucleus, 217
 enkephalin analogs
 heart rate conditioning
 opiate receptors
 rabbits

Analgesia
 acetylcholine, 419
 body temperature, 733
 cardiac rates, 733
 cold water swims, 1175
 collateral inhibition, 1175
 corpus striatum, 419
 dog, conscious, 733
 dose-response, 757, 1213
 formalin test, 1213
 goldfish, 757
 MIF-1, 757
 morphine, 419, 757, 1161, 1175
 morphine tolerance, 1213
 naloxone, 1175
 naloxone, 757
 naltrexone, 733
 nicotine, 733
 prenatal exposure, 1161
 pupillary diameter, 733
 respiratory rates, 733
 tail-flick test, 1161, 1213

Analgesia, stress-induced, 1019
 endogenous opiates
 inescapable shock
 learned helplessness
 morphine hyperreactivity
 naltrexone

Angiotensin, 741
 blood pressure, arterial
 crinia-angiotensin II
 drinking
 pigeons
 rats

Anhedonia paradigm refinements, 987
 clozapine
 fluphenazine
 pimozide

Animal models, 381
 affective behavior
 amphetamine psychosis
 chronic administration
 defensive flight

Anisomycin, 187
 amnesia
 catecholamine biochemistry
 cycloheximide
 protein synthesis inhibitors

Anorexia
 adipsia, 249
 amphetamine, 99, 255, 271
 brain catecholamine levels, 271
 catecholamine agonists, 1135
 catecholamines, 255
 consummatory behavior, 1135
 drinking, 249
 eating, 99, 249, 255, 539
 fenfluramine, 99
 GABA, 99
 genetically obese mice, 271
 hallucinogens, 539
 6-hydroxydopamine, 99
 hyperglycemia, 271
 hyperphagia, 271, 539
 hypothalamus, 249
 locomotor activity, 99
 log survivor analysis, 255
 metergoline, 99
 microstructural analysis, 255
 monoamine inhibitors, 1135
 obesity, 271
 propranolol, 255
 starvation, 249
 TRH, 249

Antabuse[®], 1103
 acetaldehyde
 blood pressure
 disulfiram
 ethanol
 heart rate
 4-methylpyrazole

Antagonism
 amphetamine, 671
 discriminative stimulus, 223, 671
 generalization, 671
 morphine, 223
 naloxone, 223
 pigeons, 223, 671
 tolerance, 223

- Antemortem violence, 171
 - human studies
 - postmortem plasma LH
- Antianxiety drugs
 - bupirone, s25, s37
 - comparative neuropharmacology, s37
 - dopamine, s25
 - pharmacotherapy, s25
- Anticholinergics, 85
 - atropine
 - benactyzine
 - DRL schedule
 - rhesus monkey
 - schedule-controlled behavior
 - scopolamine
- Anticonflict effects, 1
 - drinking
 - isoproterenol
- Antidepressants
 - acute administration, 461
 - kindling, amygdaloid, 461
 - muricide, 847
 - seizures, 461
 - serotonin, 847
 - subacute administration, 461
- Antipsychotics, 1049
 - clozapine
 - collateral behavior
 - drinking
 - eating
 - haloperidol
 - operant behavior
 - rabbits
 - schedule-induced behavior
 - scheduled responding
 - thiothixene
- Anxiety
 - aggression, 623
 - apomorphine, 59
 - conditioned suppression, 59
 - diazepam, 59
 - lesions, septum, 623
 - locomotor activity, 59
 - neurotoxins, 623
 - social interaction, 623
- Anxiolytics
 - benzodiazepines, 645
 - conditioned defensive burying, 359
 - conflict test, 645
 - diazepam, 359
 - ethanol, 645
 - GABAergic system, 359
 - meprobamate, 645
 - phenobarbital, 645
 - picrotoxin, 359
 - squirrel monkeys, male, 645
- Apparatus, 823
 - tethering system for primate catheterization
- Appetitive conditioning, 1281
 - apomorphine
 - attention deficit disorder
 - dopamine depletion
 - 6-hydroxydopamine
 - hyperactivity
- Appetitive tasks, 909
 - aversive tasks
 - learning
 - memory, long-term
 - sodium barbitone
 - Y-maze
- Apomorphine
 - ambulatory activity, 1251
 - amphetamine, 375, 1305
 - anxiety, 59
 - appetitive conditioning, 1281
 - attention deficit disorder, 1281
 - circadian variation, 1251
 - circling behavior, 1233
 - climbing behavior, 651
 - conditioned suppression, 59
 - consolidation, 11
 - diazepam, 59
 - dopamine, 1305
 - dopamine autoreceptors, 375
 - dopamine depletion, 1281
 - dopamine receptors, 967
 - dopaminergic action, 393
 - drug discrimination, 393
 - electroconvulsive shock, 375
 - GABA, 651
 - gerbils, 1305
 - glycoprotein synthesis, 11
 - haloperidol, 393
 - hippocampus, 11
 - 6-hydroxydopamine, 1233, 1281
 - hyperactivity, 1281
 - indomethacin, 1233
 - intracranial self-stimulation, 1015
 - in vivo studies, 651
 - lesions, nucleus accumbens, 1015
 - lesions, 6-OHDA, 1015
 - locomotor activity, 59, 967
 - methamphetamine, 1251
 - methysergide, 393
 - muscimol, 651
 - neurotransmitters, 1305
 - picrotoxin, 651
 - pimozide, 967, 1305
 - prostaglandins, 1233
 - quantitative behavioral analysis, 873
 - quipazine, 393
 - serotonin, 393
 - social behavior, 1305
 - stereotyped behavior, 873
 - stereotypy, 967, 1305
 - strain differences, 967
- Apomorphine antagonism, 1309
 - benzamides
 - butyropheromes
 - locomotor activity
 - neuroleptics
 - phenothiazines
 - rhesus monkey
- Apomorphine stereotypy, 1115
 - locomotor activity
 - strain differences
 - striatal dopamine receptors
- N-methyl-D-Aspartate, 715
 - glutamic acid diethylester
 - kainic acid
 - morphine
 - muscular rigidity
 - quisqualic acid
 - striatum
- Aspartic acid, 1265
 - core temperature
 - drinking
 - eating
 - urine outflow
- Ataxia, 1165
 - chlordiazepoxide
 - exploratory behavior
 - locomotor activity
 - muscimol
 - muscle relaxation
 - naloxone
 - picrotoxin
- Atropine
 - anticholinergics, 85
 - benactyzine, 85

- benztropine, 851
- diphenhydramine, 851
- DRL schedule, 85
- haloperidol, 851
- rhesus monkey, 85
- schedule-controlled behavior, 85
- scopolamine, 85
- self-stimulation, 851
- Atropine methyl nitrate, 863
 - cholinergic blockade
 - diet palatability
 - hunger
 - sham feeding
- Attention, 915
 - cigarette smoking
 - human studies
 - nicotine
 - visual evoked response
- Attention deficit disorder
 - amphetamine, 5
 - apomorphine, 1281
 - appetitive conditioning, 1281
 - developing rats, 5
 - dopamine depletion, 1281
 - 6-hydroxydopamine, 5, 1281
 - hyperactivity, 5, 1281
 - hyperkinesis, 5
- Avoidance, 1245
 - cue discrimination
 - neuroleptic treatment
 - pimozide
 - response-choice discrimination
- Avoidance behavior
 - acetylcholine release, 933
 - H-Phe-Ile-Tyr-His-Ser-Tyr-Lys-OH, 633
 - lesions, magnocellular forebrain nuclei, 933
 - open-field, 633
 - scopolamine, 933
- Avoidance suppression, 131
 - haloperidol
 - repeated administration
- Aversive tasks, 909
 - appetitive tasks
 - learning
 - memory, long-term
 - sodium barbitone
 - Y-maze
- Baboons
 - cocaine, 823
 - hashish, 209
 - primates, 823
 - self-administration, 823
 - social behavior, male baboons, 209
 - tether restraint for catheterization, 823
- Baclofen
 - catalepsy, haloperidol-induced, 855
 - clonidine, 1207
 - extinction, 1207
 - GABA receptors, 855
 - haloperidol, 1207
 - intracranial self-stimulation, 1207
 - methocarbamol, 1207
 - metoclopramide, 1207
 - prazosin, 1207
 - response decrement patterns, 1207
- BASIC, 583
 - behavioral pharmacology
 - operant research
 - TRS-80 microcomputer
- Behavior, 111
 - blood alcohol levels
 - ethanol
 - oral intubation
 - pregnancy
 - squirrel monkeys
- Behavioral augmentation, 547
 - amphetamine
 - locomotor activity
 - repeated administration
 - stereotypy
 - sympathomimetics
- Behavioral depression, 1271
 - bradycardia
 - endogenous opioid-like peptide
 - hibernation "trigger"
 - hypophagia
 - hypothermia
 - opioid antagonists
 - plasma albumin fraction
 - rhesus monkey
- Behavioral effects, 703
 - catalepsy
 - β -endorphin
 - morphine
 - opiates
- Behavioral pharmacology, 583
 - BASIC
 - operant research
 - TRS-80 microcomputer
- Behavioral side-effects, 1225
 - body weight
 - cancer chemotherapy
 - drinking
 - glucocorticoids
 - gonads
 - nociception
 - pituitary-adrenal axis
 - prednisolone
- Behavioral toxicity, 399
 - cardioglycosides
 - clonidine
 - digitoxin
 - propranolol
- Benactyzine, 85
 - anticholinergics
 - atropine
 - DRL schedule
 - rhesus monkey
 - schedule-controlled behavior
 - scopolamine
- Benzamides, 1309
 - apomorphine antagonism
 - butyrophenones
 - locomotor activity
 - neuroleptics
 - phenothiazines
 - rhesus monkey
- Benzodiazepines
 - aging mice, 313
 - anxiolytic agents, 645
 - caffeine, 481
 - chlordiazepoxide, 709
 - cholinergic receptors, 313
 - conflict test, 645
 - drinking, 481
 - drug discrimination, 709
 - drug experience effects, 43
 - environmental enrichment, 313
 - ethanol, 645
 - GABA, 973
 - Geller-Selfter conflict test, 43
 - 5-hydroxytryptamine, 973
 - hypodipsia, 481
 - individual variability, 43
 - locomotor activity, 973
 - meprobamate, 645
 - muscimol, 973
 - oxazepam, 43
 - passive avoidance, 313

- phenobarbital, 645
- rate dependency, 43
- satiety, 481
- squirrel monkeys, male, 645
- tolerance, 43
- triazolopyridazines, 709
- ventral tegmental nuclei of Gudden, 973
- Benzodiazepine antagonists, 457
 - 3-carbomethoxy- β -carboline
 - CGS 8216
 - diazepam
 - RO 15-1788
 - seizures
- Benzodiazepine receptors, 367
 - diazepam
 - tofizopam
- Benztropine, 851
 - atropine
 - diphenhydramine
 - haloperidol
 - self-stimulation
- Bethanechol, 727
 - drinking
 - parasympathomimetic agents
 - renin-angiotensin system
- Biochanin A, 405
 - dietary supplements
 - ferulic acid
 - quail
 - sexual behavior, birds
- Blood alcohol levels, 111
 - behavior
 - ethanol
 - oral intubation
 - pregnancy
 - squirrel monkeys
- Blood-brain barrier
 - age, 1187
 - central nervous system, 1199
 - cerebrospinal fluid, 1009
 - column chromatography, 1009
 - delta sleep-inducing peptide (DSIP), 1187
 - dogs, 1009
 - DSIP, 1009
 - DSIP analogs, 1187
 - α -MSH, 1199
 - protein binding, 1009
 - radioimmunoassay, 1187
 - ^{99m}Tc-sodium pertechnetate, 1199
- Blood levels, 183
 - body temperature
 - Implantable Nicotine Reservoir
 - nicotine
 - sustained release
- Blood pressure
 - acetaldehyde, 1103
 - amitriptyline, 1221
 - Antabuse®, 1103
 - cardiovascular system, 1221
 - disulfiram, 1103
 - ethanol, 1103
 - heart rate, 1103, 1221
 - iprindole, 1221
 - 4-methylpyrazole, 1103
 - trazodone, 1221
- Blood pressure, arterial, 741
 - angiotensin
 - crinia-angiotensin II
 - drinking
 - pigeons
 - rats
- Body temperature
 - analgesia, 733
 - blood levels, 183
 - cardiac rates, 733
 - diarrhea, 885
 - diisopropyl phosphorofluoridate, 885
 - dog, conscious, 733
 - fixed-ratio responding, 885
 - generalization, 885
 - hypothermia, ethanol-induced, 119
 - Implantable Nicotine Reservoir, 183
 - locomotor activity, 885
 - naloxone, 119
 - naltrexone, 733
 - nicotine, 183, 733
 - pupillary diameter, 733
 - respiratory rates, 733
 - selective breeding, 885
 - stress, 119
 - sustained release, 183
- Body weight
 - acetaldehyde, 807
 - behavioral side-effects, 1225
 - cancer chemotherapy, 1225
 - drinking, 1225
 - food deprivation, 807
 - glucocorticoids, 1225
 - gonads, 1225
 - nociception, 1225
 - photoperiod, 807
 - pituitary-adrenal axis, 1225
 - prednisolone, 1225
 - schedule-controlled responding, 807
 - self-injection, 807
- Bradycardia, 1271
 - behavioral depression
 - endogenous opioid-like peptides
 - hibernation "trigger"
 - hypophagia
 - hypothermia
 - opioid antagonists
 - plasma albumin fraction
 - rhesus monkey
- Brain
 - amygdala, 249, 461, 1111, 1193
 - amygdala central nucleus, 217
 - basal ganglia, 77, 1061
 - caudate nucleus, s43, 797, 1061
 - cerebellum, 37, 313, 569, 1067
 - cerebral cortex, 313, 431, 749, 933
 - cerebral ventricle, 1271
 - corpus striatum, 283, 419
 - cortex, 37, 461, 813, 1061, 1193
 - diagonal band of Broca, 841
 - dorsal noradrenergic bundle, 435, 639
 - dorsal premamillary nucleus, 797
 - dorsomedial nucleus of thalamus, 797
 - entorhinal cortex, 77
 - frontal cortex, 77, 677
 - globus pallidus, 249
 - hippocampus, 11, 37, 193, 203, 313, 797, 813
 - hypothalamus, 37, 147, 271, 677, 721, 797, 1093
 - lateral habenula, 841
 - lateral hypothalamus, 249
 - lateral preoptic area, 797
 - limbic forebrain, 1115
 - magnocellular forebrain nuclei, 933
 - medial forebrain bundle, 769, 841
 - medial hypothalamus, 249
 - medial raphe nucleus, 597
 - medial septal nucleus, 797
 - mesencephalic reticular formation, 797
 - mesocortex, s1
 - mesolimbic, s1
 - nigrostriatum, s1
 - nucleus accumbens, 193, 249, 283, 797, 1015
 - nucleus accumbens septum, 579
 - olfactory bulb, 37
 - parietal cortex, 797

- pituitary, 1067
 - pons-medulla, 1193
 - raphe nuclei, 435
 - septum, 77, 297, 623
 - striatum, 313, 445, 715, 1115, 1193, 1233
 - substantia nigra, 249, 431, 1061
 - superior colliculus, 1313
 - tectum, 37
 - thalamus, 37, 677
 - ventral noradrenergic bundle, 619
 - ventral tegmental nuclei of Gudden, 973
 - ventral tegmentum, 841, 901
 - ventromedial hypothalamus, 1141
 - visual cortex, 1313
- Brain catecholamine levels, 271
 - amphetamine
 - anorexia
 - genetically obese mice
 - hyperglycemia
 - hyperphagia
 - obesity
- Brain development, 473
 - corticosteroids
 - neonates, rats
 - radial maze
 - T-maze
 - triamcinolone acetonide
- Brain indoleamines, 857
 - estrous cycle
 - ovariectomized rats
 - paced coital stimulation
- Brain reward systems
 - alcohol, 233
 - drugs of abuse, 233, 239
 - opiates, 239
- Brain slice technique, 699
 - chronic treatment
 - dopamine receptors
 - opiate receptors
 - phencyclidine receptors
- Brain stimulation
 - alcohol, 1093
 - amphetamine, 431
 - circling behavior, 431
 - dopaminergic system, 431
 - drug discrimination, 1093
 - pimozide, 431
 - reward, 1093
 - substantia nigra, 431
- Brain stimulation, electrical, 147
 - aggression inhibition
 - DU 27716
 - hypothalamus
 - phenylpiperazines
- Buspirone
 - antianxiety drugs, s25, s37
 - comparative neuropharmacology, s37
 - dopamine, s25
 - pharmacotherapy, s25
- γ -Butyrolactone- γ -carbonyl-histidyl-prolinamide citrate (DN-1417), 797
 - cholinergic mechanisms
 - hypothalamus
 - pentobarbital antagonists
 - sleep
 - TRH
- Butyrophenones, 1309
 - apomorphine antagonism
 - benzamides
 - locomotor activity
 - neuroleptics
 - phenothiazines
 - rhesus monkey
- Caffeine
 - amphetamine, 613
 - benzodiazepines, 481
 - drinking, 481
 - early development, 137
 - haloperidol, 613
 - hypodipsia, 481
 - jewel fish, 137
 - pimozide, 613
 - satiety, 481
 - self-biting, 613
 - spatial behavior, 137
- Cancer anorexia, 1043
 - p-chlorophenylalanine
 - dopamine
 - eating
 - 5-hydroxyindoleacetic acid
 - norepinephrine
 - serotonin
 - tryptophan
- Cancer chemotherapy, 1225
 - behavioral side-effects
 - body weight
 - drinking
 - glucocorticoids
 - gonads
 - nociception
 - pituitary-adrenal axis
 - prednisolone
- Carbachol-induced fighting, 371
 - cats
 - cholinergic neurons
 - depressants
 - morphine
- β -Carbolines, 831
 - alcohol preference
 - drinking
 - ICV infusion
- 3-Carbomethoxy- β -carboline, 457
 - benzodiazepine antagonists
 - CGS 8216
 - diazepam
 - RO 15-1788
 - seizures
- Cardiac rates, 733
 - analgesia
 - body temperature
 - dog, conscious
 - naltrexone
 - nicotine
 - pupillary diameter
 - respiratory rates
- Cardiac tissue, transplant, 1285
 - drug effects
 - microvasculature
- Cardioglycosides, 399
 - behavioral toxicity
 - clonidine
 - digitoxin
 - propranolol
- Cardiovascular activity, 1301
 - dog
 - Leu-enkephalin
 - MIF-1
 - naloxone
- Cardiovascular reflex, 19
 - D-Ala²-Met⁵-enkephalinamide
 - morphine
 - motor activity
 - phenyldiguanide
 - pulmonary J-receptors
 - pulmonary opiate receptors
 - vagal afferents
- Cardiovascular system, 1221
 - amitriptyline

- blood pressure
- heart rate
- iprindole
- trazodone
- Castration, 681
 - flupenthixol
 - haloperidol
 - luteinizing hormone
 - testosterone
- Catalepsy
 - behavioral effects, 703
 - β -endorphin, 703
 - estrogen, 1027
 - haloperidol, 1027
 - morphine, 703
 - neuroleptics, 1027
 - opiates, 703
- Catalepsy, haloperidol-induced, 855
 - baclofen
 - GABA receptors
- Catecholamine agonists, 1135
 - anorexia
 - consummatory behavior
 - monoamine inhibitors
- Catecholamine biochemistry, 187
 - amnesia
 - anisomycin
 - cycloheximide
 - protein synthesis inhibitors
- Catecholamine excretion, 555
 - cortisol excretion
 - human studies
 - response consistency
 - sex differences
 - stress
- Catecholamines
 - adrenergics, 1257
 - aggregation toxicity, 467
 - amphetamine, 255
 - anorexia, 255
 - eating, 255
 - p-chloroamphetamine, 467
 - environmental effects, 467
 - hippocampus, 1257
 - in vitro studies, 1257
 - learning and memory, 1257
 - log survivor analysis, 255
 - long-term potentiation, 1257
 - microstructural analysis, 255
 - neuroleptics, 1257
 - propranolol, 255
 - stress, 467
- Cats
 - carbachol-induced fighting, 371
 - cholinergic neurons, 371
 - cross-tolerance, 589
 - depressants, 371
 - β -endorphin, 1317
 - limb-flicks, 589
 - lithium, 1317
 - LSD, 589
 - morphine, 371
 - morphine-induced behavior, 297
 - naloxone, 297
 - opiate receptors, 297, 1317
 - opioid peptides, 297
 - psychomotor excitation, 1317
 - septum, 297
 - synergism, 589
 - tactile stimulus, 589
- Cellular dehydration, 73
 - acetylsalicylic acid
 - drinking
 - hypovolemia
 - indomethacin
 - plasma angiotensin II
 - prostaglandin E
- Central acting drugs, 425
 - Sidman avoidance response
 - strain differences
- Central nervous system, 1199
 - blood-brain barrier
 - α -MSH
 - ^{99m}Tc-sodium pertechnetate
- Cerebellum
 - corticosterone, 1067
 - cyclic AMP
 - cyclic GMP
 - ethanol, 569
 - growth hormone, 1067
 - hypnotic effects, 569
 - inbred strains, mice, 569
 - pituitary, 1067
 - prolactin, 1067
 - Purkinje neurons, 569
 - righting reflex, 569
 - stress, 1067
- Cerebral cortical prisms, 749
 - adenosine
 - dipyridamole
 - morphine
 - ³H-purines release
- Cerebrospinal fluid, 1009
 - blood-brain barrier
 - column chromatography
 - dogs
 - DSIP
 - protein binding
- CGS 8216, 457
 - benzodiazepine antagonists
 - 3-carbomethoxy- β -carboline
 - diazepam
 - RO 15-1788
 - seizures
- Characterization, 1193
 - N-Tyr-MIF-1 binding sites
 - Tyr-MIF-1 receptors
- Chicks, 893
 - memory
 - L-prolyl-L-leucyl-glycineamide
- Chlordiazepoxide
 - ataxia, 1165
 - benzodiazepines, 709
 - N-demethylchlordiazepoxide, 141
 - drug discrimination, 709
 - drug interactions, 141
 - ethanol, 1239
 - ethanol-induced sleep time, 141
 - exploratory behavior, 1165
 - locomotor activity, 1165
 - muscimol, 1165
 - muscle relaxation, 1165
 - naloxone, 1165
 - naltrexone, 921
 - physical dependence, 1239
 - picrotoxin, 1165
 - thirst, hypervolemic, 921
 - thirst, osmotic, 921
 - tolerance, 1239
 - triazolopyridazines, 709
 - withdrawal, 1239
- p-Chloroamphetamine, 467
 - aggregation toxicity
 - catecholamines
 - environmental effects
 - stress
- p-Chlorophenylalanine
 - aggression, shock-induced, 945
 - cancer anorexia, 1043
 - dopamine, 1043

- eating, 1043
- 5-hydroxyindoleacetic acid, 1043
- medial raphe nucleus, 597
- norepinephrine, 1043
- pressing responses, 945
- self-stimulation, 597
- serotonin, 597, 945, 1043
- time course analysis, 597
- tryptophan, 1043
- Chlorpromazine, 385
 - continuous avoidance
 - head-poke response
- Cholinergic blockade, 863
 - atropine methyl nitrate
 - diet palatability
 - hunger
 - sham feeding
- Cholinergic mechanisms, 797
 - γ -butyrolactone- γ -carbonyl-histidyl-prolinamide citrate (DN-1417)
 - hypothalamus
 - pentobarbital antagonists
 - sleep
 - TRH
- Cholinergic neurons, 371
 - carbachol-induced fighting
 - cats
 - depressants
 - morphine
- Cholinergic receptors
 - aging mice, 313
 - benzodiazepine, 313
 - depression, 159
 - environmental enrichment, 313
 - imipramine, 159
 - passive avoidance, 313
 - serotonin, 159
 - suicide, 159
- Chronic administration
 - abstinence syndrome, 389
 - affective behavior, 381
 - amphetamine psychosis, 381
 - animal models, 381
 - defensive flight, 381
 - dependence, 389
 - morphine, 389
 - motor activity, 489
 - naloxone, 389
 - narcotics, 489
 - opiates, 389
 - supersensitivity, 489
- Chronic ethanol, 629
 - estrous cycle, female rats
 - ovarian function
 - pregnant rats
 - vaginal patency, 629
- Chronic treatment, 699
 - brain slice technique
 - dopamine receptors
 - opiate receptors
 - phencyclidine receptors
- Cigarette smoking
 - attention, 915
 - human studies, 155, 523, 915
 - nicotine, 915
 - schedule-induced behavior, 523
 - self-administration, 155, 523
 - tobacco, 155
 - visual evoked response, 915
- Circadian rhythms, 511
 - DSIP
 - neurotransmitters
 - plasma proteins
- Circadian variation, 1251
 - ambulatory activity
 - apomorphine
 - methamphetamine
- Circling behavior
 - amphetamine, 431
 - apomorphine, 1233
 - brain stimulation, 431
 - dopaminergic system, 431
 - 6-hydroxydopamine, 1233
 - indomethacin, 1233
 - pimozide, 431
 - prostaglandins, 1233
 - substantia nigra, 431
- Climbing behavior, 651
 - apomorphine
 - GABA
 - in vivo studies
 - muscimol
 - picrotoxin
- Clonidine
 - ambulatory activity, 519
 - baclofen, 1207
 - behavioral toxicity, 399
 - cardioglycosides, 399
 - digitoxin, 399
 - drinking, 519
 - extinction, 1207
 - guanfacine, 519
 - haloperidol, 1207
 - hypertension, 519
 - intracranial self-stimulation, 1207
 - methocarbamol, 1207
 - methylxanthines, 655
 - metoclopramide, 1207
 - naloxone, 655
 - prazosin, 1207
 - propranolol, 399
 - response decrement patterns, 1207
 - withdrawal syndrome, 655
- Clozapine
 - anhedonia paradigm refinements, 987
 - antipsychotics, 1049
 - collateral behavior, 1049
 - drinking, 1049
 - eating, 1049
 - fluphenazine, 987
 - haloperidol, 1049
 - operant behavior, 1049
 - pimozide, 987
 - rabbits, 1049
 - schedule-induced behavior, 1049
 - scheduled responding, 1049
 - thiothixene, 1049
- Coca, 1087
 - cocaine
 - lethality
- Cocaine
 - baboons, 823
 - coca, 1087
 - haloperidol, 1295
 - lesions, 6-OHDA, 901
 - lesions, ventral tegmental area, 901
 - lethality, 1087
 - physostigmine, 1295
 - primates, 823
 - procaine, 1295
 - self-administration, 823, 901, 1295
 - tether restraint for catheterization, 823
- Cognition, 165
 - acquisition deficits
 - diazepam
 - free recall
 - human studies
 - paired-associate learning
 - serial learning
 - serial position effects

- Cohabitation, 1097
 - alcohol preference
 - lactation
 - post-lactation
 - pregnancy
- Cold water swims, 1175
 - analgesia
 - collateral inhibition
 - morphine
 - naloxazone
- Collateral behavior, 1049
 - antipsychotics
 - clozapine
 - drinking
 - eating
 - haloperidol
 - operant behavior
 - rabbits
 - schedule-induced behavior
 - scheduled responding
 - thiothixene
- Collateral inhibition, 1175
 - analgesia
 - cold water swims
 - morphine
 - naloxazone
- Column chromatography, 1009
 - blood-brain barrier
 - cerebrospinal fluid
 - dogs
 - DSIP
 - protein binding
- Comparative neuropharmacology, 337
 - antianxiety drugs
 - bupirone
- Concurrent schedule
 - drinking, 341
 - eating, 341
 - ethanol reinforced responding, 333
 - fixed-ratio, 341
 - food deprivation, 341
 - phencyclidine, 341
 - rhesus monkeys, 341
 - satiety, 341
 - self-administration, 341
 - sucrose, 333
- Conditioned avoidance, 1001
 - acetylcholinesterase reactivation
 - DFP
 - oximes
 - PAM
 - proPAM
 - thermoregulation
- Conditioned defensive burying, 359
 - anxiolytics
 - diazepam
 - GABAergic system
 - picrotoxin
- Conditioned drug effects, 695
 - drug associations
 - hypothermia
 - lithium chloride
 - pentobarbital
- Conditioned suppression, 59
 - anxiety
 - apomorphine
 - diazepam
 - locomotor activity
- Conditioned taste aversion
 - amphetamine, 1129
 - desipramine, 435
 - dexamethasone, 305
 - fluoxetine, 435
 - lesions, dorsal noradrenergic bundle, 435
 - lesions, raphe nuclei, 435
 - lithium, 435
 - nausea, 305
 - pretreatment effect, 435
 - radiation and behavior, 305
 - route of administration, 1129
 - saccharin, 1129
- Conditioned taste preference, 609
 - ethanol dependence
 - withdrawal syndrome
- Conflict test, 645
 - anxiolytic agents
 - benzodiazepines
 - ethanol
 - meprobamate
 - phenobarbital
 - squirrel monkeys, male
- Consolidation, 11
 - apomorphine
 - glycoprotein synthesis
 - hippocampus
- Consummatory behavior, 1135
 - anorexia
 - catecholamine agonists
 - monoamine inhibitors
- Continuous avoidance, 385
 - chlorpromazine
 - head-poke response
- Core temperature, 1265
 - aspartic acid
 - drinking
 - eating
 - urine outflow
- Corpus striatum
 - acetylcholine, 419
 - analgesia, 419
 - hypokinesia, 283
 - locomotion, 283
 - morphine, 419
 - nucleus accumbens, 283
 - reserpine, 283
- Cortical neurons, 813
 - Met-enkephalin
 - ethanol
 - hippocampal pyramidal neurons
 - naloxone
 - opiates
 - salsolinol
 - tetrahydroisoquinolines
 - tetrahydropapaveroline
- Corticosteroids
 - brain development, 473
 - dysphoria, 107
 - neonates, rats, 473
 - opiate analgesics, 107
 - radial maze, 473
 - self-administration, 107
 - T-maze, 473
 - triamcinolone acetonide, 473
- Corticosterone
 - adrenalectomy, 529
 - cerebellum, 1067
 - cyclic AMP, 1067
 - cyclic GMP, 1067
 - emotionality, 1077
 - endocrine effects, 529
 - ergot drugs, 837
 - estradiol, 529
 - ethanol, 529
 - growth hormone, 837, 1067
 - hamsters, 529
 - lactation, 837
 - locomotor activity, 1077
 - luteinizing hormone, 837
 - open field, 1077
 - ovariectomy, 529

- pituitary, 1067
 - prenatal nicotine, 1077
 - prolactin, 837, 1067
 - rearing, 1077
 - sex differences, 1077
 - stress, 1067
- Corticotropin releasing factor (CRF), 1203
 - ACTH
 - β -endorphin
 - hypothermia
 - α -MSH
 - naloxone
 - ptosis
 - reserpine
 - sedation
 - temperature
- Cortisol excretion, 555
 - catecholamine excretion
 - human studies
 - response consistency
 - sex differences
 - stress
- Crinia-angiotensin II, 741
 - angiotensin
 - blood pressure, arterial
 - drinking
 - pigeons
 - rats
- Cross-tolerance, 589
 - cats
 - limb-flicks
 - LSD
 - synergism
 - tactile stimulus
- Cue discrimination, 1245
 - avoidance
 - neuroleptic treatment
 - pimozide
 - response-choice discrimination
- Cyclic AMP
 - cerebellum, 1067
 - corticosterone, 1067
 - cyclic GMP, 1067
 - growth hormone, 1067
 - memory, 677
 - passive avoidance, 677
 - pituitary, 1067
 - prolactin, 1067
 - Rolipram, 677
 - stress, 1067
- Cyclic GMP, 1067
 - cerebellum
 - corticosterone
 - cyclic AMP
 - growth hormone
 - pituitary
 - prolactin
 - stress
- Cycloheximide, 187
 - amnesia
 - anisomycin
 - catecholamine biochemistry
 - protein synthesis inhibitors
- Defecation, 961
 - alcohol
 - emotionality
 - genetic differences
 - open field reactivity
 - sex differences
- Defensive fighting, 451
 - footshock
 - GABA
- Defensive flight, 381
 - affective behavior
 - amphetamine psychosis
 - animal models
 - chronic administration
- Delta sleep-inducing peptide (DSIP)
 - age, 1187
 - blood-brain barrier, 1009, 1187
 - cerebrospinal fluid, 1009
 - column chromatography, 1009
 - dogs, 1009
 - DSIP analogs, 1187
 - protein binding, 1009
 - radioimmunoassay, 1187
- N-Demethylchlorodiazepoxide, 141
 - chlordiazepoxide
 - drug interactions
 - ethanol-induced sleep time
- 2-Deoxy-D-glucose, 955
 - drinking
 - eating
 - glucoprivation
 - water deficits
- ¹⁴C-2-Deoxyglucose autoradiography, 841
 - diagonal band of Broca
 - lateral habenula
 - medial forebrain bundle
 - pimozide
 - reinforcement
 - self-stimulation
 - ventral tegmentum
- Deoxyglucose uptake, 37
 - ACTH₁₋₂₄
 - footshock
 - MSH/ACTH₄₋₁₀
 - naloxone
- 2-Deoxyglucose, 1145
 - ethanolamine-O-sulfate
 - GABA
 - glucoprivic feeding
 - insulin
- Dependence, 389
 - abstinence syndrome
 - chronic administration
 - endorphins
 - morphine
 - naloxone
 - opiates
- Depressants
 - carbachol-induced fighting, 371
 - cats, 371
 - cholinergic neurons, 371
 - cholinergic receptors, 159
 - imipramine, 159
 - morphine, 371
 - serotonin, 159
 - suicide, 159
- 1-Desamino-8-D-arginine (DDAVP), 1123
 - d-amphetamine
 - matching-to-sample
 - memory, short-term
 - pigeons
 - scopolamine
 - vasopressin analogues
- Desipramine
 - aggression, 377
 - conditioned taste aversion, 435
 - electroshock, 377
 - fluoxetine, 435
 - lesions, dorsal noradrenergic bundle, 435
 - lesions, raphe nuclei, 435
 - lithium, 377, 435
 - pretreatment effect, 435
- Developing rats, 5
 - amphetamine
 - attentional deficit disorder
 - 6-hydroxydopamine

- hyperactivity
- hyperkinesis
- Development, 659
 - estrous cycle
 - malnutrition, postnatal
 - malnutrition, prenatal
 - sexual behavior
- Dexamethasone, 305
 - conditioned taste aversion
 - nausea
 - radiation and behavior
- Diagonal band of Broca, 841
 - ¹⁴C-2-deoxyglucose autoradiography
 - lateral habenula
 - medial forebrain bundle
 - pimozide
 - reinforcement
 - self-stimulation
 - ventral tegmentum
- Diarrhea, 885
 - body temperature
 - diisopropyl phosphorofluoridate
 - fixed-ratio responding
 - generalization
 - locomotor activity
 - selective breeding
- Diazepam
 - acquisition, 1055
 - acquisition deficits, 165
 - anxiety, 59
 - anxiolytics, 359
 - apomorphine, 59
 - benzodiazepine antagonists, 457
 - benzodiazepine receptors, 367
 - 3-carbomethoxy- β -carboline, 457
 - CGS 8216, 457
 - cognition, 165
 - conditioned defensive burying, 359
 - conditioned suppression, 59
 - drug discrimination, 1171
 - drug stimulus complex, 1171
 - free recall, 165
 - GABAergic system, 359
 - human studies, 165, 1055
 - locomotor activity, 59
 - paired-associate learning, 165
 - pirototoxin, 359
 - RO 15-1788, 457
 - scheduled responding, 1055
 - seizures, 457
 - serial learning, 165
 - serial position effects, 165
 - tofizopam, 367
- Dietary supplements, 405
 - biochanin A
 - ferulic acid
 - quail
 - sexual behavior, birds
- Diet palatability, 863
 - atropine methyl nitrate
 - cholinergic blockade
 - hunger
 - sham feeding
- Digitoxin, 399
 - behavioral toxicity
 - cardioglycosides
 - clonidine
 - propranolol
- Diisopropyl phosphorofluoridate (DFP)
 - acetylcholinesterase reactivation, 1001
 - body temperature, 885
 - conditioned avoidance, 1001
 - diarrhea, 885
 - fixed-ratio responding, 885
 - generalization, 885
 - locomotor activity, 885
 - oximes, 1001
 - PAM, 1001
 - proPAM, 1001
 - selective breeding, 885
 - thermoregulation, 1001
- Diphenhydramine, 851
 - atropine
 - benztropine
 - haloperidol
 - self-stimulation
- Diprenorphine, 347
 - naloxone
 - narcotic antagonists
 - spontaneous activity
- Dipyridamole, 749
 - adenosine
 - cerebral cortical prisms
 - morphine
 - ³H-purines release
- Discriminative stimulus, 671
 - amphetamine
 - antagonism
 - generalization
 - pigeons
- Discriminative stimulus properties
 - amphetamines, 603
 - antagonism, 223
 - hallucinogens, 603
 - methoxyphenylisopropylamines, 603
 - morphine, 223
 - naloxone, 223
 - phenylisopropylamines, 603
 - pigeons, 223
 - structure-activity relationships, 603
 - tolerance, 223
- Disulfiram, 1103
 - acetaldehyde
 - Antabuse[®]
 - blood pressure
 - ethanol
 - heart rate
 - 4-methylpyrazole
- Dog
 - analgesia, 733
 - blood-brain barrier, 1009
 - body temperature, 733
 - cardiac rates, 733
 - cardiovascular activity, 1301
 - cerebrospinal fluid, 1009
 - column chromatography, 1009
 - DSIP, 1009
 - Leu-enkephalin, 1301
 - MIF-1, 1301
 - naloxone, 1301
 - naltrexone, 733
 - nicotine, 733
 - protein binding, 1009
 - pupillary diameter, 733
 - respiratory rates, 733
- Dopamine
 - amphetamine, 1305
 - antianxiety drugs, s25
 - apomorphine, 1305
 - bupirone, s25
 - cancer anorexia, 1043
 - p-chlorophenylalanine, 1043
 - eating, 1043
 - extinction, 769
 - fucose, 203
 - fucosyltransferase, 203
 - GDP-fucose, 203
 - gerbils, 1305
 - glycoprotein synthesis, 203
 - hippocampus, 203

5-hydroxyindoleacetic acid, 1043
 neuroleptics, 769
 neurotransmitters, 1305
 norepinephrine, 1043
 pharmacotherapy, s25
 pimozide, 769, 1305
 reinforcement, 769
 self-stimulation, 769
 serotonin, 1043
 social behavior, 1305
 stereotypy, 1305
 tryptophan, 1043
Dopamine agonists
 ACTH, 31
 dopamine antagonists, 31
 dopamine autoreceptors, 1
 dopaminergic system, 31
 grooming, 31
 locomotor activity, 31
Dopamine autoreceptors
 amphetamine, 375
 apomorphine, 375
 dopamine agonists, s1
 electroconvulsive shock, 375
Dopamine binding sites, s43
 iron deficiency
Dopamine depletion, 1281
 apomorphine
 appetitive conditioning
 attention deficit disorder
 6-hydroxydopamine
 hyperactivity
Dopamine receptor agonists, s11
 structure-activity relationships
Dopamine receptors
 apomorphine, 967
 brain slice technique, 699
 chronic treatment, 699
 locomotor activity, 967
 motor activity, 951
 nomifensine, 951
 opiate receptors, 699
 phencyclidine receptors, 699
 pimozide, 967
 stereotypy, 967
 strain differences, 967
Dopaminergic action, 393
 apomorphine
 drug discrimination
 haloperidol
 methysergide
 quipazine
 serotonin
Dopaminergic agents, s21
 stress
 time
Dopaminergic agonists
 haloperidol, 995
 lesions, ventral noradrenergic bundle, 619
 α -methylparatyrosine, 995
 noradrenergic-dopaminergic interaction, 619
 pigeons, 995
 pibedil, 995
 rotational behavior, 619
 scheduled responding, 995
 tetrabenzine, 995
Dopaminergic system
 ACTH, 31
 amphetamine, 431
 brain stimulation, 431
 circling behavior, 431
 dopamine agonists, 31
 dopamine antagonists, 31
 grooming, 31
 lesions, hippocampus, 193
 locomotor activity, 31
 nucleus accumbens, 193
 open field, 193
 pimozide, 431
 recovery of function, 193
 substantia nigra, 431
Dose-dependent effects, 177
 ACTH₄₋₉ analog
 active avoidance
 ORG-2766
 passive avoidance
Dose response
 analgesia, 757
 food deprivation, 563
 goldfish, 757
 MIF-1, 757
 morphine, 757
 naloxone, 757
 reward deprivation, 563
 self-administration, 563
 water deprivation, 563
Dose-response relationships, 1213
 analgesia
 Formalin test
 morphine tolerance
 tail-flick test
Drinking
 acetylsalicylic acid, 73
 adipsia, 249
 alcohol preference, 763, 831, 861
 ambulatory activity, 519
 angiotensin, 741
 anorexia, 249
 anticonflict effects, 1
 antipsychotics, 1049
 aspartic acid, 1265
 behavioral side-effects, 1225
 benzodiazepines, 481
 bethanechol, 727
 blood pressure, arterial, 741
 body weight, 1225
 caffeine, 481
 cancer chemotherapy, 1225
 β -carbolines, 831
 cellular dehydration, 73
 clonidine, 519
 clozapine, 1049
 collateral behavior, 1049
 concurrent schedule, 341
 core temperature, 1265
 crinia-angiotensin II, 741
 2-deoxy-D-glucose, 955
 eating, 249, 341, 955, 1049, 1265
 endorphins, 1275
 fixed-ratio, 341
 food deprivation, 341
 glucocorticoids, 1225
 glucoprivation, 955
 gonads, 1225
 guanfacine, 519
 haloperidol, 1049
 hypertension, 519
 hypodipsia, 481
 hypothalamus, 249
 hypovolemia, 73
 ICV infusion, 831
 indomethacin, 73
 intravenous infusion, 763
 isoproterenol, 1
 methylphenidate, 1089
 4-methylpyrazole, 763
 milk intake, 1089, 1275
 naloxone, 1287
 naloxone methobromide, 1287
 nociception, 1225

operant behavior, 1049
 opiate agonists, 1275
 opiate antagonists, 1275, 1287
 opiate receptors, 1275
 parasympathomimetic agents, 727
 phencyclidine, 341
 pigeons, 741
 pituitary-adrenal axis, 1225
 plasma angiotensin II, 73
 prednisolone, 1225
 primates, 1275
 prostaglandin E, 73
 rabbits, 1049
 rats, 741
 renin-angiotensin system, 727
 rhesus monkeys, 341
 route of administration, 1089
 satiety, 341, 481
 schedule-induced behavior, 1049
 scheduled responding, 1049
 self-administration, 341
 squirrel monkeys, 1275
 starvation, 249
 thiothixene, 1049
 TRH, 249
 urine outflow, 1265
 water deficits, 955
DRL schedule, 85
 anticholinergics
 atropine
 benactyzine
 rhesus monkey
 schedule-controlled behavior
 scopolamine
Drug
 acetaldehyde, 807, 1103
 acetylcholine, 1285
 acetylsalicylic acid, 73, 305
 adenosine, 749, 1285
 alcohol, 831, 961, 1093
 amitriptyline, 461, 645, 847, 1221
 amphetamine, 5, 15, s43, 99, 255, 271, 375, 381, 431, 445, 547,
 563, 613, 619, 671, 709, 1257, 1305
 d-amphetamine, 25, 413, 539, 645, 1123
 d,l-amphetamine, 1129
 anisomycin, 187
 Antabuse®, 1103
 apomorphine, s1, 11, s21, 31, s43, 59, 375, 393, 619, 651, 671,
 873, 967, 1015, 1115, 1233, 1251, 1281, 1305, 1309
 arecoline, 703
 N-methyl-D-aspartate, 715
 atropine, 85, 851
 atropine methyl bromide, 797
 atropine methyl nitrate, 19, 863
 atropine sulfate, 727
 baclofen, 855, 1207
 l-baclofen, 451
 benactyzine, 85
 benzodiazepine, 313
 benztropine, 851
 bethanecol, 727
 bicuculline, 451, 709, 973
 biochanin A, 405
 bromocriptine, s1, 837
 buspirone, s25, s37
 butaclamol, 31
 γ-butyrolactone-γ-carbonyl-histidyl-prolinamide citrate (DN-
 1417), 797
 caffeine, 481, 613
 calmodulin, 1257
 captopril, 727
 carbachol, 371
 3-carbomethoxy-β-carboline, 457
 1,2,3,4-tetrahydro-β-carboline, 831
 1-methyl-1,2,3,4-tetrahydro-β-carboline, 831
 CGS 8216, 457
 chlordiazepoxide, 141, 645, 709, 921, 973, 1165
 p-chloroamphetamine, 467
 p-chlorophenylalanine, 597, 945, 1043
 chlorpheniramine, 305
 chlorpromazine, 385, 425, 645, 1061, 1309
 cimetidine, 305
 clonidine, 399, 519, 655, 1207
 clozapine, 987, 1049
 coca, 1087
 cocaine, 563, 671, 823, 901, 1087, 1295
 codeine, 1141
 cycloheximide, 187
 N-demethylchlordiazepoxide, 141
 2-deoxy-D-glucose, 955
 2-deoxyglucose, 1145
 desipramine, 377, 435
 desmethylimipramine, 847, 1281
 dexamethasone, 305
 dextrorphan, 1141
 diazepam, 1, 59, 165, 359, 367, 457, 481, 645, 1055, 1171
 digitoxin, 399
 ³H-dihydroalprenolol, 159
 [³H]dihydromorphine, 699
 5,7-dihydroxytryptamine, 973
 diisopropyl phosphorofluoridate (DFP), 885, 1001
 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM), 603
 dimethyl sulfoxide, 305
 diphenhydramine, 851
 diprenorphine, 347, 1275
 dipyridamole, 749
 disulfiram, 1103
 domperidone, 305
 dopamine, 203
 DSP-4, 1257
 DU27716, 147
 D-Ala²-Met⁵-enkephalinamide, 19
 ergocornine, 837
 ethanol, 111, 119, 125, 141, 233, 245, 323, 333, 529, 563, 569, 609,
 629, 685, 763, 813, 927, 1037, 1073, 1097, 1103, 1239, 1313
 ethanolamine-O-sulfate, 1145
 ethylketocyclazocine, 1275
 etonitazene, 563, 703
 etorphine, 1275
 fenfluramine, 99
 fentanyl, 297
 ferulic acid, 405
 [³H]flunitrazepam, 313
 fluoxetine, 435
 flupenthixol, 681
 fluphenazine, 987
 fluphenazine decanoate, 25
 flurothyl, 91
 GABA, 651, 703
 γ-vinyl GABA, 99, 451
 glutamic acid diethylester, 715
 guanfacine, 519
 haloperidol, 15, 31, 131, 263, 305, 393, 503, 613, 671, 681, 703,
 851, 855, 951, 995, 1027, 1049, 1207, 1295, 1309
 hashish, 209
 heroin, 563
 6-hydroxydopamine, 5, 77, 99, 1281
 imipramine, 159, 461, 645, 847, 1119
 indomethacin, 73, 1233
 insulin, 1145
 iprindole, 461, 1221
 isoproterenol, 1, 727, 1257, 1285
 kainic acid, 715
 ketamine, 291
 ketocyclazocine, 1141, 1275
 levorphanol, 1141
 lithium, 377, 435
 lithium carbonate, 1317
 lithium chloride, 695, 1317
 lysergic acid diethylamide (LSD), 539, 589

LSD-25, 671
 MD 790501, 1309
 meperidine, 489
 meprobamate, 645
 metergoline, 99
 methadone, 371, 489
 methamphetamine, 425, 1251
 methocarbamol, 1207
 methyl atropine, 53
 α -methylparatyrosine, 995
 methylphenidate, 1089
 4-methylpyrazole, 763, 1103
 3-methyl-6-[3-trifluoromethylphenyl]-1,2,4-triazolo[4,3-b]pyridazine
 (CL 218,872), 709
 N-methyl-1,6-dihydro-pyridine-2-carbaldoxime hydrochloride
 (proPAM), 1001
 iso-butyl-methylxanthine, 655
 methysergide, 393, 503, 877
 metoclopramide, 31, 1207
 mianserin, 461
 midazolam, 481
 morphine, 1141, 1161, 1175, 1213, 1275
 morphine sulfate, 19, 107, 223, 229, 297, 389, 371, 419, 489, 495,
 645, 671, 703, 715, 749, 757, 789, 897, 1019, 1181
 muscimol, 451, 651, 973, 1165
 naloxazone, 1175
 naloxone, 19, 37, 119, 223, 297, 305, 347, 387, 655, 691, 749, 757,
 789, 813, 897, 905, 1083, 1141, 1165, 1181, 1203, 1271, 1275,
 1287, 1301
 naloxone methobromide, 1287
 naltrexone, 297, 691, 733, 921, 1019, 1271, 1275
 nialamide, 1135
 nicotine, 183, 579, 733, 915, 1077
 nitroglycerine, 1285
 nomifensine, 951
 norepinephrine, 1257, 1285
 ORG-2766, 177
 oxazepam, 43
 oxotremorine, 53
 pargyline, 1135
 pentazocine, 107, 489, 789
 pentobarbital, 245, 353, 695, 797
 pentylenetetrazol, 709, 1111
 pethidine, 371
 phencyclidine, 53, 291, 341, 353, 503, 539, 563, 1141
 [³H]phencyclidine, 699
 phenobarbital, 645
 phenyldiguanide, 19
 phenylethylamine, 1291
 phenylpiperazine, 147
 physostigmine, 1119, 1295
 picrotoxin, 359, 451, 651, 1165
 pilocarpine, 425
 pimozide, 31, 431, 613, 665, 769, 783, 841, 967, 987, 1245, 1305
 piribedil, 995
 polyethylene glycol, 921
 prazosin, 1207
 prednisolone, 1225
 procaine, 1295
 propranolol, 255, 399, 671, 727
 N-propylapomorphine, s1
 pyridine-2-aldoxime methyl iodide (PAM), 1001
 [³H]-quinuclidinyl benzilate, 159, 313
 quipazine, 393
 quisqualic acid, 715
 R 18 503, 1155
 reserpine, 283, 1203, 1257
 Ro5-3663, 481
 Ro 15-1788, 457
 Rolipram, 677
 saccharin, 1129
 salsolinol, 813
 scopolamine, 85, 425, 933, 1123
 SKF 10,047, 539, 789
 sodium barbitone, 909
 sodium n-dipropylacetate, 451
 sodium pentobarbital, 539
^{99m}Tc-sodium pertechnetate, 1199
 [³H]spiperone, 699
 streptomycin, 363
 strychnine, 709
 sucrose, 333
 sulpiride, 1257
 sultopride, 1309
 tetrabenzine, 995
 Δ -tetrahydrocannabinol, 539, 671
 tetrahydropapaveroline, 813
 thioridazine, 1309
 thiothixene, 1049
 tofizopam, 367
 tranlycypromane, 1135
 trazodone, 1221
 triamcinolone acetonide, 473
 trifluoperazine, 1257
 tripeleennamine, 789
 l-tryptophan, 877
 tyramine, 1291
 U-49,274A, 107
 U-50,488, 107
 valerian, 65
 valproic acid, 49
Drug associations, 695
 conditioned drug effects
 hypothermia
 lithium chloride
 pentobarbital
Drug discrimination
 alcohol, 1093
 apomorphine, 393
 benzodiazepines, 709
 brain stimulation, 1093
 chlordiazepoxide, 709
 diazepam, 1171
 dopaminergic action, 393
 drug stimulus complex, 1171
 haloperidol, 393
 ketamine, 291
 methysergide, 393
 morphine, 789
 N-allyl-normetazocine (SKF10,047), 789
 naloxone, 789
 pentazocine, 789
 phencyclidine, 291
 quipazine, 393
 reward, 1093
 schedule-controlled behavior, 291
 serotonin, 393
 stereospecificity, 291
 triazolopyridazines, 709
 tripeleennamine, 789
Drug effects, 1285
 cardiac tissue, transplant
 microvasculature
Drug experience effects, 43
 benzodiazepines
 Geller-Seifter conflict test
 individual variability
 oxazepam
 rate dependency
 tolerance
Drug interaction
 chlordiazepoxide, 141
 N-demethylchlordiazepoxide, 141
 drug discrimination, 789
 ethanol-induced sleep time, 141
 fixed-ratio, 353
 methyl atropine, 53
 morphine, 789
 motor performance, 53
 N-allyl normetazocine (SKF 10,047), 789

- naloxone, 789
- operant behavior, 353
- oxotremorine, 53
- pentazocine, 789
- pentobarbital, 353
- phencyclidine, 353
- phencyclidine lethality, 53
- phencyclidine metabolites, 53
- pigeons, 353
- repeated acquisition, 353
- response chains, 353
- tripelennamine, 789
- Drug stimulus complex, 1171
 - diazepam
 - drug discrimination
- Drugs of abuse
 - alcohol, 233
 - brain reward systems, 233, 239
 - opiates, 239
- DSIP, 511
 - circadian rhythms
 - neurotransmitters
 - plasma proteins
- DSIP analogs, 1187
 - age
 - blood-brain barrier
 - delta sleep-inducing peptide (DSIP)
 - radioimmunoassay
- DU27716, 147
 - aggression inhibition
 - brain stimulation, electrical
 - hypothalamus
 - phenylpiperazines
- Dysphoria, 107
 - corticosteroids
 - opiate analgesics
 - self-administration
- Early development, 137
 - caffeine
 - jewel fish
 - spatial behavior
- Eating
 - adipsia, 249
 - amphetamine, 99, 255
 - anorexia, 99, 249, 255, 539
 - antipsychotics, 1049
 - aspartic acid, 1265
 - cancer anorexia, 1043
 - catecholamines, 255
 - p-chlorophenylalanine, 1043
 - clozapine, 1049
 - collateral behavior, 1049
 - concurrent schedule, 341
 - core temperature, 1265
 - 2-deoxy-D-glucose, 955
 - dopamine, 1043
 - drinking, 249, 341, 955, 1049, 1265
 - fenfluramine, 99
 - fixed-ratio, 341
 - food deprivation, 341
 - GABA, 99
 - glucoprivation, 955
 - hallucinogens, 539
 - haloperidol, 1049
 - 6-hydroxydopamine, 99
 - 5-hydroxyindoleacetic acid, 1043
 - hyperphagia, 539
 - hyperthermia, 1141
 - hypothalamus, 249
 - locomotor activity, 99
 - log survivor analysis, 255
 - metergoline, 99
 - microstructural analysis, 255
 - morphine, 1141
 - norepinephrine, 1043
 - operant behavior, 1049
 - opiate receptors, 1141
 - phencyclidine, 341
 - propranolol, 255
 - rabbits, 1049
 - rhesus monkeys, 341
 - satiety, 341
 - schedule-induced behavior, 1049
 - scheduled responding, 1049
 - self-administration, 341
 - serotonin, 1043
 - starvation, 249
 - thiothixene, 1049
 - TRH, 249
 - tryptophan, 1043
 - urine outflow, 1265
 - ventromedial hypothalamus, 1141
 - water deficits, 955
- Eclampsia, 91
 - aldehyde dehydrogenase
 - aldehyde oxidase
 - flurothyl
 - pregnancy, mice
 - pyridoxal kinase
 - pyridoxamine phosphate oxidase
 - seizure susceptibility
- Electroconvulsive shock, 375
 - amphetamine
 - apomorphine
 - dopamine autoreceptors
- Electroshock, 377
 - aggression
 - desipramine
 - lithium
- Emotionality
 - alcohol, 961
 - corticosterone, 1077
 - defecation, 961
 - genetic differences, 961
 - locomotor activity, 1077
 - open field, 961, 1077
 - prenatal nicotine, 1077
 - rearing, 1077
 - sex differences, 961, 1077
- Endocrine effects, 529
 - adrenalectomy
 - corticosterone
 - estradiol
 - ethanol
 - hamsters
 - ovariectomy
- Endogenous opiates, 1019
 - analgesia, stress-induced
 - inescapable shock
 - learned helplessness
 - morphine hyperreactivity
 - naltrexone
- Endogenous opioid-like peptide, 1271
 - behavioral depression
 - bradycardia
 - hibernation "trigger"
 - hypophagia
 - hypothermia
 - opioid antagonists
 - plasma albumin fraction
 - rhesus monkey
- Endorphins
 - abstinence syndrome, 389
 - chronic administration, 389
 - dependence, 389
 - drinking, 1275
 - milk intake, 1275
 - morphine, 389

- naloxone, 389
- opiates, 389
- opiate agonists, 1275
- opiate antagonists, 1275
- opiate receptors, 1275
- primates, 1275
- squirrel monkeys, 1275
- β -Endorphin
 - ACTH, 1203
 - behavioral effects, 703
 - cat, 1317
 - catalepsy, 703
 - corticotropin releasing factor (CRF), 1203
 - hypothermia, 1203
 - lithium, 1317
 - morphine, 703
 - α -MSH, 1203
 - naloxone, 1203
 - opiates, 703
 - opiate receptors, 1317
 - ptosis, 1203
 - psychomotor excitation, 1317
 - reserpine, 1203
 - sedation, 1203
 - temperature, 1203
- Enkephalin analogs, 217
 - amygdala central nucleus
 - heart rate conditioning
 - opiate receptors
 - rabbits
- Leu-Enkephalin, 1301
 - cardiovascular activity
 - dog
 - MIF-1
 - naloxone
- Met-Enkephalin, 813
 - cortical neurons
 - ethanol
 - hippocampal pyramidal neurons
 - naloxone
 - opiates
 - salsolmiol
 - tetrahydroisoquinolines
 - tetrahydropaveroline
- D-Ala²-Met⁵-Enkephalinamide, 19
 - cardiovascular reflex
 - morphine
 - motor activity
 - phenyldiguanide
 - pulmonary J-receptors
 - pulmonary opiate receptors
 - vagal afferents
- Entorhinal cortex, 77
 - 6-hydroxydopamine
 - lesions, A10
 - passive avoidance
 - septum
 - tree shrews
 - tyrosine hydroxylase
- Environmental effects, 467
 - aggregation toxicity
 - catecholamines
 - p-chloroamphetamine
 - stress
- Environmental enrichment, 313
 - aging mice
 - benzodiazepine
 - cholinergic receptors
 - passive avoidance
- Environmental influences, 49
 - housing, group
 - housing, isolation
 - serotonin metabolism
 - valproic acid
- Ergot drugs, 837
 - corticosterone
 - growth hormone
 - lactation
 - luteinizing hormone
 - prolactin
- Escape performance, 263
 - haloperidol
 - inescapable shock
 - stress
- Estradiol, 529
 - adrenalectomy
 - corticosterone
 - endocrine effects
 - ethanol
 - hamsters
 - ovariectomy
- Estrogen, 1027
 - catalepsy
 - haloperidol
 - neuroleptics
- Estrous cycle
 - brain indoleamines, 857
 - chronic ethanol, 629
 - development, 659
 - ethanol preference, 323
 - lactation, 323
 - malnutrition, postnatal, 659
 - malnutrition, prenatal, 659
 - ovarian function, 629
 - ovariectomy, 323, 857
 - paced coital stimulation, 857
 - pregnancy, 323, 629
 - reproductive state, female rat, 323
 - sexual behavior, 659
 - taste, 323
 - vaginal patency, 629
- Ethanol
 - acetaldehyde, 1103
 - adenosine triphosphatase, 927
 - adrenalectomy, 529
 - age differences, 1037
 - albino rats, 1313
 - Antabuse®, 1103
 - anxiolytic agents, 645
 - behavior, 111
 - benzodiazepines, 645
 - blood alcohol levels, 111
 - blood pressure, 1103
 - cerebellum, 569
 - chlordiazepoxide, 1239
 - conflict test, 645
 - cortical neurons, 813
 - corticosterone, 529
 - disulfiram, 1103
 - endocrine effects, 529
 - Met-enkephalin, 813
 - estradiol, 529
 - fetal alcohol syndrome, animal model, 125
 - genetic differences, 1073
 - hamsters, 529
 - heart rate, 1103
 - hippocampal pyramidal neurons, 813
 - hypnotic effects, 569
 - inbred strains, mice, 569
 - intoxication, 1037
 - maternal behavior, female rat, 125
 - meprobamate, 645
 - 4-methylpyrazole, 1103
 - naloxone, 813
 - opiates, 813
 - oral intubation, 111
 - ovariectomy, 529
 - phenobarbital, 645
 - photic evoked potentials, 1313

- physical dependence, 1239
- postnatal exposure, 927
- pregnancy, 111, 125
- prenatal exposure, 927
- Purkinje neurons, 569
- righting reflex, 569
- salsolinol, 813
- squirrel monkeys, 111
- squirrel monkeys, male, 645
- superior colliculus, 1313
- tetrahydroisoquinolines, 813
- tetrahydropapaveroline, 813
- tolerance, 1073, 1239
- visual cortex, 1313
- withdrawal, 125, 1037, 1239
- Ethanol dependence, 609
 - conditioned taste preference
 - withdrawal syndrome
- Ethanol-induced sleep time, 141
 - chlordiazepoxide
 - N-demethylchlordiazepoxide
 - drug interactions
- Ethanol preference, 323
 - estrous cycle
 - lactation
 - ovariectomy
 - pregnancy
 - reproductive state, female rat
 - taste
- Ethanol reinforced responding, 333
 - concurrent schedules
 - sucrose
- Ethanol sensitivity, 245
 - hypnosis
 - hypothermia
 - pentobarbital
 - pharmacogenetics
 - pharmacokinetics
- Ethanol tolerance, 685
 - neurohypophyseal peptides
 - vasopressin
- Ethanolamine-O-sulfate, 1145
 - 2-deoxyglucose
 - GABA
 - glucoprivic feeding
 - insulin
- Evoked potentials, 1061
 - neuroleptics
 - oral dyskinesia
 - substantia nigra
 - tardive dyskinesia
- Extinction
 - baclofen, 1207
 - clonidine, 1207
 - dopamine, 769
 - haloperidol, 1207
 - intracranial self-stimulation, 1207
 - methocarbamol, 1207
 - metoclopramide, 1207
 - morphine analgesia, 229
 - neuroleptics, 769
 - nociception, 229
 - pimozide, 769
 - prazosin, 1207
 - reinforcement, 769
 - response decrement patterns, 1207
 - self-stimulation, 769
 - stress, 229
 - tolerance, 229
- Exploratory behavior, 1165
 - ataxia
 - chlordiazepoxide
 - locomotor activity
 - muscimol
 - muscle relaxation
- naloxone
- picrotoxin
- Fenfluramine, 99
 - amphetamine
 - anorexia
 - eating
 - GABA
 - 6-hydroxydopamine
 - locomotor activity
 - metergoline
- Ferulic acid, 405
 - biochanin A
 - dietary supplements
 - quail
 - sexual behavior, birds
- Fetal alcohol syndrome, animal model, 125
 - ethanol
 - maternal behavior, female rat
 - pregnancy
 - withdrawal
- Fixed-ratio
 - body temperature, 885
 - concurrent schedule, 341
 - diarrhea, 885
 - diisopropyl phosphorofluoridate, 885
 - drinking, 341
 - drug interactions, 353
 - eating, 341
 - food deprivation, 341
 - generalization, 885
 - locomotor activity, 885
 - operant behavior, 353
 - pentobarbital, 353
 - phencyclidine, 341, 353
 - pigeons, 353
 - repeated acquisition, 353
 - response chains, 353
 - rhesus monkeys, 341
 - satiety, 341
 - selective breeding, 885
 - self-administration, 341
- Fluoxetine, 435
 - conditioned taste aversion
 - desipramine
 - lesions, dorsal noradrenergic bundle
 - lesions, raphe nuclei
 - lithium
 - pretreatment effect
- Flupenthixol, 681
 - castration
 - haloperidol
 - luteinizing hormone
 - testosterone
- Fluphenazine, 987
 - anhedonia paradigm refinements
 - clozapine
 - pimozide
- Fluphenazine decanoate, 25
 - d-amphetamine
 - locomotor activity
 - sensitivity
 - serum prolactin
- Flurothyl, 91
 - aldehyde dehydrogenase
 - aldehyde oxidase
 - eclampsia
 - pregnancy, mice
 - pyridoxal kinase
 - pyridoxamine phosphate oxidase
 - seizure susceptibility
- Food deprivation
 - acetaldehyde, 807
 - body weight, 807

- concurrent schedule, 341
- dose response, 563
- drinking, 341
- eating, 341
- fixed-ratio, 341
- phencyclidine, 341
- photoperiod, 807
- reward deprivation, 563
- rhesus monkeys, 341
- satiety, 341
- schedule-controlled responding, 807
- self-administration, 341, 563
- self-injection, 807
- water deprivation, 563
- Footshock
 - ACTH₁₋₂₄, 37
 - defensive fighting, 451
 - deoxyglucose uptake, 37
 - GABA, 451
 - MSH/ACTH₄₋₁₀, 37
 - naloxone, 37
- Formalin test, 1213
 - analgesia
 - dose-response relationships
 - morphine tolerance
 - tail-flick test
- Free recall, 165
 - acquisition deficits
 - cognition
 - diazepam
 - human studies
 - paired-associate learning
 - serial learning
 - serial position effects
- Fucose, 203
 - dopamine
 - fucosyltransferase
 - GDB-fucose
 - glycoprotein synthesis
 - hippocampus
- GDP-fucose, 203
 - dopamine
 - fucose
 - fucosyltransferase
 - glycoprotein synthesis
 - hippocampus
- Fucosyltransferase, 203
 - dopamine
 - fucose
 - GDP-fucose
 - glycoprotein synthesis
 - hippocampus
- GABA
 - amphetamine, 99
 - anorexia, 99
 - apomorphine, 651
 - benzodiazepines, 973
 - climbing behavior, 651
 - defensive fighting, 451
 - 2-deoxyglucose, 1145
 - eating, 99
 - ethanolamine-O-sulfate, 1145
 - fenfluramine, 99
 - footshock, 451
 - glucoprivic feeding, 1145
 - 6-hydroxydopamine, 99
 - 5-hydroxytryptamine, 973
 - insulin, 1145
 - in vivo studies, 651
 - locomotor activity, 99, 973
 - metergoline, 99
 - muscimol, 651, 973
 - picROTOXIN, 651
 - ventral tegmental nuclei of Gudden, 973
- GABA receptors, 855
 - baclofen
 - catalepsy, haloperidol-induced
- GABAergic system, 359
 - anxiolytics
 - conditioned defensive burying
 - diazepam
 - picROTOXIN
- Geller-Seifter conflict test, 43
 - benzodiazepines
 - drug experience effects
 - individual variability
 - oxazepam
 - rate dependency
 - tolerance
- Generalization
 - amphetamine, 671
 - antagonism, 671
 - body temperature, 885
 - diarrhea, 885
 - diisopropyl phosphorofluoridate, 885
 - discriminative stimulus, 671
 - fixed-ratio responding, 885
 - locomotor activity, 885
 - pigeons, 671
 - selective breeding, 885
- Genetic differences
 - alcohol, 961
 - defecation, 961
 - emotionality, 961
 - ethanol, 1073
 - open field reactivity, 961
 - sex differences, 961
 - tolerance, 1073
- Genetically obese mice, 271
 - amphetamine
 - anorexia
 - brain catecholamine levels
 - hyperglycemia
 - hyperphagia
 - obesity
- Gerbils
 - amphetamine, 1305
 - apomorphine, 1305
 - dopamine, 1305
 - MIF-1, 1083
 - naloxone, 1083
 - neurotransmitters, 1305
 - opiate antagonists, 1083
 - pimozide, 1305
 - social behavior, 1305
 - stereotypy, 1305
 - vascular stroke, 1083
- Glucocorticoids, 1225
 - behavioral side-effects
 - body weight
 - cancer chemotherapy
 - drinking
 - gonads
 - nociception
 - pituitary-adrenal axis
 - prednisolone
- Glucoprivation, 955
 - 2-deoxy-D-glucose
 - drinking
 - eating
 - water deficits
- Glucoprivic feeding, 1145
 - 2-deoxyglucose
 - ethanolamine-O-sulfate
 - GABA
 - insulin
- Glutamic acid diethylester, 715
 - kainic acid
 - N-methyl-D-aspartate

- morphine
 - muscular rigidity
 - quisqualic acid
 - striatum
- Glycoprotein synthesis
 - apomorphine, 11
 - consolidation, 11
 - dopamine, 203
 - fucose, 203
 - GDP-fucose, 203
 - fucosyltransferase, 203
 - hippocampus, 11, 203
- Goldfish, 757
 - analgesia
 - dose-response
 - MIF-1
 - morphine
 - naloxone
- Gonads, 1225
 - behavioral side-effects
 - body weight
 - cancer chemotherapy
 - drinking
 - glucocorticoids
 - nociception
 - pituitary-adrenal axis
 - prednisolone
- Grooming, 31
 - ACTH
 - dopamine agonists
 - dopamine antagonists
 - dopaminergic system
 - locomotor activity
- Growth hormone
 - cerebellum, 1067
 - corticosterone, 837, 1067
 - cyclic AMP, 1067
 - cyclic GMP, 1067
 - ergot drugs, 837
 - lactation, 837
 - luteinizing hormone, 837
 - pituitary, 1067
 - prolactin, 837, 1067
 - stress, 1067
- Guanfacine, 519
 - ambulatory activity
 - clonidine
 - drinking
 - hypertension

- H-Phe-Ile-Tyr-His-Ser-Tyr-Lys-OH, 633
 - avoidance behavior
 - open-field
- Hair cells, 363
 - aminoglycosides
 - ototoxicity
 - schooling behavior
 - streptomycin
 - tadpoles
- Hallucinogens
 - amphetamines, 603
 - anorexia, 539
 - discriminative stimulus properties, 603
 - eating, 539
 - hyperphagia, 539
 - methoxyphenylisopropylamines, 603
 - phenylisopropylamines, 603
 - structure-activity relationships, 603
- Haloperidol
 - active avoidance, 15
 - amphetamine, 15, 613
 - antipsychotics, 1049
 - apomorphine, 393
 - atropine, 851
 - avoidance suppression, 131
 - baclofen, 1207
 - benztropine, 851
 - caffeine, 613
 - catalepsy, 1027
 - castration, 681
 - clonidine, 1207
 - clozapine, 1049
 - cocaine, 1295
 - collateral behavior, 1049
 - diphenhydramine, 851
 - dopaminergic action, 393
 - dopaminergic agonists, 995
 - drinking, 1049
 - drug discrimination, 393
 - eating, 1049
 - escape performance, 263
 - estrogen, 1027
 - extinction, 1207
 - flupenthixol, 681
 - inescapable shock, 263
 - intracranial self-stimulation, 1207
 - luteinizing hormone, 681
 - β -[Tyr⁹]melanotropin-(9-18), 15
 - methocarbamol, 1207
 - metoclopramide, 1207
 - α -methylparatyrosine, 995
 - methysergide, 393
 - neuroleptics, 1027
 - open field, 15
 - operant behavior, 1049
 - physostigmine, 1295
 - pigeons, 995
 - pimozide, 613
 - piribedil, 995
 - prazosin, 1207
 - procaine, 1295
 - quipazine, 393
 - rabbits, 1049
 - repeated administration, 131
 - response decrement patterns, 1207
 - schedule-induced behavior, 1049
 - scheduled responding, 995, 1049
 - self-administration, 1295
 - self-biting, 613
 - self-stimulation, 851
 - serotonin, 393
 - stress, 263
 - testosterone, 681
 - tetrabenzine, 995
 - thiothixene, 1049
- Hamsters, 529
 - adrenalectomy
 - corticosterone
 - endocrine effects
 - estradiol
 - ethanol
 - ovariectomy
- Hashish, 209
 - baboons
 - social behavior, male baboons
- Head-poke response, 385
 - chlorpromazine
 - continuous avoidance
- Heart rate
 - acetaldehyde, 1103
 - amitriptyline, 1221
 - Antabuse[®], 1103
 - blood pressure, 1103, 1221
 - cardiovascular system, 1221
 - disulfiram, 1103
 - ethanol, 1103
 - iprindole, 1221
 - 4-methylpyrazole, 1103
 - trazodone, 1221

Heart rate conditioning, 217
 amygdala central nucleus
 enkephalin analogs
 opiate receptors
 rabbits

Hibernation "trigger", 1271
 behavioral depression
 bradycardia
 endogenous opioid-like peptide
 hypophagia
 hypothermia
 opioid antagonists
 plasma albumin fraction
 rhesus monkey

Hippocampal pyramidal neurons, 813
 cortical neurons
 Met-enkephalin
 ethanol
 naloxone
 opiates
 salsolinol
 tetrahydroisoquinolines
 tetrahydropapaveroline

Hippocampus
 adrenergics, 1257
 apomorphine, 11
 catecholamines, 1257
 consolidation, 11
 dopamine, 203
 fucose, 203
 GDP-fucose, 203
 fucosyltransferase, 203
 glycoprotein synthesis, 11, 203
 in vitro studies, 1257
 learning and memory, 1257
 long-term potentiation, 1257
 neuroleptics, 1257

Hormone
 adrenaline, 555
 1-desamino-8-D-arginine, 1123
 corticosterone, 529, 837, 1067, 1077
 estradiol, 529
 estrogen, 1027
 growth hormone, 837, 1067
 insulin, 305
 luteinizing hormone (LH), 171, 681, 837
 noradrenaline, 555
 prolactin, 25, 837, 1067, 1149
 prostaglandin, 1233
 prostaglandin E, 73
 testosterone, 681

Housing, group, 49
 environmental influences
 housing, isolation
 serotonin metabolism
 valproic acid

Housing, isolation, 49
 environmental influences
 housing, group
 serotonin metabolism
 valproic acid

Human studies
 acquisition, 1055
 acquisition deficits, 165
 antemortem violence, 171
 attention, 915
 catecholamine excretion, 555
 cigarette smoking, 155, 523, 915
 cognition, 165
 cortisol excretion, 555
 diazepam, 165, 1055
 free recall, 165
 nicotine, 915
 paired-associate learning, 165
 postmortem plasma LH, 171
 response consistency, 555
 schedule-induced behavior, 523
 scheduled responding, 1055
 self-administration, 155, 523
 serial learning, 165
 serial position effects, 165
 sex differences, 555
 sleep latency, 65
 sleep quality, 65
 stress, 555
 tobacco, 155
 valerian, 65
 visual evoked response, 915

Hunger, 863
 atropine methyl nitrate
 cholinergic blockade
 diet palatability
 sham feeding

6-Hydroxydopamine
 amphetamine, 5, 99
 anorexia, 99
 apomorphine, 1233, 1281
 appetitive conditioning, 1281
 attentional deficit disorder, 5, 1281
 circling behavior, 1233
 developing rats, 5
 dopamine depletion, 1281
 eating, 99
 entorhinal cortex, 77
 fenfluramine, 99
 GABA, 99
 hyperactivity, 5, 1281
 hyperkinesis, 5
 indomethacin, 1233
 lesions, A10, 77
 locomotor activity, 99
 metergoline, 99
 passive avoidance, 77
 prostaglandins, 1233
 septum, 77
 tree shrews, 77
 tyrosine hydroxylase, 77

5-Hydroxyindoleacetic acid, 1043
 cancer anorexia
 p-chlorophenylalanine
 dopamine
 eating
 norepinephrine
 serotonin
 tryptophan

5-Hydroxytryptamine, 973
 benzodiazepines
 GABA
 locomotor activity
 muscimol
 ventral tegmental nuclei of Gudden

Hyperactivity
 aggressive behavior, 503
 amphetamine, 5
 apomorphine, 1281
 appetitive conditioning, 1281
 attentional deficit disorders, 5, 1281
 developing rats, 5
 dopamine depletion, 1281
 6-hydroxydopamine, 5, 1281
 hyperkinesis, 5
 phencyclidine, 503

Hyperglycemia, 271
 amphetamine
 anorexia
 brain catecholamine levels
 genetically obese mice
 hyperphagia
 obesity

Hyperkinesis, 5
 amphetamine
 attentional deficit disorder
 developing rats
 6-hydroxydopamine
 hyperactivity
 Hyperphagia
 amphetamine, 271
 anorexia, 271, 539
 brain catecholamine levels, 271
 eating, 539
 genetically obese mice, 271
 hallucinogens, 539
 hyperglycemia, 271
 obesity, 271
 Hypertension, 519
 ambulatory activity
 clonidine
 drinking
 guanfacine
 Hyperthermia, 1141
 eating
 morphine
 opiate receptors
 ventromedial hypothalamus
 Hypnosis, 245
 ethanol sensitivity
 hypothermia
 pentobarbital
 pharmacogenetics
 pharmacokinetics
 Hypnotic effects, 569
 cerebellum
 ethanol
 inbred strains, mice
 Purkinje neurons
 righting reflex
 Hypodipsia, 481
 benzodiazepines
 caffeine
 drinking
 satiety
 Hypokinesia, 283
 corpus striatum
 locomotion
 nucleus accumbens
 reserpine
 Hypophagia, 1271
 behavioral depression
 bradycardia
 endogenous opioid-like peptide
 hibernation "trigger"
 hypothermia
 opioid antagonists
 plasma albumin fraction
 rhesus monkey
 Hypothalamic-pituitary-adrenal axis, 721
 norepinephrine
 plasma corticosterone
 prenatal stress
 serotonin
 Hypothalamus
 adipsia, 249
 aggression inhibition, 147
 anorexia, 249
 brain stimulation, electrical, 147
 γ -butyrolactone- γ -carbonyl-histidyl-prolinamide citrate (DN-1417), 797
 cholinergic mechanisms, 797
 drinking, 249
 DU27716, 147
 eating, 249
 pentobarbital antagonists, 797
 phenylpiperazines, 147
 sleep, 797
 starvation, 249
 TRH, 249, 797
 Hypothermia
 ACTH, 1203
 behavioral depression, 1271
 bradycardia, 1271
 conditioned drug effects, 695
 corticotropin releasing factor (CRF), 1203
 drug associations, 695
 endogenous opioid-like peptide, 1271
 β -endorphin, 1203
 ethanol sensitivity, 245
 hibernation "trigger", 1271
 hypnosis, 245
 hypophagia, 1271
 lithium chloride, 695
 α -MSH, 1203
 naloxone, 1203
 opioid antagonists, 1271
 pentobarbital, 245, 695
 pharmacogenetics, 245
 pharmacokinetics, 245
 plasma albumin fraction, 1271
 ptosis, 1203
 reserpine, 1203
 rhesus monkey, 1271
 sedation, 1203
 temperature, 1203
 Hypothermia, ethanol-induced, 119
 body temperature
 naloxone
 stress
 Hypovolemia, 73
 acetylsalicylic acid
 cellular dehydration
 drinking
 indomethacin
 plasma angiotensin II
 prostaglandin E

 ICV infusion, 831
 alcohol preference
 β -carbolines
 drinking
 Imipramine
 cholinergic receptors, 159
 depression, 159
 memory, 1119
 physostigmine, 119
 REM sleep deprivation, 1119
 serotonin, 159
 suicide, 159
 Implantable Nicotine Reservoir, 183
 blood levels
 body temperature
 nicotine
 sustained release
 Inbred strains, mice, 569
 cerebellum
 ethanol
 hypnotic effects
 Purkinje neurons
 righting reflex
 Individual variability, 43
 benzodiazepines
 drug experience effect
 Geller-Seifter conflict test
 oxazepam
 rate dependency
 tolerance
 Indomethacin
 acetylsalicylic acid, 73
 apomorphine, 1233
 cellular dehydration, 73

- circling behavior, 1233
 - drinking, 73
 - 6-hydroxydopamine, 1233
 - hypovolemia, 73
 - plasma angiotensin II, 73
 - prostaglandin E, 73
 - prostaglandins, 1233
- Inescapable shock
 - analgesia, stress-induced, 1019
 - endogenous opiates, 1019
 - escape performance, 263
 - haloperidol, 263
 - learned helplessness, 877, 1019
 - methysergide, 877
 - morphine hyperreactivity, 1019
 - naltrexone, 1019
 - serotonin, 877
 - stress, 263
 - tryptophan, 877
- Ingestion method, 495
 - morphine intoxication
- Insulin, 1145
 - 2-deoxyglucose
 - ethanolamine-O-sulfate
 - GABA
 - glucoprivic feeding
- Intoxication, 1037
 - age differences
 - ethanol
 - withdrawal
- Intracerebral electrochemistry, 445
 - amphetamine
 - locomotion
 - nucleus accumbens
 - striatum
- Intracranial self-stimulation
 - apomorphine, 1015
 - baclofen, 1207
 - clonidine, 1207
 - extinction, 1207
 - haloperidol, 1207
 - lesions, nucleus accumbens, 1015
 - lesions, 6-OHDA, 1015
 - methocarbamol, 1207
 - metoclopramide, 1207
 - prazosin, 1207
 - response decrement patterns, 1207
- Intravenous infusion, 763
 - alcohol preference
 - drinking
 - 4-methylpyrazole
- In vitro studies, 1257
 - adrenergics
 - catecholamines
 - hippocampus
 - learning and memory
 - long-term potentiation
 - neuroleptics
- In vivo studies, 651
 - apomorphine
 - climbing behavior
 - GABA
 - muscimol
 - picrotoxin
- Iprindole, 1221
 - amitriptyline
 - blood pressure
 - cardiovascular system
 - heart rate
 - trazodone
- Iron deficiency, s43
 - dopamine binding sites
- Isolation housing, 691
 - aggressive behavior
 - opiate antagonists
 - social behavior
- Isolation syndrome, 1291
 - aggressive behavior
 - phenylethylamine
 - stress
- Isoproterenol, 1
 - anticonflict effects
 - drinking
- Jewel fish, 137
 - caffeine
 - early development
 - spatial behavior
- Kainic acid, 715
 - glutamic acid diethylester
 - N-methyl-D-aspartate
 - morphine
 - muscular rigidity
 - quisgualic acid
 - striatum
- Ketamine, 291
 - drug discrimination
 - phencyclidine
 - schedule-controlled behavior
 - stereospecificity
- Kindling, 1111
 - pentylene-tetrazol
 - seizures
 - transfer
- Kindling, amygdaloid, 461
 - acute administration
 - antidepressants
 - seizures
 - subacute administration
- Lactation
 - alcohol preference, 1097
 - cohabitation, 1097
 - corticosterone, 837
 - ergot drugs, 837
 - estrous cycle, 323
 - ethanol preference, 323
 - growth hormone, 837
 - luteinizing hormone, 837
 - ovariectomy, 323
 - post-lactation, 1097
 - pregnancy, 323, 1097
 - prolactin, 837
 - reproductive state, female rat, 323
- Lateral habenula, 841
 - ¹⁴C-2-deoxyglucose autoradiography
 - diagonal band of Broca
 - medial forebrain bundle
 - pimozide
 - reinforcement
 - self-stimulation
 - ventral tegmentum
- Learned helplessness
 - analgesia, stress-induced, 1019
 - endogenous opiates, 1019
 - inescapable shock, 877, 1019
 - methysergide, 877
 - morphine hyperreactivity, 1019
 - naltrexone, 1019
 - serotonin, 877
 - tryptophan, 877
- Learning, 909
 - appetitive tasks
 - aversive tasks
 - memory, long-term
 - sodium barbitone
 - Y-maze

- Learning and memory, 1257
 - adrenergics
 - catecholamines
 - hippocampus
 - in vitro studies
 - long-term potentiation
 - neuroleptics
- Lesions, A10, 77
 - entorhinal cortex
 - 6-hydroxydopamine
 - passive avoidance
 - septum
 - tree shrews
 - tyrosine hydroxylase
- Lesions, dorsal noradrenergic bundle
 - conditioned taste aversion, 435
 - desipramine, 435
 - fluoxetine, 435
 - lesions, raphe nuclei, 435
 - lithium, 435
 - neophobia, 639
 - plasma corticosterone, 639
 - pretreatment effect, 435
- Lesions, hippocampus, 193
 - dopaminergic systems
 - nucleus accumbens
 - open field
 - recovery of function
- Lesions, magnocellular forebrain, 933
 - acetylcholine release
 - avoidance behavior
 - scopolamine
- Lesions, nucleus accumbens
 - apomorphine, 1015
 - intracranial self-stimulation, 1015
 - lesions, 6-OHDA, 579, 1015
 - nicotine, 579
 - schedule-induced behavior, 579
 - self-injection, 579
- Lesions, 6-OHDA
 - apomorphine, 1015
 - cocaine, 901
 - intracranial self-stimulation, 1015
 - lesions, nucleus accumbens, 579, 1015
 - lesions, ventral tegmental area, 901
 - nicotine, 579
 - schedule-induced behavior, 579
 - self-administration, 901
 - self-injection, 579
- Lesions, raphe nuclei, 435
 - conditioned taste aversion
 - desipramine
 - fluoxetine
 - lesions, dorsal noradrenergic bundle
 - lithium
 - pretreatment effect
- Lesions, septum, 623
 - anxiety
 - aggression
 - neurotoxins
 - social interaction
- Lesions, ventral noradrenergic bundle, 619
 - dopaminergic agonists
 - noradrenergic-dopaminergic interaction
 - rotational behavior
- Lesions, ventral tegmental area, 901
 - cocaine
 - lesions, 6-OHDA
 - self-administration
- Lethality, 1087
 - coca
 - cocaine
- Lithium
 - aggression, 377
 - cats, 589, 1317
 - conditioned drug effects, 695
 - conditioned taste aversion, 435
 - cross-tolerance, 589
 - desipramine, 377, 435
 - drug associations, 695
 - electroshock, 377
 - β -endorphin, 1317
 - fluoxetine, 435
 - hypothermia, 695
 - lesions, dorsal noradrenergic bundle, 435
 - lesions, raphe nuclei, 435
 - LSD, 589
 - opiate receptors, 1317
 - pentobarbital, 695
 - pheromones, maternal, 1149
 - pretreatment effect, 435
 - prolactin, 1149
 - psychomotor excitation, 1317
 - synergism, 589
 - tactile stimulus, 589
- Locomotion
 - amphetamine, 445
 - corpus striatum, 283
 - hypokinesia, 283
 - intracerebral electrochemistry, 445
 - nucleus accumbens, 283, 445
 - reserpine, 283
 - striatum, 445
- Locomotor activity
 - ACTH, 31
 - amphetamine, 99, 547
 - d-amphetamine, 25
 - anorexia, 99
 - anxiety, 59
 - apomorphine, 59, 967
 - apomorphine antagonism, 1309
 - apomorphine stereotypy, 1115
 - ataxia, 1165
 - behavioral augmentation, 547
 - benzamides, 1309
 - benzodiazepines, 987
 - body temperature, 885
 - butyrophenones, 1309
 - chlordiazepoxide, 1165
 - conditioned suppression, 59
 - corticosterone, 1077
 - diarrhea, 885
 - diazepam, 59
 - diisopropyl phosphorofluoridate, 885
 - dopamine agonists, 31
 - dopamine antagonists, 31
 - dopamine receptors, 967
 - dopaminergic system, 31
 - eating, 99
 - emotionality, 1077
 - exploratory behavior, 1165
 - fenfluramine, 99
 - fixed-ratio responding, 885
 - fluphenazine decanoate, 25
 - GABA, 99, 987
 - generalization, 885
 - grooming, 31
 - 6-hydroxydopamine, 99
 - 5-hydroxytryptamine, 987
 - metergoline, 99
 - mice, male, 1181
 - muscimol, 987, 1165
 - muscle relaxation, 1165
 - naloxone, 1165
 - neuroleptics, 1309
 - open field, 1077
 - opiates, 1181
 - phenothiazines, 1309
 - pitrotoxin, 1165
 - pimozide, 967

- prenatal nicotine, 1077
- rearing, 1077
- repeated administration, 547
- rhesus monkey, 1309
- selective breeding, 885
- sensitivity, 25
- serum prolactin, 25
- sex differences, 1077
- sociosexual behavior, male mice, 1181
- stereotypy, 547, 967
- strain differences, 967, 1115
- striatal dopamine receptors, 1115
- sympathomimetics, 547
- ventral tegmental nuclei of Gudden, 987
- Log survivor analysis, 255
 - amphetamine
 - anorexia
 - catecholamines
 - eating
 - microstructural analysis
 - propranolol
- Long-term potentiation, 1257
 - adrenergics
 - catecholamines
 - hippocampus
 - in vitro studies
 - learning and memory
 - neuroleptics
- Luteinizing hormone
 - castration, 681
 - corticosterone, 837
 - ergot drugs, 837
 - flupenthixol, 681
 - growth hormone, 837
 - haloperidol, 681
 - lactation, 837
 - prolactin, 837
 - testosterone, 681
- Lysergic acid diethylamide (LSD), 589
 - cats
 - cross-tolerance
 - limb-flicks
 - synergism
 - tactile stimulus
- Malnutrition, postnatal, 659
 - development
 - estrous cycle
 - malnutrition, prenatal
 - sexual behavior
- Malnutrition, prenatal, 659
 - development
 - estrous cycle
 - malnutrition, postnatal
 - sexual behavior
- Matching-to-sample, 1123
 - d-amphetamine
 - 1-desamino-8-D-arginine
 - memory, short-term
 - pigeons
 - scopolamine
 - vasopressin analogues
- Maternal behavior, female rat, 125
 - ethanol
 - fetal alcohol syndrome, animal model
 - pregnancy
 - withdrawal
- Medial forebrain bundle, 841
 - ¹⁴C-2-deoxyglucose autoradiography
 - diagonal band of Broca
 - lateral habenula
 - pimozide
 - reinforcement
 - self-stimulation
 - ventral tegmentum
- Medial raphe nucleus, 597
 - p-chlorophenylalanine
 - β -[Tyr⁹]melanotropin-(9-18), 15
 - self-stimulation
 - serotonin
 - time course analysis
 - active avoidance
 - amphetamine
 - haloperidol
 - open field
- Memory
 - chicks, 893
 - cyclic AMP, 677
 - imipramine, 1119
 - passive avoidance, 677
 - physostigmine, 1119
 - L-prolyl-L-leucyl-glycineamide, 893
 - REM sleep deprivation, 1119
 - Rolipram, 677
- Memory, long-term, 909
 - appetitive tasks
 - aversive tasks
 - learning
 - sodium barbitone
 - Y-maze
- Memory, short term, 1123
 - d-amphetamine
 - 1-desamino-8-D-arginine
 - matching-to-sample
 - pigeons
 - scopolamine
 - vasopressin analogues
- Meprobamate, 645
 - anxiolytic agents
 - benzodiazepines
 - conflict test
 - ethanol
 - phenobarbital
 - squirrel monkeys, male
- Metergoline, 99
 - amphetamine
 - anorexia
 - eating
 - fenfluramine
 - GABA
 - 6-hydroxydopamine
 - locomotor activity
- Methamphetamine, 1251
 - ambulatory activity
 - apomorphine
 - circadian variation
- Methocarbamol, 1207
 - baclofen
 - clonidine
 - extinction
 - haloperidol
 - intracranial self-stimulation
 - metoclopramide
 - prazosin
 - response decrement patterns
- Method
 - anhedonia paradigm refinements, 987
 - brain slice technique, 699
 - ¹⁴C-2-deoxyglucose autoradiography, 841
 - ICV technique, 651
 - ingestion method, 495
 - log survivor analysis, 255
 - microstructural analysis, 255
 - radioimmunoassay, 1187
 - TRS-80-based system for operant research, 583
- Methoxyphenylisopropylamines, 603
 - amphetamines
 - discriminative stimulus properties
 - hallucinogens
 - phenylisopropylamines

- structure-activity relationships
- Methyl atropine, 53
 - drug interactions
 - motor performance
 - oxotremorine
 - phencyclidine lethality
 - phencyclidine metabolites
- N-Methyl-1,6-dihydro-pyridine-2-carbaldoxime hydrochloride (proPAM), 1001
 - acetylcholinesterase reactivation
 - conditioned avoidance
 - DFP
 - oximes
 - PAM
 - thermoregulation
- α -Methylparatyrosine, 995
 - dopaminergic agonists
 - haloperidol
 - pigeons
 - piribedil
 - scheduled responding
 - tetrabenzine
- Methylphenidate, 1089
 - drinking
 - milk intake
 - route of administration
- 4-Methylpyrazole
 - acetaldehyde, 1103
 - alcohol preference, 763
 - Antabuse[®], 1103
 - blood pressure, 1103
 - disulfiram, 1103
 - drinking, 763
 - ethanol, 1103
 - heart rate, 1103
 - intravenous infusion, 763
- Methylxanthines, 655
 - clonidine
 - naloxone
 - withdrawal syndrome
- Methysergide
 - apomorphine, 393
 - dopaminergic action, 393
 - drug discrimination, 393
 - haloperidol, 393
 - inescapable, 877
 - learned helplessness, 877
 - quipazine, 393
 - serotonin, 393, 877
 - tryptophan, 877
- Metoclopramide, 1207
 - baclofen
 - clonidine
 - extinction
 - haloperidol
 - intracranial self-stimulation
 - methocarbamol
 - prazosin
 - response decrement patterns
- Mice, male, 1181
 - locomotor activity
 - opiates
 - sociosexual behavior, male mice
- Microstructural analysis, 255
 - amphetamine
 - anorexia
 - catecholamines
 - eating
 - log survivor analysis
 - propranolol
- Microvasculature, 1285
 - cardiac tissue, transplant
 - drug effects
- MIF-1
 - analgesia, 757
 - cardiovascular activity, 1301
 - dog, 1301
 - dose response, 757
 - Leu-enkephalin, 1301
 - gerbils, 1083
 - goldfish, 757
 - morphine, 757
 - naloxone, 757, 1083, 1301
 - opiate antagonists, 1083
 - vascular stroke, 1083
- N-Tyr-MIF-1 binding sites, 1193
 - characterization
 - Tyr-MIF-1 receptors
- Tyr-MIF-1 receptors, 1193
 - characterization
 - N-Tyr-MIF-1 binding sites
- Milk intake
 - drinking, 1089, 1275
 - endorphins, 1275
 - methylphenidate, 1089
 - opiate agonists, 1275
 - opiate antagonists, 1275
 - opiate receptors, 1275
 - primates, 1275
 - route of administration, 1089
 - squirrel monkeys, 1275
- Monoamine inhibitors, 1135
 - anorexia
 - catecholamine agonists
 - consummatory behavior
- Morphine
 - abstinence syndrome, 389
 - acetylcholine, 419
 - adenosine, 749
 - N-allyl normetazocine (SKF 10,047), 789
 - analgesia, 419, 757, 1161, 1175
 - antagonism, 223
 - behavioral effects, 703
 - carbachol-induced fighting, 371
 - cardiovascular reflex, 19
 - catalepsy, 703
 - cats, 371
 - cerebral cortical prisms, 749
 - cholinergic neurons, 371
 - chronic administration, 389
 - cold water swims, 1175
 - collateral inhibition, 1175
 - corpus striatum, 419
 - dependence, 389
 - depressants, 371
 - dipyridamole, 749
 - discriminative stimulus properties, 223
 - dose-response, 757
 - drug discrimination, 789
 - drug interaction, 789
 - eating, 1141
 - endorphins, 389
 - β -endorphin, 703
 - D-Ala²-Met⁵-enkephalinamide, 19
 - glutamic acid diethylester, 715
 - goldfish, 757
 - hyperthermia, 1141
 - kainic acid, 715
 - N-methyl-D-aspartate, 715
 - MIF-1, 757
 - motor activity, 19
 - muscular rigidity, 715
 - mydriasis, 897
 - naloxazone, 1175
 - naloxone, 223, 389, 757, 789, 897
 - opiate receptors, 1141
 - opiates, 389, 703, 897
 - pentazocine, 789
 - phenyldiguanide, 19
 - pigeons, 223

- prenatal exposure, 1161
 - pulmonary J-receptors, 19
 - pulmonary opiate receptors, 19
 - ³H-purines release, 749
 - quisqualic acid, 715
 - striatum, 715
 - tail flick, 1161
 - tolerance, 223
 - tripelennamine, 789
 - vagal afferents, 19
 - ventromedial hypothalamus, 1141
- Morphine analgesia, 229
 - extinction
 - nociception
 - stress
 - tolerance
- Morphine hyperreactivity, 1019
 - analgesia, stress-induced
 - endogenous opiates
 - inescapable shock
 - learned helplessness
 - naltrexone
- Morphine-induced behavior, 297
 - cat
 - naloxone
 - opiate receptors
 - opioid peptides
 - septum
- Morphine intoxication, 495
 - ingestion method
- Morphine tolerance, 1213
 - analgesia
 - dose-response relationships
 - Formalin test
 - tail-flick test
- Motor activity
 - cardiovascular reflex, 19
 - chronic administration, 489
 - dopamine receptors, 951
 - D-Ala⁻²-Met⁵-enkephalinamide, 19
 - morphine, 19
 - narcotics, 489
 - nomifensine, 951
 - phenyldiguanide, 19
 - pulmonary J-receptors, 19
 - pulmonary opiate receptors, 19
 - supersensitivity, 489
 - vagal afferents, 19
- Motor performance, 53
 - drug interactions
 - methyl atropine
 - oxotremorine
 - phencyclidine lethality
 - phencyclidine metabolites
- MSH/ACTH₄₋₁₀, 37
 - ACTH₁₋₂₄
 - deoxyglucose uptake
 - footshock
 - naloxone
- α-MSH
 - ACTH, 1203
 - blood-brain barrier, 1199
 - central nervous system, 1199
 - corticotropin releasing factor (CRF), 1203
 - β-endorphin, 1203
 - hypothermia, 1203
 - naloxone, 1203
 - ptosis, 1203
 - reserpine, 1203
 - sedation, 1203
 - ^{99m}Tc-sodium pertechnetate, 1199
 - temperature, 1203
- Muricide, 847
 - antidepressants
 - serotonin
- Muscimol
 - apomorphine, 651
 - ataxia, 1165
 - benzodiazepines, 973
 - chlordiazepoxide, 1165
 - climbing behavior, 651
 - exploratory behavior, 1165
 - GABA, 651, 973
 - 5-hydroxytryptamine, 973
 - in vivo studies, 651
 - locomotor activity, 973, 1165
 - muscle relaxation, 1165
 - naloxone, 1165
 - picrotoxin, 651, 1165
 - ventral tegmental nuclei of Gudden, 973
- Muscle relaxation, 1165
 - ataxia
 - chlordiazepoxide
 - exploratory behavior
 - locomotor activity
 - muscimol
 - naloxone
 - picrotoxin
- Muscular rigidity, 715
 - glutamic acid diethylester
 - kainic acid
 - N-methyl-D-aspartate
 - morphine
 - quisqualic acid
 - striatum
- Mydriasis, 897
 - morphine
 - naloxone
 - opiates
- N-Allyl normetazocine (SKF 10,047), 789
 - drug discrimination
 - drug interaction
 - morphine
 - naloxone
 - pentazocine
 - tripelennamine
- Naloxazone, 1175
 - analgesia
 - cold water swims
 - collateral inhibition
 - morphine
- Naloxone
 - abstinence syndrome, 389
 - ACTH, 1203
 - ACTH₁₋₂₄, 37
 - analgesia, 757
 - antagonism, 223
 - ataxia, 1165
 - body temperature, 119
 - cardiovascular activity, 1301
 - cat, 297
 - chlordiazepoxide, 1165
 - chronic administration, 389
 - clonidine, 655
 - cortical neurons, 813
 - corticotropin releasing factor (CRF), 1203
 - deoxyglucose uptake, 37
 - dependence, 389
 - diprenorphine, 347
 - discriminative stimulus properties, 223
 - dog, 1301
 - dose-response, 757
 - drinking, 1287
 - drug discrimination, 789
 - drug interaction, 789
 - β-endorphin, 1203
 - endorphins, 389
 - Leu-enkephalin, 1301

- Met-enkephalin, 813
- ethanol, 813
- exploratory behavior, 1165
- footshock, 37
- gerbils, 1083
- goldfish, 757
- hippocampal pyramidal neurons, 813
- hypothermia, 1203
- hypothermia, ethanol-induced, 119
- locomotor activity, 1165
- methylxanthines, 655
- MIF-1, 757, 1083, 1301
- morphine, 223, 389, 789, 897
- morphine-induced behavior, 297
- α -MSH, 1203
- MSH/ACTH⁴⁻¹⁰, 37
- muscimol, 1165
- muscle relaxation, 1165
- mydriasis, 897
- naloxone methobromide, 1287
- narcotic antagonists, 347
- N-allyl normetazocine (SKF 10,047), 789
- opiate antagonists, 1083, 1287
- opiate receptors, 297
- opiates, 389, 813, 897
- opioid peptides, 297
- pentazocine, 789
- picrotoxin, 1165
- pigeons, 223
- play fighting, 905
- ptosis, 1203
- reserpine, 1203
- salsolinol, 813
- sedation, 1203
- septum, 297
- social behavior, 905
- spontaneous activity, 347
- stress, 119
- temperature, 1203
- tetrahydroisoquinolines, 813
- tetrahydropapaveroline, 813
- tolerance, 223
- tripelennamine, 789
- vascular stroke, 1083
- withdrawal syndrome, 655

Naloxone methobromide, 1287

- drinking
- naloxone
- opiate antagonists

Naltrexone

- analgesia, 733
- analgesia, stress-induced, 1019
- body temperature, 733
- cardiac rates, 733
- chlordiazepoxide, 921
- dog, conscious, 733
- endogenous opiates, 1019
- inescapable shock, 1019
- learned helplessness, 1019
- morphine hyperreactivity, 1019
- nicotine, 733
- pupillary diameter, 733
- respiratory rates, 733
- thirst, hypervolemic, 921
- thirst, osmotic, 921

Narcotic analgesics, 1155

- neuroleptics
- noradrenaline
- R 18 503
- serotonin
- withdrawal

Narcotic antagonists, 347

- diprenorphine
- naloxone
- spontaneous activity

Narcotics, 489

- chronic administration
- motor activity
- supersensitivity

Nausea, 305

- conditioned taste aversion
- dexamethasone
- radiation and behavior

Neonates, rats, 473

- brain development
- corticosteroids
- radial maze
- T-maze
- triamcinolone acetonide

Neophobia, 639

- lesions, dorsal noradrenergic bundle
- plasma corticosterone

Neurohypophyseal peptides, 685

- ethanol tolerance
- vasopressin

Neuroleptics

- adrenergics, 1257
- apomorphine antagonism, 1309
- avoidance, 1245
- benzamides, 1309
- butyrophenones, 1309
- catalepsy, 1027
- catecholamines, 1257
- cue discrimination, 1245
- dopamine, 769
- estrogen, 1027
- evoked potentials, 1061
- extinction, 769
- haloperidol, 1027
- hippocampus, 1257
- in vitro studies, 1257
- learning and memory, 1257
- locomotor activity, 1309
- long-term potentiation, 1257
- narcotic analgesics, 1155
- noradrenaline, 1155
- oral dyskinesia, 1061
- phenothiazines, 1309
- pimozide, 769, 1245
- R 18 503, 1155
- reinforcement, 769
- response-choice discrimination, 1245
- rhesus monkey, 1309
- self-stimulation, 769
- serotonin, 1155
- substantia nigra, 1061
- tardive dyskinesia, 1061
- withdrawal, 1155

Neurotoxins, 623

- aggression
- anxiety
- lesions, septum
- social interaction

Neurotransmitters

- amphetamine, 1305
- apomorphine, 1305
- circadian rhythms, 511
- dopamine, 1305
- DSIP, 511
- gerbils, 1305
- pimozide, 1305
- plasma proteins, 511
- social behavior, 1305
- stereotypy, 1305

Nicotine

- analgesia, 733
- attention, 915
- blood levels, 183

- body temperature, 183, 733
- cardiac rates, 733
- cigarette smoking, 915
- dog, conscious, 733
- human studies, 915
- Implantable Nicotine Reservoir, 183
- lesions, 6-OHDA, 579
- lesions, nucleus accumbens septum, 579
- naltrexone, 733
- pupillary diameter, 733
- respiratory rates, 733
- schedule-induced behavior, 579
- self-injection, 579
- sustained release, 183
- visual evoked response, 915
- Nociception
 - behavioral side-effects, 1225
 - body weight, 1225
 - cancer chemotherapy, 1225
 - drinking, 1225
 - extinction, 229
 - glucocorticoids, 1225
 - gonads, 1225
 - morphine analgesia, 229
 - pituitary-adrenal axis, 1225
 - prednisolone, 1225
 - stress, 229
 - tolerance, 229
- Nomifensine, 951
 - dopamine receptors
 - motor activity
- Noradrenaline, 1155
 - narcotic analgesics
 - neuroleptics
 - R 18 503
 - serotonin
 - withdrawal
- Noradrenergic-dopaminergic interaction, 619
 - dopaminergic agonists
 - lesions, ventral noradrenergic bundle
 - rotational behavior
- Norepinephrine
 - cancer anorexia, 1043
 - p-chlorophenylalanine, 1043
 - dopamine, 1043
 - eating, 1043
 - 5-hydroxyindoleacetic acid, 1043
 - hypothalamic-pituitary-adrenal axis, 721
 - plasma corticosterone, 721
 - prenatal stress, 721
 - serotonin, 721, 1043
 - tryptophan, 1043
- Nucleus accumbens
 - amphetamine, 445
 - corpus striatum, 283
 - dopaminergic systems, 193
 - hypokinesia, 283
 - intracerebral electrochemistry, 445
 - lesions, hippocampus, 193
 - locomotion, 283, 445
 - open field, 193
 - recovery of function, 193
 - reserpine, 283
 - striatum, 445
- Obesity, 271
 - amphetamine
 - anorexia
 - brain catecholamine levels
 - genetically obese mice
 - hyperglycemia
 - hyperphagia
- Obesity, genetic, 939
 - amino acids
 - serotonin
 - tryptophan
 - Zucker rats
- Open field
 - active avoidance, 15
 - amphetamine, 15
 - avoidance behavior, 633
 - corticosterone, 1077
 - dopaminergic systems, 193
 - emotionality, 1077
 - H-Phe-Ile-Tyr-His-Ser-Tyr-Lys-OH, 633
 - haloperidol, 15
 - lesions, hippocampus, 193
 - locomotor activity, 1077
 - β -[Tyr⁹]melanotropin-(9-18), 15
 - nucleus accumbens, 193
 - prenatal nicotine, 1077
 - rearing, 1077
 - recovery of function, 193
 - sex differences, 1077
- Open field reactivity, 961
 - alcohol
 - defecation
 - emotionality
 - genetic differences
 - sex differences
- Operant behavior
 - antipsychotics, 1049
 - clozapine, 1049
 - collateral, 1049
 - drinking, 1049
 - drug interactions, 353
 - eating, 1049
 - fixed-ratio, 353
 - haloperidol, 1049
 - pentobarbital, 353
 - phencyclidine, 353
 - pigeons, 353
 - rabbits, 1049
 - repeated acquisition, 353
 - response chains, 353
 - schedule-induced behavior, 1049
 - scheduled responding, 1049
 - thiothixene, 1049
- Operant research, 583
 - BASIC
 - behavioral pharmacology
 - TRS-80 microcomputer
- Opiate agonists, 1275
 - drinking
 - endorphins
 - milk intake
 - opiate antagonists
 - opiate receptors
 - primates
 - squirrel monkeys
- Opiate analgesics, 107
 - corticosteroids
 - dysphoria
 - self-administration
- Opiate antagonists
 - aggressive behavior, 691
 - drinking, 1275, 1287
 - endorphins, 1275
 - gerbils, 1083
 - isolation housing, 691
 - MIF-1, 1083
 - milk intake, 1275
 - naloxone, 1083, 1287
 - naloxone methobromide, 1287
 - opiate agonists, 1275
 - opiate receptors, 1275
 - primates, 1275
 - social behavior, 691
 - squirrel monkeys, 1275
 - vascular stroke, 1083

- Opiate receptors
 - amygdala central nucleus, 217
 - brain slice technique, 699
 - cat, 297, 1317
 - chronic treatment, 699
 - dopamine receptors, 699
 - drinking, 1275
 - eating, 1141
 - endorphins, 1275
 - β -endorphin, 1317
 - enkephalin analogs, 217
 - heart rate conditioning, 217
 - hyperthermia, 1141
 - lithium, 1317
 - milk intake, 1275
 - morphine, 1141
 - morphine-induced behavior, 297
 - naloxone, 297
 - opiate agonists, 1275
 - opiate antagonists, 1275
 - opioid peptides, 297
 - phencyclidine receptors, 699
 - primates, 1275
 - psychomotor excitation, 1317
 - rabbits, 217
 - septum, 297
 - squirrel monkeys, 1275
 - ventromedial hypothalamus, 1141
- Opiates
 - abstinence syndrome, 389
 - behavioral effects, 703
 - brain reward systems, 239
 - catalepsy, 703
 - chronic administration, 389
 - cortical neurons, 813
 - dependence, 389
 - drugs of abuse, 239
 - endorphins, 389
 - β -endorphin, 703
 - Met-enkephalin, 813
 - ethanol, 813
 - hippocampal pyramidal neurons, 813
 - locomotor activity, 1181
 - mice, male, 1181
 - morphine, 389, 703, 897
 - mydriasis, 897
 - naloxone, 389, 813, 897
 - salsolinol, 813
 - sociosexual behavior, male mice, 1181
 - tetrahydroisoquinolines, 813
 - tetrahydropapaveroline, 813
- Opioid antagonists, 1271
 - behavioral depression
 - bradycardia
 - endogenous opioid-like peptide
 - hibernation "trigger"
 - hypophagia
 - hypothermia
 - plasma albumin fraction
 - rhesus monkey
- Opioid peptides, 297
 - cat
 - morphine-induced behavior
 - naloxone
 - opiate receptors
 - septum
- Oral dyskinesia, 1061
 - evoked potentials
 - neuroleptics
 - substantia nigra
 - tardive dyskinesia
- Oral intubation, 111
 - behavior
 - blood alcohol levels
 - ethanol
 - pregnancy
 - squirrel monkeys
- ORG-2766, 177
 - ACTH₄₋₉ analog
 - active avoidance
 - dose-dependent effects
 - passive avoidance
- Ototoxicity, 363
 - aminoglycosides
 - hair cells
 - schooling behavior
 - streptomycin
 - tadpoles
- Ovarian function, 629
 - chronic ethanol
 - estrous cycle, female rats
 - pregnant rats
 - vaginal patency
- Ovariectomized rats, 857
 - brain indoleamines
 - estrous cycle
 - paced coital stimulation
- Ovariectomy
 - adrenalectomy, 529
 - corticosterone, 529
 - endocrine effects, 529
 - estradiol, 529
 - estrous cycle, 323
 - ethanol, 529
 - ethanol preference, 323
 - hamsters, 529
 - lactation, 323
 - pregnancy, 323
 - reproductive state, female rat, 323
 - taste, 323
- Oxazepam, 43
 - benzodiazepines
 - drug experience effects
 - Geller-Seifter conflict test
 - individual variability
 - rate dependency
 - tolerance
- Oximes, 1001
 - acetylcholinesterase reactivation
 - conditioned avoidance
 - DFP
 - PAM
 - proPAM
 - thermoregulation
- Oxotremorine, 53
 - drug interactions
 - methyl atropine
 - motor performance
 - phencyclidine lethality
 - phencyclidine metabolites
- Paced coital stimulation, 857
 - brain indoleamines
 - estrous cycle
 - ovariectomized rats
- Paired-associate learning, 165
 - acquisition deficits
 - cognition
 - diazepam
 - free recall
 - human studies
 - serial learning
 - serial position effects
- Parasympathomimetic agents, 727
 - bethanechol
 - drinking
 - renin-angiotensin system
- Passive avoidance
 - ACTH₄₋₉ analog, 177

- active avoidance, 177
- aging mice, 313
- benzodiazepine, 313
- cholinergic receptors, 313
- cyclic AMP, 677
- dose-dependent effects, 177
- entorhinal cortex, 77
- environmental enrichment, 313
- 6-hydroxydopamine, 77
- lesions, A10, 77
- memory, 677
- ORG-2766, 177
- Rolipram, 677
- septum, 77
- tree shrews, 77
- tyrosine hydroxylase, 77
- Pentazocine, 789
 - drug discrimination
 - drug interaction
 - morphine
 - N-allyl normetazocine (SKF 10,047)
 - naloxone
 - tripelennamine
- Pentobarbital
 - conditioned drug effects, 695
 - drug associations, 695
 - drug interactions, 353
 - ethanol sensitivity, 245
 - fixed-ratio, 353
 - hypnosis, 245
 - hypothermia, 245, 695
 - lithium chloride, 695
 - operant behavior, 353
 - pharmacogenetics, 245
 - pharmacokinetics, 245
 - phencyclidine, 353
 - pigeons, 353
 - repeated acquisition, 353
 - response chains, 353
- Pentobarbital antagonists, 797
 - γ -butyrolactone- γ -carbonyl-histidyl-prolinamide citrate (DN-1417)
 - cholinergic mechanisms
 - hypothalamus
 - sleep
 - TRH
- Pentylentetrazol, 1111
 - kindling
 - seizures
 - transfer
- Peptide
 - ACTH, 31, 1203
 - ACTH₁₋₂₄, 37
 - angiotensin I, 1285
 - angiotensin II, 73, 741, 1285
 - corticotropin releasing factor (CRF), 1203
 - crinia-angiotensin II, 741
 - DSIP, 511, 1009, 1187
 - β -endorphin, 297, 703, 1203, 1317
 - Leu-enkephalin, 1301
 - D-Ala²-D-Leu³-enkephalin, 217
 - Met-enkephalin, 297, 813
 - H-Phe-Ile-Tyr-His-Ser-Tyr-Lys-OH, 633
 - D-Ala²-Met⁵-enkephalinamide, 217
 - β -[Tyr⁹]melanotropin-(9-18), 15
 - MIF-1, 757, 1083, 1301, 1193
 - N-Tyr-MIF-1, 1193
 - MSH, 893
 - α -MSH, 1199, 1203
 - MSH/ACTH₄₋₁₀, 37
 - oxytocin, 893
 - L-prolyl-L-leucyl-glycineamide, 893
 - thyrotropin-releasing hormone (TRH), 249, 797
 - vasopressin, 685
- Pharmacogenetics, 245
 - ethanol sensitivity
 - hypnosis
 - hypothermia
 - pentobarbital
 - pharmacokinetics
- Pharmacokinetics, 245
 - ethanol sensitivity
 - hypnosis
 - hypothermia
 - pentobarbital
 - pharmacogenetics
- Pharmacotherapy, s25
 - antianxiety drugs
 - bupirone
 - dopamine
- Phencyclidine
 - aggressive behavior, 503
 - concurrent schedule, 341
 - drinking, 341
 - drug discrimination, 291
 - drug interactions, 353
 - eating, 341
 - fixed-ratio, 341, 353
 - food deprivation, 341
 - hyperactivity, 503
 - ketamine, 291
 - operant behavior, 353
 - pentobarbital, 353
 - pigeons, 353
 - repeated acquisition, 353
 - response chains, 353
 - rhesus monkeys, 341
 - satiety, 341
 - schedule-controlled behavior, 291
 - self-administration, 341
 - stereospecificity, 291
- Phencyclidine lethality, 53
 - drug interactions
 - methyl atropine
 - motor performance
 - oxotremorine
 - phencyclidine metabolites
- Phencyclidine metabolites, 53
 - drug interactions
 - methyl atropine
 - motor performance
 - oxotremorine
 - phencyclidine lethality
- Phencyclidine receptors, 699
 - brain slice technique
 - chronic treatment
 - dopamine receptors
 - opiate receptors
- Phenobarbital, 645
 - anxiolytic agents
 - benzodiazepines
 - conflict test
 - ethanol
 - meprobamate
 - squirrel monkeys, male
- Phenothiazines, 1309
 - apomorphine antagonism
 - benzamides
 - butyrophenones
 - locomotor activity
 - neuroleptics
 - rhesus monkey
- Phenyldiguanide, 19
 - cardiovascular reflex
 - D-Ala²-Met⁵-enkephalinamide
 - morphine
 - motor activity
 - pulmonary J-receptors
 - pulmonary opiate receptors

- vagal afferents
- Phenylethylamine, 1291
 - aggressive behavior
 - isolation syndrome
 - stress
 - tyramine
- Phenylisopropylamines, 603
 - amphetamines
 - discriminative stimulus properties
 - hallucinogens
 - methoxyphenylisopropylamines
 - structure-activity relationships
- Phenylpiperazines, 147
 - aggression inhibition
 - brain stimulation, electrical
 - DU27716
 - hypothalamus
- Pheromones, maternal, 1149
 - liver membranes
 - prolactin
- Photic evoked potentials, 1313
 - albino rats
 - ethyl alcohol
 - superior colliculus
 - visual cortex
- Photoperiod, 807
 - acetaldehyde
 - body weight
 - food deprivation
 - schedule-controlled responding
 - self-injection
- Physical dependence, 1239
 - chlordiazepoxide
 - ethanol
 - tolerance
 - withdrawal
- Physostigmine
 - cocaine, 1295
 - haloperidol, 1295
 - imipramine, 1119
 - memory, 1119
 - procaine, 1295
 - REM sleep deprivation, 1119
 - self-administration, 1295
- Picrotoxin
 - anxiolytics, 359
 - apomorphine, 651
 - ataxia, 1165
 - chlordiazepoxide, 1165
 - climbing behavior, 651
 - conditioned defensive burying, 359
 - diazepam, 359
 - exploratory behavior, 1165
 - GABA, 651
 - GABAergic system, 359
 - in vivo studies, 651
 - locomotor activity, 1165
 - muscimol, 651, 1165
 - muscle relaxation, 1165
 - naloxone, 1165
- Pigeons
 - amphetamine, 671
 - d-amphetamine, 1123
 - angiotensin, 741
 - antagonism, 223, 671
 - blood pressure, arterial, 741
 - crinia-angiotensin II, 741
 - l-desamino-8-D-arginine, 1123
 - discriminative stimulus, 223, 671
 - dopaminergic agonists, 995
 - drinking, 741
 - drug interactions, 353
 - fixed-ratio, 353
 - generalization, 671
 - haloperidol, 995
 - matching-to-sample, 1123
 - memory, short-term, 1123
 - α -methylparatyrosine, 995
 - morphine, 223
 - naloxone, 223
 - operant behavior, 353
 - pentobarbital, 353
 - phencyclidine, 353
 - piribedil, 995
 - rats, 741
 - repeated acquisition, 353
 - response chains, 353
 - scheduled responding, 995
 - scopolamine, 1123
 - tetrabenzine, 995
 - tolerance, 223
 - vasopressin analogues, 1123
- Pimozide
 - amphetamine, 431, 613, 1305
 - anhedonia paradigm refinements, 987
 - apomorphine, 967, 1305
 - avoidance, 1245
 - brain stimulation, 431
 - caffeine, 613
 - circling behavior, 431
 - clozapine, 987
 - cue discrimination, 1245
 - ¹⁴C-2-deoxyglucose autoradiography, 841
 - diagonal band of Broca, 841
 - dopamine, 769, 1305
 - dopamine receptors, 967
 - dopaminergic system, 431
 - extinction, 769
 - fluphenazine, 987
 - gerbils, 1305
 - haloperidol, 613
 - lateral habenula, 841
 - locomotor activity, 967
 - medial forebrain bundle, 841
 - neuroleptic treatment, 1245
 - neuroleptics, 769
 - neurotransmitters, 1305
 - place preference, 665
 - priming, 783
 - reinforcement, 769, 783, 841
 - response-choice discrimination, 1245
 - secondary reinforcement, 665
 - self-biting, 613
 - self-stimulation, 769, 783, 841
 - sign tracking, 665
 - social behavior, 1305
 - stereotypy, 967, 1305
 - strain differences, 967
 - substantia nigra, 431
 - ventral tegmentum, 841
- Piribedil, 995
 - dopaminergic agonists
 - haloperidol
 - α -methylparatyrosine
 - pigeons
 - scheduled responding
 - tetrabenzine
- Pituitary, 1067
 - cerebellum
 - corticosterone
 - cyclic AMP
 - cyclic GMP
 - growth hormone
 - prolactin
 - stress
- Pituitary-adrenal axis, 1225
 - behavioral side-effects
 - body weight
 - cancer chemotherapy
 - drinking

- glucocorticoids
- gonads
- nociception
- prednisolone
- Place preference, 665
- pimozide
- secondary reinforcement
- sign tracking
- Plasma albumin fraction, 1271
- behavioral depression
- bradycardia
- endogenous opioid-like peptide
- hibernation "trigger"
- hypophagia
- hypothermia
- opioid antagonists
- rhesus monkey
- Plasma angiotensin II, 73
- acetylsalicylic acid
- cellular dehydration
- drinking
- hypovolemia
- indomethacin
- prostaglandin E
- Plasma corticosterone
- hypothalamic-pituitary-adrenal axis, 721
- lesions, dorsal noradrenergic bundle, 639
- neophobia, 639
- norepinephrine, 721
- prenatal stress, 721
- serotonin, 721
- Plasma proteins, 511
- circadian rhythms
- DSIP
- neurotransmitters
- Play fighting, 905
- naloxone
- social behavior
- Post-lactation, 1097
- alcohol preference
- cohabitation
- lactation
- pregnancy
- Postmortem plasma LH, 171
- antemortem violence
- human studies
- Postnatal exposure, 927
- adenosine triphosphatase
- ethanol
- prenatal exposure
- Prazosin, 1207
- baclofen
- clonidine
- extinction
- haloperidol
- intracranial self-stimulation
- methocarbamol
- metoclopramide
- response decrement patterns
- Prednisolone, 1225
- behavioral side-effects
- body weight
- cancer chemotherapy
- drinking
- glucocorticoids
- gonads
- nociception
- pituitary-adrenal axis
- Pregnancy
- alcohol preference, 1097
- behavior, 111
- blood alcohol levels, 111
- cohabitation, 1097
- estrous cycle, 323
- ethanol, 111, 125
- ethanol preference, 323
- fetal alcohol syndrome, animal model, 125
- lactation, 323, 1097
- maternal behavior, female rat, 125
- oral intubation, 111
- ovariectomy, 323
- post-lactation, 1097
- reproductive state, female rat, 323
- squirrel monkeys, 111
- taste, 323
- withdrawal, 125
- Pregnancy, mice, 91
- aldehyde dehydrogenase
- aldehyde oxidase
- eclampsia
- flurothyl
- pyridoxal kinase
- pyridoxamine phosphate oxidase
- seizure susceptibility
- Pregnant rats, 629
- chronic ethanol
- estrous cycle, female rats
- ovarian function
- vaginal patency
- Prenatal exposure
- adenosine triphosphatase, 927
- analgesia, 1161
- ethanol, 927
- morphine, 1161
- postnatal exposure, 927
- tail flick, 1161
- Prenatal nicotine, 1077
- corticosterone
- emotionality
- locomotor activity
- open field
- rearing
- sex differences
- Prenatal stress, 721
- hypothalamic-pituitary-adrenal axis
- norepinephrine
- plasma corticosterone
- serotonin
- Pressing responses, 945
- aggression, shock-induced
- p-chlorophenylalanine
- serotonin
- Pretreatment effect, 435
- conditioned taste aversion
- desipramine
- fluoxetine
- lesions, dorsal noradrenergic bundle
- lesions, raphe nuclei
- lithium
- Primates
- baboons, 823
- cocaine, 823
- drinking, 1275
- endorphins, 1275
- milk intake, 1275
- opiate agonists, 1275
- opiate antagonists, 1275
- opiate receptors, 1275
- self-administration, 823
- squirrel monkeys, 1275
- tether restraint for catheterization, 823
- Priming, 783
- pimozide
- reinforcement
- self-stimulation
- Procaine, 1295
- cocaine
- haloperidol
- physostigmine
- self-administration

Prolactin
 cerebellum, 1067
 corticosterone, 837, 1067
 cyclic AMP, 1067
 cyclic GMP, 1067
 ergot drugs, 837
 growth hormone, 837, 1067
 lactation, 837
 liver membranes, 1149
 luteinizing hormone, 837
 pheromones, maternal, 1149
 pituitary, 1067
 stress, 1067
L-Prolyl-L-leucyl-glycineamide, 893
 chicks
 memory
Propranolol
 amphetamine, 255
 anorexia, 255
 behavioral toxicity, 399
 cardioglycosides, 399
 catecholamines, 255
 clonidine, 399
 digitoxin, 399
 eating, 255
 log survivor analysis, 255
 microstructural analysis, 255
Prostaglandins, 1233
 apomorphine
 circling behavior
 6-hydroxydopamine
 indomethacin
Prostaglandin E, 73
 acetylsalicylic acid
 cellular dehydration
 drinking
 hypovolemia
 indomethacin
 plasma angiotensin II
Protein binding, 1009
 blood-brain barrier
 cerebrospinal fluid
 column chromatography
 dogs
 DSIP
Protein synthesis inhibitors, 187
 amnesia
 anisomycin
 catecholamine biochemistry
 cycloheximide
Psychomotor excitation, 1317
 cats
 β -endorphin
 lithium
 opiate receptors
Ptoxis, 1203
 ACTH
 corticotropin releasing factor (CRF)
 β -endorphin
 hypothermia
 α -MSH
 naloxone
 reserpine
 sedation
 temperature
Pulmonary J-receptors, 19
 cardiovascular reflex
 D-Ala²-Met⁵-enkephalinamide
 morphine
 motor activity
 phenyldiguanide
 pulmonary opiate receptors
 vagal afferents
Pulmonary opiate receptors, 19
 cardiovascular reflex
 D-Ala²-Met⁵-enkephalinamide
 morphine
 motor activity
 phenyldiguanide
 pulmonary J-receptors
 vagal afferents
Pupillary diameter, 733
 analgesia
 body temperature
 cardiac rates
 dog, conscious
 naltrexone
 nicotine
 respiratory rates
³H-Purines release, 749
 adenosine
 cerebral cortical prisms
 dipyrindamole
 morphine
Purkinje neurons, 569
 cerebellum
 ethanol
 hypnotic effects
 inbred strains, mice
 righting reflex
Pyridine-2-aldoxime methyl iodide (PAM), 1001
 acetylcholinesterase reactivation
 conditioned avoidance
 DFP
 oximes
 proPAM
 thermoregulation
Pyridoxal kinase, 91
 aldehyde dehydrogenase
 aldehyde oxidase
 eclampsia
 flurothyl
 pregnancy, mice
 pyridoxamine phosphate oxidase
 seizure susceptibility
Pyridoxamine phosphate oxidase, 91
 aldehyde dehydrogenase
 aldehyde oxidase
 eclampsia
 flurothyl
 pregnancy, mice
 pyridoxal kinase
 seizure susceptibility
Quail, 405
 biochanin A
 dietary supplements
 ferulic acid
 sexual behavior, birds
Quantitative behavioral analysis, 873
 apomorphine
 stereotyped behavior
Quipazine, 393
 apomorphine
 dopaminergic action
 drug discrimination
 haloperidol
 methysergide
 serotonin
Quisqualic acid, 715
 glutamic acid diethylester
 kainic acid
 N-methyl-D-aspartate
 morphine
 muscular rigidity
 striatum
R 18 503 (α -(p-chlorophenyl)- β , β -dimethylimidazole-1-ethanol), 1155

- narcotic analgesics
- neuroleptics
- noradrenaline
- serotonin
- withdrawal
- Rabbits
 - amygdala central nucleus, 217
 - antipsychotics, 1049
 - clozapine, 1049
 - collateral behavior, 1049
 - drinking, 1049
 - eating, 1049
 - enkephalin analogs, 217
 - haloperidol, 1049
 - heart rate conditioning, 217
 - operant behavior, 1049
 - opiate receptors, 217
 - schedule-induced behavior, 1049
 - scheduled responding, 1049
 - thiothixene, 1049
- Radial maze, 473
 - brain development
 - corticosteroids
 - neonates, rats
 - T-maze
 - triamcinolone acetonide
- Radiation and behavior, 305
 - conditioned taste aversion
 - dexamethasone
 - nausea
- Radioimmunoassay, 1187
 - age
 - blood-brain barrier
 - delta sleep-inducing peptide (DSIP)
 - DSIP analogs
- Rate dependency, 43
 - benzodiazepines
 - drug experience effects
 - Geller-Seifter conflict test
 - individual variability
 - oxazepam
 - tolerance
- Rats, 741
 - angiotensin
 - blood pressure, arterial
 - crinia-angiotensin II
 - drinking
 - pigeons
- Rearing, 1077
 - corticosterone
 - emotionality
 - locomotor activity
 - open field
 - prenatal nicotine
 - sex differences
- Recovery of function, 193
 - dopaminergic systems
 - lesions, hippocampus
 - nucleus accumbens
 - open field
- Reinforcement
 - ¹⁴C-2-deoxyglucose autoradiography, 841
 - diagonal band of Broca, 841
 - dopamine, 769
 - extinction, 769
 - lateral habenula, 841
 - medial forebrain bundle, 841
 - neuroleptics, 769
 - pimozide, 769, 783, 841
 - priming, 783
 - self-stimulation, 769, 783, 841
 - ventral tegmentum, 841
- REM sleep deprivation, 1119
 - imipramine
 - memory
 - physostigmine
- Renin-angiotensin system, 727
 - bethanechol
 - drinking
 - parasympathomimetic agents
- Repeated acquisition, 353
 - drug interactions
 - fixed-ratio
 - operant behavior
 - pentobarbital
 - phencyclidine
 - pigeons
 - response chains
- Repeated administration
 - amphetamine, 547
 - avoidance suppression, 131
 - behavioral augmentation, 547
 - haloperidol, 131
 - locomotor activity, 547
 - stereotypy, 547
 - sympathomimetics, 547
- Reproductive state, female rat, 323
 - estrous cycle
 - ethanol preference
 - lactation
 - ovariectomy
 - pregnancy
 - taste
- Reserpine
 - ACTH, 1203
 - corpus striatum, 283
 - corticotropin releasing factor (CRF), 1203
 - β -endorphin, 1203
 - hypokinesia, 283
 - hypothermia, 1203
 - locomotion, 283
 - α -MSH, 1203
 - naloxone, 1203
 - nucleus accumbens, 283
 - ptosis, 1203
 - sedation, 1203
 - temperature, 1203
- Respiratory rates, 733
 - analgesia
 - body temperature
 - cardiac rates
 - dog, conscious
 - naltrexone
 - nicotine
 - pupillary diameter
- Response chains, 353
 - drug interactions
 - fixed-ratio
 - operant behavior
 - pentobarbital
 - phencyclidine
 - pigeons
 - repeated acquisition
- Response-choice discrimination, 1245
 - avoidance
 - cue discrimination
 - neuroleptic treatment
 - pimozide
- Response consistency, 555
 - catecholamine excretion
 - cortisol excretion
 - human studies
 - sex differences
 - stress
- Response decrement patterns, 1207
 - baclofen
 - clonidine
 - extinction
 - haloperidol
 - intracranial self-stimulation

- methocarbamol
- metoclopramide
- prazosin
- Reward, 1093
 - alcohol
 - brain stimulation
 - drug discrimination
- Reward deprivation, 563
 - dose response
 - food deprivation
 - self-administration
 - water deprivation
- Rhesus monkey
 - anticholinergics, 85
 - apomorphine antagonism, 1309
 - atropine, 85
 - behavioral depression, 1271
 - benactyzine, 85
 - benzamides, 1309
 - bradycardia, 1271
 - butyrophenones, 1309
 - concurrent schedule, 341
 - drinking, 341
 - DRL schedule, 85
 - eating, 341
 - endogenous opioid-like peptide, 1271
 - fixed-ratio, 341
 - food deprivation, 341
 - hibernation "trigger", 1271
 - hypophagia, 1271
 - hypothermia, 1271
 - locomotor activity, 1309
 - neuroleptics, 1309
 - opioid antagonists, 1271
 - phencyclidine, 341
 - phenothiazines, 1309
 - plasma albumin fraction, 1271
 - satiety, 341
 - schedule-controlled behavior, 85
 - scopolamine, 85
 - self-administration, 341
- Righting reflex, 569
 - cerebellum
 - ethanol
 - hypnotic effects
 - inbred strains, mice
 - Purkinje neurons
- RO 15-1788, 457
 - benzodiazepine antagonists
 - 3-carbomethoxy- β -carboline
 - CGS 8216
 - diazepam
 - seizures
- Rolipram, 677
 - cyclic AMP
 - memory
 - passive avoidance
- Rotational behavior, 619
 - dopaminergic agonists
 - lesions, ventral noradrenergic bundle
 - noradrenergic-dopaminergic interaction
- Route of administration
 - amphetamine, 1129
 - conditioned taste aversion, 1129
 - drinking, 1089
 - methylphenidate, 1089
 - milk intake, 1089
 - saccharin, 1129
- Saccharin, 1129
 - amphetamine
 - conditioned taste aversion
 - route of administration
- Salsolinol, 813
- cortical neurons
- Met-enkephalin
- ethanol
- hippocampal pyramidal neurons
- naloxone
- opiates
- tetrahydroisoquinolines
- tetrahydropapaveroline
- Satiety
 - benzodiazepines, 481
 - caffeine, 481
 - concurrent schedule, 341
 - drinking, 341, 481
 - eating, 341
 - fixed-ratio, 341
 - food deprivation, 341
 - hypodipsia, 481
 - phencyclidine, 341
 - rhesus monkeys, 341
 - self-administration, 341
- Schedule-controlled responding
 - acetaldehyde, 807
 - anticholinergics, 85
 - atropine, 85
 - benactyzine, 85
 - body weight, 807
 - DRL schedule, 85
 - drug discrimination, 291
 - food deprivation, 807
 - ketamine, 291
 - phencyclidine, 291
 - photoperiod, 807
 - rhesus monkey, 85
 - scopolamine, 85
 - self-injection, 807
 - stereospecificity, 291
- Schedule-induced behavior
 - antipsychotics, 1049
 - cigarette smoking, 523
 - clozapine, 1049
 - collateral behavior, 1049
 - drinking, 1049
 - eating, 1049
 - haloperidol, 1049
 - human studies, 523
 - lesions, nucleus accumbens septum, 579
 - lesions, 6-OHDA, 579
 - nicotine, 579
 - operant behavior, 1049
 - rabbits, 1049
 - scheduled responding, 1049
 - self-administration, 523
 - self-injection, 579
 - thiothixene, 1049
- Scheduled responding
 - acquisition, 1055
 - antipsychotics, 1049
 - clozapine, 1049
 - collateral behavior, 1049
 - diazepam, 1055
 - dopaminergic agonists, 995
 - drinking, 1049
 - eating, 1049
 - haloperidol, 995, 1049
 - human studies, 1055
 - α -methylparatyrosine, 995
 - operant behavior, 1049
 - pigeons, 995
 - piribedil, 995
 - rabbits, 1049
 - schedule-induced behavior, 1049
 - tetrabenzine, 995
 - thiothixene, 1049
- Schizophrenia, etiology, 413
 - acoustic startle

- d-amphetamine
- sensitization
- stress
- Schooling behavior, 363
 - aminoglycosides
 - hair cells
 - ototoxicity
 - streptomycin
 - tadpoles
- Scopolamine
 - acetylcholine release, 933
 - d-amphetamine, 1123
 - anticholinergics, 85
 - atropine, 85
 - avoidance behavior, 933
 - benactyzine, 85
 - 1-desamino-8-D-arginine, 1123
 - DRL schedule, 85
 - lesions, magnocellular forebrain nuclei, 933
 - matching-to-sample, 1123
 - memory, short-term, 1123
 - pigeons, 1123
 - rhesus monkey, 85
 - schedule-controlled behavior, 85
 - vasopressin analogues, 1123
- Secondary reinforcement, 665
 - pimozide
 - place preference
 - sign tracking
- Sedation, 1203
 - ACTH
 - corticotropin releasing factor (CRF)
 - β -endorphin
 - hypothermia
 - α -MSH
 - naloxone
 - ptosis
 - reserpine
 - temperature
- Seizures
 - acute administration, 461
 - antidepressants, 461
 - benzodiazepine antagonists, 457
 - 3-carbomethoxy- β -carboline, 457
 - CGS 8216, 457
 - diazepam, 457
 - kindling, 1111
 - kindling, amygdaloid, 461
 - pentylentetrazol, 1111
 - RO 15-1788, 457
 - subacute administration, 461
 - transfer, 1111
- Seizure susceptibility, 91
 - aldehyde dehydrogenase
 - aldehyde oxidase
 - eclampsia
 - flurothyl
 - pregnancy, mice
 - pyridoxal kinase
 - pyridoxamine phosphate oxidase
- Selective breeding, 885
 - body temperature
 - diarrhea
 - diisopropyl phosphorofluoridate
 - fixed-ratio responding
 - generalization
 - locomotor activity
- Self-administration
 - baboons, 823
 - cigarette smoking, 155, 523
 - cocaine, 823, 901, 1295
 - concurrent schedule, 341
 - corticosteroids, 107
 - dose response, 563
 - drinking, 341
 - dysphoria, 107
 - eating, 341
 - fixed-ratio, 341
 - food deprivation, 341, 563
 - haloperidol, 1295
 - human studies, 155, 523
 - lesions, 6-OHDA, 901
 - lesions, ventral tegmental area, 901
 - opiate analgesics, 107
 - phencyclidine, 341
 - physostigmine, 1295
 - primates, 823
 - procaine, 1295
 - reward deprivation, 563
 - rhesus monkeys, 341
 - satiety, 341
 - schedule-induced behavior, 523
 - tether restraint for catheterization, 823
 - tobacco, 155
 - water deprivation, 563
- Self-biting, 613
 - amphetamine
 - caffeine
 - haloperidol
 - pimozide
- Self-injection
 - acetaldehyde, 807
 - body weight, 807
 - food deprivation, 807
 - lesions, nucleus accumbens septum, 579
 - lesions, 6-OHDA, 579
 - nicotine, 579
 - photoperiod, 807
 - schedule-controlled responding, 807
 - schedule-induced behavior, 579
- Self-stimulation
 - atropine, 851
 - benzotropine, 851
 - p-chlorophenylalanine, 597
 - ¹⁴C-2-deoxyglucose autoradiography, 841
 - diagonal band of Broca, 841
 - diphenhydramine, 851
 - dopamine, 769
 - extinction, 769
 - haloperidol, 851
 - lateral habenula, 841
 - medial forebrain bundle, 841
 - medial raphe nucleus, 597
 - neuroleptics, 769
 - pimozide, 769, 783, 841
 - priming, 783
 - reinforcement, 769, 783, 841
 - serotonin, 597
 - time course analysis, 597
 - ventral tegmentum, 841
- Sensitivity, 25
 - d-amphetamine
 - fluphenazine decanoate
 - locomotor activity
 - serum prolactin
- Sensitization, 413
 - acoustic startle
 - d-amphetamine
 - schizophrenia, etiology
 - stress
- Septum
 - cat, 297
 - entorhinal cortex, 77
 - 6-hydroxydopamine, 77
 - lesions, A10, 77
 - morphine-induced behavior, 297
 - naloxone, 297
 - opiate receptors, 297
 - opioid peptides, 297
 - passive avoidance, 77

- tree shrews, 77
- tyrosine hydroxylase, 77
- Serial learning, 165
 - acquisition deficits
 - cognition
 - diazepam
 - free recall
 - human studies
 - paired-associate learning
 - serial position effects
- Serial position effects, 165
 - acquisition deficits
 - cognition
 - diazepam
 - free recall
 - human studies
 - paired-associate learning
 - serial learning
- Serotonin
 - aggression, shock-induced, 945
 - amino acids, 939
 - antidepressants, 847
 - apomorphine, 393
 - cancer anorexia, 1043
 - p-chlorophenylalanine, 597, 945, 1043
 - cholinergic receptors, 159
 - depression, 159
 - dopamine, 1043
 - dopaminergic action, 393
 - drug discrimination, 393
 - eating, 1043
 - haloperidol, 393
 - 5-hydroxyindoleacetic acid, 1043
 - hypothalamic-pituitary-adrenal axis, 721
 - imipramine, 159
 - inescapable shock, 877
 - learned helplessness, 877
 - medial raphe nucleus, 597
 - methysergide, 393, 597
 - muricide, 847
 - narcotic analgesics, 1155
 - neuroleptics, 1155
 - noradrenaline, 1155
 - norepinephrine, 721, 1043
 - obesity, genetic, 939
 - plasma corticosterone, 721
 - prenatal stress, 721
 - pressing responses, 945
 - quipazine, 393
 - R 18503, 1155
 - self-stimulation, 597
 - suicide, 159
 - time course analysis, 597
 - tryptophan, 877, 939, 1043
 - withdrawal, 1155
 - Zucker rats, 939
- Serotonin metabolism, 49
 - environmental influences
 - housing, group
 - housing, isolation
 - valproic acid
- Serum prolactin, 25
 - d-amphetamine
 - fluphenazine decanoate
 - locomotor activity
 - sensitivity
- Sex differences
 - alcohol, 961
 - catecholamine excretion, 555
 - corticosterone, 1077
 - cortisol excretion, 555
 - defecation, 961
 - emotionality, 961, 1077
 - genetic differences, 961
 - human studies, 555
 - locomotor activity, 1077
 - open field, 1077
 - open field reactivity, 961
 - prenatal nicotine, 1077
 - rearing, 1077
 - response consistency, 555
 - stress, 555
- Sexual behavior, 659
 - development
 - estrous cycle
 - malnutrition, postnatal
 - malnutrition, prenatal
- Sexual behavior, birds, 405
 - biochanin A
 - dietary supplements
 - ferulic acid
 - quail
- Sham feeding, 863
 - atropine methyl nitrate
 - cholinergic blockade
 - diet palatability
 - hunger
- Sidman avoidance response, 425
 - central acting drugs
 - strain differences
- Sign tracking, 665
 - pimozide
 - place preference
 - secondary reinforcement
- Sleep, 797
 - γ -butyrolactone- γ -carbonyl-histidyl-prolinamide citrate (DN-1417)
 - cholinergic mechanisms
 - hypothalamus
 - pentobarbital antagonists
 - TRH
- Sleep latency, 65
 - human studies
 - sleep quality
 - valerian
- Sleep quality, 65
 - human studies
 - sleep latency
 - valerian
- Social behavior
 - amphetamine, 1305
 - aggressive behavior, 691
 - apomorphine, 1305
 - dopamine, 1305
 - gerbils, 1305
 - isolation housing, 691
 - naloxone, 905
 - neurotransmitters, 1305
 - opiate antagonists, 691
 - pimozide, 1305
 - play fighting, 905
 - stereotypy, 1305
- Social behavior, male baboons, 209
 - baboons
 - hashish
- Social interaction, 623
 - aggression
 - anxiety
 - lesions, septum
 - neurotoxins
- Sociosexual behavior, male mice, 1181
 - locomotor activity
 - mice, male
 - opiates
- Sodium barbitone, 909
 - appetitive tasks
 - aversive tasks
 - learning
 - memory, long-term
 - Y-maze

^{99m}Tc-sodium pertechnetate, 1199
 blood-brain barrier
 central nervous system
 α -MSH

Spatial behavior, 137
 caffeine
 early development
 jewel fish

Spontaneous activity, 347
 diprenorphine
 naloxone
 narcotic antagonists

Squirrel monkeys
 behavior, 111
 blood alcohol levels, 111
 drinking, 1275
 endorphins, 1275
 ethanol, 111
 milk intake, 1275
 opiate agonists, 1275
 opiate antagonists, 1275
 opiate receptors, 1275
 oral intubation, 111
 pregnancy, 111
 primates, 1275

Squirrel monkeys, male, 645
 anxiolytic agents
 benzodiazepines
 conflict test
 ethanol
 meprobamate
 phenobarbital

Starvation, 249
 adipia
 anorexia
 drinking
 eating
 hypothalamus
 TRH

Stereospecificity, 291
 drug discrimination
 ketamine
 phencyclidine
 schedule-controlled behavior

Stereotyped behavior, 873
 apomorphine
 quantitative behavioral analysis

Stereotypy
 amphetamine, 547, 1305
 apomorphine, 967, 1035
 behavioral augmentation, 547
 dopamine, 1305
 dopamine receptors, 967
 gerbils, 1305
 locomotor activity, 547, 967
 neurotransmitters, 1305
 pimozone, 967, 1305
 repeated administration, 547
 social behavior, 1305
 strain differences, 967
 sympathomimetics, 547

Stress
 acoustic startle, 413
 aggregation toxicity, 467
 aggressive behavior, 1291
 d-amphetamine, 413
 body temperature, 119
 catecholamine excretion, 555
 catecholamines, 467
 cerebellum, 1067
 p-chloroamphetamine, 467
 corticosterone, 1067
 cortisol excretion, 555
 cyclic AMP, 1067
 cyclic GMP, 1067
 dopaminergic agents, s21
 environmental effects, 467
 escape performance, 263
 extinction, 229
 growth hormone, 1067
 haloperidol, 263
 human studies, 555
 hypothermia, ethanol-induced, 119
 inescapable shock, 263
 isolation syndrome, 1291
 morphine analgesia, 229
 naloxone, 119
 nociception, 229
 phenylethylamine, 1291
 pituitary, 1067
 prolactin, 1067
 response consistency, 555
 schizophrenia, etiology, 413
 sensitization, 413
 sex differences, 555
 time, s21
 tolerance, 229
 tyramine, 1291

Strain differences
 apomorphine, 967
 apomorphine stereotypy, 1115
 central acting drugs, 425
 dopamine receptors, 967
 locomotor activity, 967, 1115
 pimozone, 967
 Sidman avoidance response, 425
 stereotypy, 967
 striatal dopamine receptors, 1115

Streptomycin, 363
 aminoglycosides
 hair cells
 ototoxicity
 schooling behavior
 tadpoles

Striatal dopamine receptors, 1115
 apomorphine stereotypy
 locomotor activity
 strain differences

Striatum
 amphetamine, 445
 glutamic acid diethylester, 715
 intracerebral electrochemistry, 445
 kainic acid, 715
 locomotion, 445
 N-methyl-D-aspartate, 715
 morphine, 715
 muscular rigidity, 715
 nucleus accumbens, 445
 quisqualic acid, 715

Structure-activity relationships
 amphetamines, 603
 discriminative stimulus properties, 603
 dopamine receptor agonists, s11
 hallucinogens, 603
 methoxyphenylisopropylamines, 603
 phenylisopropylamines, 603

Subacute administration, 461
 acute administration
 antidepressants
 kindling, amygdaloid
 seizures

Substantia nigra
 amphetamine, 431
 brain stimulation, 431
 circling behavior, 431
 dopaminergic system, 431
 evoked potentials, 1061
 neuroleptics, 1061
 oral dyskinesia, 1061
 pimozone, 431

- tardive dyskinesia, 1061
- Sucrose, 333
 - concurrent schedules
 - ethanol reinforced responding
- Suicide, 159
 - cholinergic receptors
 - depression
 - imipramine
 - serotonin
- Superior colliculus, 1313
 - albino rats
 - ethyl alcohol
 - photic evoked potentials
 - visual cortex
- Supersensitivity, 489
 - chronic administration
 - motor activity
 - narcotics
- Sustained release, 183
 - blood levels
 - body temperature
 - Implantable Nicotine Reservoir
 - nicotine
- Sympathomimetics, 547
 - amphetamine
 - behavioral augmentation
 - locomotor activity
 - repeated administration
 - stereotypy
- Synergism, 589
 - cats
 - cross-tolerance
 - limb-flicks
 - LSD
 - tactile stimulus
- Tactile stimulus, 589
 - cats
 - cross-tolerance
 - limb-flicks
 - LSD
 - synergism
- Tadpoles, 363
 - aminoglycosides
 - hair cells
 - ototoxicity
 - schooling behavior
 - streptomycin
- Tail-flick test
 - analgesia, 1161, 1213
 - dose-response relationships, 1213
 - Formalin test, 1213
 - morphine, 1161
 - morphine tolerance, 1213
 - prenatal exposure, 1161
- Tardive dyskinesia, 1061
 - evoked potentials
 - neuroleptics
 - oral dyskinesia
 - substantia nigra
- Taste, 323
 - estrous cycle
 - ethanol preference
 - lactation
 - ovariectomy
 - pregnancy
 - reproductive state, female rat
- Temperature, 1203
 - ACTH
 - corticotropin releasing factor (CRF)
 - β -endorphin
 - hypothermia
 - α -MSH
 - naloxone
 - ptosis
 - reserpine
 - sedation
- Testosterone, 681
 - castration
 - flupenthixol
 - haloperidol
 - luteinizing hormone
- Tether restraint, 823
 - baboons
 - cocaine
 - primates
 - self-administration
- Tetrabenzine, 995
 - dopaminergic agonists
 - haloperidol
 - α -methylparatyrosine
 - pigeons
 - piribedil
 - scheduled responding
- Tetrahydroisoquinolines, 813
 - cortical neurons
 - Met-enkephalin
 - ethanol
 - hippocampal pyramidal neurons
 - naloxone
 - opiates
 - salsolinol
 - tetrahydropapaveroline
- Tetrahydropapaveroline, 813
 - cortical neurons
 - Met-enkephalin
 - ethanol
 - hippocampal pyramidal neurons
 - naloxone
 - opiates
 - salsolinol
 - tetrahydroisoquinolines
- Thermoregulation, 1001
 - acetylcholinesterase reactivation
 - conditioned avoidance
 - DFP
 - oximes
 - PAM
 - proPAM
- Thiothixene, 1049
 - antipsychotics
 - clozapine
 - collateral behavior
 - drinking
 - eating
 - haloperidol
 - operant behavior
 - rabbits
 - schedule-induced behavior
 - scheduled responding
- Thirst, hypervolemic, 921
 - chlordiazepoxide
 - naltrexone
 - thirst, osmotic
- Thirst, osmotic, 921
 - chlordiazepoxide
 - naltrexone
 - thirst, hypovolemic
- Thyrotropin-releasing hormone (TRH)
 - adipsia, 249
 - anorexia, 249
 - γ -butyrolactone- γ -carbonyl-histidyl-prolinamide citrate (DN-1417), 797
 - cholinergic mechanisms, 797
 - drinking, 249
 - eating, 249
 - hypothalamus, 249, 797
 - pentobarbital antagonists, 797
 - starvation, 249

Time, s21
 dopaminergic agents
 stress
 Time course analysis, 597
 p-chlorophenylalanine
 medial raphe nucleus
 self-stimulation
 serotonin
 T-maze, 473
 brain development
 corticosteroids
 neonates, rats
 radial maze
 triamcinolone acetonide
 Tobacco, 155
 cigarette smoking
 human studies
 self-administration
 Tofizopam, 367
 benzodiazepine receptors
 diazepam
 Tolerance
 antagonism, 223
 benzodiazepines, 43
 chlordiazepoxide, 1239
 discriminative stimulus properties, 223
 drug experience effects, 43
 ethanol, 1073, 1239
 extinction, 229
 Geller-Seifter conflict test, 43
 genetic differences, 1073
 individual variability, 43
 morphine, 223
 morphine analgesia, 229
 naloxone, 223
 nociception, 229
 oxazepam, 43
 physical dependence, 1239
 pigeons, 223
 rate dependency, 43
 stress, 229
 withdrawal, 1239

 Transfer, 1111
 kindling
 pentylentetrazol
 seizures
 Trazodone, 1221
 amitriptyline
 blood pressure
 cardiovascular system
 heart rate
 iprindole
 Tree shrews, 77
 entorhinal cortex
 6-hydroxydopamine
 lesions, A10
 passive avoidance
 septum
 tyrosine hydroxylase
 Triamcinolone acetonide, 473
 brain development
 corticosteroids
 neonates, rats
 radial maze
 T-maze
 Triazolopyridazines, 709
 benzodiazepines
 chlordiazepoxide
 drug discrimination
 Tripelennamine, 789
 drug discrimination
 drug interaction
 morphine
 naloxone

 N-allyl normetazocine (SKF 10,047)
 pentozocine
 TRS-80 microcomputer, 583
 BASIC
 behavioral pharmacology
 operant research
 Tryptophan
 amino acids, 939
 cancer anorexia, 1043
 p-chlorophenylalanine, 1043
 dopamine, 1043
 eating, 1043
 5-hydroxyindoleacetic acid, 1043
 inescapable shock, 877
 learned helplessness, 877
 methysergide, 877
 norepinephrine, 1043
 obesity, genetic, 939
 serotonin, 877, 939, 1043
 Zucker rats, 939
 Tyramine, 1291
 aggressive behavior
 isolation syndrome
 phenylethylamine
 stress
 Tyrosine hydroxylase, 77
 entorhinal cortex
 6-hydroxydopamine
 lesions, A10
 passive avoidance
 septum
 tree shrews

 Urine outflow, 1265
 aspartic acid
 core temperature
 drinking
 eating

 Vagal afferents, 19
 cardiovascular reflex
 D-Ala²-Met⁵-enkephalinamide
 morphine
 motor activity
 phenyldiguanide
 pulmonary J-receptors
 pulmonary opiate receptors
 Vaginal patency, 629
 chronic ethanol
 estrous cycle, female rats
 ovarian function
 pregnant rats
 Valerian, 65
 human studies
 sleep latency
 sleep quality
 Valproic acid, 49
 environmental influences
 housing, group
 housing, isolation
 serotonin metabolism
 Vascular stroke, 1083
 gerbils
 MIF-1
 naloxone
 opiate antagonists
 Vasopressin, 685
 ethanol tolerance
 neurohypophyseal peptides
 Vasopressin analogues, 1123
 d-amphetamine
 1-desamino-8-D-arginine
 matching-to-sample

- memory, short-term
- pigeons
- scopolamine
- Ventral tegmental nuclei of Gudden, 973
 - benzodiazepines
 - GABA
 - 5-hydroxytryptamine
 - locomotor activity
 - muscimol
- Ventral tegmentum, 841
 - ¹⁴C-2-deoxyglucose autoradiography
 - diagonal band of Broca
 - lateral habenula
 - medial forebrain bundle
 - pimozide
 - reinforcement
 - self-stimulation
- Ventromedial hypothalamus, 1141
 - eating
 - hyperthermia
 - morphine
 - opiate receptors
- Visual cortex, 1313
 - albino rats
 - ethyl alcohol
 - photic evoked potentials
 - superior colliculus
- Visual evoked response, 915
 - attention
 - cigarette smoking
 - human studies
 - nicotine

- Water deficits, 955
 - 2-deoxy-D-glucose
 - drinking
 - eating
 - glucoprivation
- Water deprivation, 563
 - dose response
 - food deprivation
 - reward deprivation
 - self-administration
- Withdrawal
 - age differences, 1037
 - chlordiazepoxide, 1239
 - ethanol, 125, 1037, 1239
 - fetal alcohol syndrome, animal model, 125
 - intoxication, 1037
 - maternal behavior, female rat, 125
 - narcotic analgesics, 1155
 - neuroleptics, 1155
 - noradrenaline, 1155
 - physical dependence, 1239
 - pregnancy, 125
 - R 18 503, 1155
 - serotonin, 1155
 - tolerance, 1239
- Withdrawal syndrome
 - clonidine, 655
 - conditioned taste preference, 609
 - ethanol dependence, 609
 - methylxanthines, 655
 - naloxone, 655

- Y-Maze, 909
 - appetitive tasks
 - aversive tasks
 - learning
 - memory, long-term
 - sodium barbitone

- Zucker rats, 939
 - amino acids
 - obesity, genetic
 - serotonin
 - tryptophan

AUTHOR INDEX

- ABBOTT, F. V., 1213
ABEL, M. S., 159
AIRAKSINEN, M. M., 831
AMIT, Z., 233
ANDERSON, G. M., 1281
ANISMAN, H., 263, 1245
ANTELMAN, S., s21
ANTKIEWICZ-MICHALUK, L.,
1115
ARMBRECHT, H. J., 1037
ARNERIC, S. P., s11
ARNOULT, D. E., 583
ASHCRAFT, L. J., 1019
ASHKENAZI, R., s43
ASHTON, D., 1155
- BABBINI, M., 43
BAETTIG, K., 915
BAKER, M. J., 389
BALSTER, R. L., 291, 1181
BALTRUS, B. M., 1061
BANDO, Y., 519
BANKS, W. A., 1009, 1187
BARRETT, J. E., 1049
BARTOLETTI, M., 43
BARTOLINI, L., 933
BAUM, M. J., 857
BAUMANN, J. B., 511
BAYORH, M. A., 699
BEATTY, W. W., 905
BEDFORD, J. A., 1087
BEER, B., 159
BELESLIN, D. B., 371, 1317
BEN-SHACHAR, D., s43
BERGER, T., 813
BERIE, J. L., 165
BERKMAN, K., 1265
BHATNAGAR, R. K., s11
BIANCHINE, J. R., 1233
BIDERMAN, M. D., 955
BIDZINSKI, A., 619
BLOOM, F. E., 813
BO, W. J., 629
BODNAR, R. J., 1175
BOE, I. N., 563
BONNET, K. A., 677
BOSH, T. K., 651
BOULTON, A. A., 1291
BOYTIM, M., 769
BOZARTH, M. A., 239
BRADFORD, L. D., 823
BRADY, J. V., 823
BRADY, K. T., 291
BREESE, G. R., 681
BROWN, D. R., 1275
BROWN, L., 877
BROWN, Z. W., 233
BROWNE, R. G., 547
BUNNELL, B. N., 1067
BUREŠOVÁ, O., 1129
BURGESS, J. W., 137
- CAIN, D. P., 1111
CAIN, M., 457
CAIRNIE, A. B., 305
CANNON, J. G., s11
CANTALAMESSA, F., 741
CAREY, R. J., 851
CARLI, M., 1
CARROLL, M. E., 341, 563
CARTER, R. B., 223
CASAMENTI, F., 933
CASBEER, D., 1239
CASTELLANOS, P. F., 1187
CHAIT, L. D., 155
CHAN, A. W. K., 141, 1239
CHAN, E., 639
CHANCE, W. T., 939, 1043
CHAPIN, R. E., 681
CHAUFFARD, F., 65
CHEAL, M. L., 1305
CHEREK, D. R., 523
CHERKIN, A., 893
CHIU, E. K. Y., 1221
CLARKE, A., 623
CLEARY, J. P., 945
CLODY, D., 847
COHEN, D. J., 1281
COLLINS, A. C., 91, 245
COLLINS, R. J., 107
CONCANNON, J. T., 5, 393
COOK, J., 457
COOLS, A. R., 297
COPPER, S. J., 481, 921
CORNISH, K. G., 1285
CORRADINI, A., 1245
COSCINA, D. V., 1145
COSTELLO, K. B., 905
COUPET, J., 159
COY, D. H., 15, 633, 1009, 1187,
1193, 1203
CREESE, I., 375
CRISP, T., 589
- DALEY, L., 823
DAVIDSON, A. B., 385
DAVIS, B. A., 1291
DAVIS, J. L., 893
DAVIS, W. M., 489
DEAN, P., 873
DE CARO, G., 741
DELORENZO, R., 823
DE MAN, E., 405
DEPAULIS, A., 451
DEROSSETT, S. E., 347, 1161
DERYCK, M., 1027
DESJARDINS, P. J., 1055
DE WIED, D., 177
DE WITTE, PH., 1093
DIETZ, P. E., 171
DOURISH, C. T., 1291
DRUGAN, R. C., 1019
DUNN, A. J., 31, 37
- DUNWIDDIE, T. V., 1257
DYCK, L. E., 1291
DYKSTRA, L. A., 223
- EHRENSING, R. H., 757
EISENSTEIN, N., 847
EISON, A. S., s25
EISON, M. S., s25
ELLINGBOE, J., 171
ELSOHLY, H. N., 1087
EMMETT-OGLESBY, M. W., 583
ERICKSON, C. K., 183
ERIKSSON, C. J. P., 831
ERSKINE, M. S., 857
ETKIN, M. W., 619
EVANS, H. L., 1123
- FABRE, L. A., 1199
FAUSTMAN, W. O., 987
FEKETE, M., 177
FELDMAN, R. S., 709
FELLEMANN, V. H., 399
FENTON, H. M., 1207
FERNANDEZ, S., 659
FIBIGER, H. C., 359, 639
FILE, S. E., 623, 1165
FINKELSTEIN, J. A., 939
FISCHER, J. E., 939, 1043
FLOREZ-LOZANO, J., 659
FLYNN, J., s11
FOLTIN, R. W., 1089
FORGER, N. G., 323, 529
FORSMAN, L., 555
FOWLER, S. C., 987
FRANKLIN, K. B. J., 431
FREEDMAN, L. S., 187
FREGLY, M. J., 727
FRENCH, E. D., 813
FREUND, G., 313
FUNG, Y. K., 651
- GAIARDI, M., 43
GALLAGHER, M., 217
GALLISTEL, C. R., 769, 783, 841
GALLUS, J. A., 467, 945, 1225
GARZA, R. DE LA 1295
GATTI, P., 19
GAULT, F. P., 467, 945
GERTNER, S. B., 19
GHONEIM, M. M., 165
GIANUTSOS, G., 951
GILES, T. D., 1301
GILMORE, J. P., 1285
GIRARD, J., 511
GLASSMAN, H. N., 1061
GLASSMAN, R. B., 1061
GLENNON, R. A., 603
GOLDSTEIN, J. M., 461
GOLUB, M. S., 473
GOMITA, Y., 769, 783, 841
GÖTESTAM, K. G., 1171

GOY, H. B., 1097
 GRAF, M., 511
 GRANDMAISON, L. J., 665
 GRANT, S. J., 655
 GRASSMAN, D. R., 651
 GRATTON, A., 597
 GRAU, J. W., 1019
 GRECKSCH, G., 11
 GREENLEAF, J. E., 727
 GREENSHAW, A. J., 1129
 GREIZERSTEIN, H. B., 141
 GRIFFITHS, R. R., 155, 823
 GRISOLÍA, S., 927
 GUERRI, C., 927
 GUILD, A. L., 31

 HALL, R., 579
 HALPERN, B., 1149
 HAMANN, S. R., 1271
 HANNIGAN, J. H., JR., 193
 HARRIS, P. F., 1119
 HARRY, G. J., 915
 HASHIMOTO, H., 131
 HAUG, T., 1171
 HAUPTMANN, M., 619
 HAVEMANN, U., 715
 HAYASHI, T., 131
 HEBERT, D., 703
 HECK, E., 65
 HEILBRONNER, R. L., 1313
 HELLSTRÖM, E., 1103
 HELPS, S. C., 885
 HEMMER, R. C., 1287
 HEMNANI, K. L., 489
 HENNESSY, M. B., 111
 HETZLER, B. E., 1313
 HILL, L. G. J., 125
 HINRICHS, J. V., 165
 HIRST, M., 1141
 HOFFER, B., 569
 HOFFMAN, P. L., 685
 HLTZMAN, S. G., 347, 1161, 1275
 HONOUR, L. C., 1203
 HOOD, J. L., 389
 HOWD, R. A., III, 1001
 HOWERTON, T. C., 245
 HRUSKA, R. E., 1027
 HUOT, S., 99
 HURD, R. W., 37
 HYSON, R. L., 1019

 IORIO, L. C., 847
 ISAACSON, R. L., 193

 JALFRE, M., 1309
 JÄRBE, T. U. C., 671
 JOHANSON, C. E., 1295
 JOHNELS, B., 283
 JOHNSON, K. M., 53
 JONES, R. S. G., 1291
 JORK, R., 11, 203
 JOYNER, W. L., 1285
 JUDGE, M. E., 187, 677
 JUSTICE, J. B., 445

 KALLMAN, M. J., 915
 KALLMAN, W. M., 915
 KAMERLING, S. G., 733
 KAMEYAMA, T., 59
 KANT, G. J., 1067
 KAPLAN, J. N., 111
 KAPP, B. S., 217
 KASTIN, A. J., 757, 1009, 1083,
 1187, 1193, 1199, 1203, 1287, 1301
 KEMPF, E., 49

 KENLEY, R. A., 1001
 KENNEY, N. J., 73
 KIIANMAA, K., 1073
 KIKTA, D. C., 727
 KIRBY, M. L., 1161
 KIRCHGESSNER, A. L., 1175
 KISARA, K., 249
 KLEBANOFF, L., 769
 KNOBLOCH, L. C., 461
 KOCH, K. I., 183
 KOHNO, H., 249
 KOIKE, Y., 519
 KOJER, G., 77
 KOKKINIDIS, L., 413
 KOOB, G. F., 901, 1015
 KORCZYN, A. D., 897
 KOSTOWSKI, W., 619
 KOYUNCUOĞLU, H., 1265
 KRIEG, E. F., JR., 1193
 KRSTIĆ, S. K., 371, 1317
 KRUEGER, W. A., 629
 KRUK, M. R., 147
 KUBANIS, P., 313
 KUCZENSKI, R., 375, 547
 KUPRYS, R., 271
 KURIBARA, H., 425, 1251
 KURKULOS, M. E., 1305
 KUSCHINSKY, K., 715

 LAHTI, R. A., 107
 LANDAUER, M. R., 1181
 LAYNG, M. P., 389
 LEACH, K. E., 305
 LEANDER, J. D., 995
 LEATHWOOD, P. D., 65
 LEBER, B. F., 1213
 LEE, C., 1149
 LEE, T. M., 1149
 LEITE, J. R., 909
 LE MAGNEN, J., 609
 LENOX, R. H., 1067
 LEONG, F. W., 1239
 LERNER, S. A., 363
 LEWIS, G., 873
 LI, T.-K., 763
 LIEBMAN, J. M., 1207
 LIGHT, S., 951
 LINDSAY, W. S., 445
 LIPPA, A. S., 159
 LOCKE, K. W., 1275
 LO CONTE, G., 933
 LONG, J. P., s11
 LORDEN, J. F., 435
 LORENS, S. A., 973
 LÖSSNER, B., 203
 LUKAS, S. E., 823
 LUM, A. M., 363
 LUMENG, L., 763
 LUNDBERG, U., 555

 McBRIDE, W. J., 763
 McDONOUGH, J. H., JR., 85
 McELROY, J. F., 709
 MCGINITY, J. W., 183
 McLEAN, J. H., 1287

 MACK, G., 49
 MACNEILL, E. P., 413
 MAIER, S. F., 1019
 MALICK, J. B., 461
 MALIN, D. H., 389
 MANDEL, P., 49, 691
 MANN, M. A., 837
 MAOR, D., 897
 MARCONCINI-PEPEU, I., 933

 MARFAING-JALLAT, P., 609
 MARÍN, B., 659
 MARTIN, W. R., 733
 MARTIN-IVERSON, M. T., 639
 MASSI, M., 741
 MATTHIES, H., 11, 203
 MEANS, L. W., 125, 1097
 MEELIS, W., 147
 MEGENS, A. A. P. H., 297
 MELTZER, H. Y., s1
 MELZACK, R., 1213
 MENDELSON, J. H., 171
 MENENDEZ-PATTERSON, A., 659
 MERALI, Z., 25
 MESSENGER, M., 885
 MEWALDT, S. P., 165
 VON MEYENFELDT, M., 1043
 MEYERHOFF, J. L., 1067
 MICHAEL, S. D., 837
 MICHALUK, J., 1115
 MICHELL, G. F., 757
 MICOSSI, L. G., 741
 MICZEK, K. A., 503
 MIGLER, B., 645
 MINAMI, M., 519
 MIYAMOTO, M., 797
 MOE, K. E., 73
 MOERSCHBAECHER, J. M., 353,
 1055
 MOLLENAUER, S., 381
 MOLTZ, H., 1149
 MORIN, L. P., 323, 529
 MORROW, G., 951
 MORTON, E. C., 539
 MOS, J., 147
 MUELLER, K., 613
 MUELLER, R. A., 681
 MUNOZ-BOX, R., 65
 MYERS, R. D., 1271
 MYERS, W. D., 807
 MYERSON, L. R., 159

 NAGAI, Y., 797
 NAGASAKA, M., 59
 NAGAWA, Y., 797
 NAKASHIMA, M., 131
 NANRY, K. P., 1225
 NARUMI, S., 797
 NEARCHOUS, N. I., 467
 NEILL, D. B., 445
 NG, K. T., 807
 NISSEN, C., 1083, 1187
 NOBREGA, J. N., 1145
 NOVIN-BAHERAN, A., 651
 NUNN, W. B., 435
 NYHAN, W. L., 613

 OAKLAY, K. E., 1313
 O'CONNOR, M. F., 245
 OELTGEN, P. R., 1271
 OLIVERIO, A., 691, 967, 1115
 OLIVIER, B., 147
 OLSON, G. A., 1287
 OLSON, R. D., 1083, 1287
 OLTMANS, G. A., 271
 ORBACH, J., 1119
 OVERSTREET, D. H., 885, 1119

 PACE, H. B., 489
 PALFAI, T., 399
 PALFREYMAN, M. G., 99
 PALMER, M., 569
 PALMOUR, R., 613
 PASCOE, J. P., 217
 PASTERNAK, G. W., 1175

PATEL, J. B., 645
 PAUL, S. M., s37, 457
 PEEKE, H. V. S., 405
 PEPEU, G., 933
 PERT, C. B., 699
 PETERS, D. A. V., 721, 1077
 PEURA, P., 831
 PHILLIS, J. W., 749
 PICO, R. M., 893
 PINEL, J. P. J., 359
 PIPKIN, B., 381
 PISA, M., 639
 PŁAZNIK, A., 619
 PLOTNIK, R., 381
 POPOV, N., 203
 PORSOLT, R. D., 1309
 POTEI, M. J., 363
 PRASAD, V., 377
 PROCTOR, C., 229
 PUCIŁOWSKI, O., 619
 PUGLISI-ALLEGRA, S., 691

QUARTERMAIN, D., 187, 677
 QUIRION, R., 699

RAAB, A., 77
 RANDALL, D. C., 1271
 RANDT, C. T., 677
 RAUH, C. E., 159
 REDGRAVE, P., 873
 REDMOND, D. E., JR., 655
 REGAN, S. G., 119
 REINSTEIN, D. K., 193
 RIBLET, L. A., s25
 RICHARDSON, A. K., 855
 RICHARDSON, J. S., 855, 1221
 RILEY, E. P., 877
 ROBERSON, N. L., 1257
 ROBERTS, D. C. S., 901, 1015
 RODGERS, R. J., 451
 RÖNNBÄCK, L., 495
 ROEHRS, T. A., 333
 ROKOSZ-PELC, A., 1115
 RONDEAU, D. B., 703
 ROSECRANS, J. A., 915
 ROSELLINI, R. A., 877
 ROSENGREN, L., 495
 ROUX, S., 1309
 RUDEEN, P. K., 629
 RUSSELL, R. W., 885

SAANO, V., 367
 SABODA, S., 613
 SAINATI, S. M., 973
 SAITO, H., 519
 SAJI, Y., 797
 SAKURADA, T., 249
 SALAMONE, J. D., 445
 SAMANIN, R., 1
 SAMARDŽIĆ, R., 1317
 SAMSON, H. H., 333
 SAMUELS, O. B., 877
 SANDER, G. E., 1301
 SANSONE, M., 967, 1115

SAPRU, H. N., 19
 SATINDER, K. P., 961
 SCHALLY, A. V., 15, 633
 SCHANLEY, D. L., 1239
 SCHECHTER, M. D., 5, 393
 SCHLEEF, C., 49
 SCHMIDT, S., 203
 SCHOENENBERGER, G. A., 511
 SCHULZECK, S., 203
 SCHWARZ, R. D., 1233
 SCHWERI, M., 457
 SEGAL, D. S., 375, 547
 SEWELL, R. G., JR., 467, 945, 1225
 SHANNON, H. E., 789
 SHAYWITZ, B. A., 1281
 SHEARD, M. H., 377
 SHERMAN, J. E., 229
 SHIER, W. T., 813
 SHIMAMURA, K., 519
 SIEBER, B., 209
 SIGGINS, G. R., 813
 SILBERGELD, E. K., 1027
 SILVA, L., 1305
 SINGER, G., 579, 807
 SKOLNICK, P., s37, 457
 SLOAN, J. W., 733
 SMITH, G. C., 1135
 SMOLEN, A., 91
 SMOLEN, T. N., 91
 SPENCER, D. G., JR., 583
 SPOERLEIN, M. T., 419
 SPUHLER, K., 569
 SPURRIER, W. A., 1271
 STANTON, H. C., s25
 STAVCHANSKY, S. A., 183
 STEFANOVIĆ-DENIĆ, K., 371
 STRAUSS, W., 141
 STRECKER, R. E., 1015
 STRUB, H., 229
 SU, T.-P., 733, 789
 SUEIRAS-DIAZ, J., 1203
 SUZUKI, T., 249
 SVARE, B., 837
 SWANK, P., 389
 SWEENEY, M. J., 951

TABAKOFF, B., 1073
 TADANO, T., 249
 TADOKORO, S., 131, 1251
 TANG, S., 1077
 TAUKULIS, H. K., 695
 TAYLOR, D. P., s25
 TEAL, J. J., 1123
 TEICHER, M. H., 1281
 TELEGDY, G., 15, 633
 TEMPLE, D. L., JR., s25
 TEPPERMAN, F. S., 1141
 THOMAS, J. R., 1055
 THOMPSON, D. M., 353, 1055
 TOBLER, H. J., 511
 TOGASHI, H., 519
 TOLLIVER, G. A., 333
 TOMBAUGH, T. N., 665, 1245
 TOMAZ, C. A. B., 909

TOTH, G., 25
 TOTTMAR, O., 1103
 TOWELL, A., 255
 TREIT, D., 359
 TRULSON, M. E., 589
 TUOMISTO, L., 831
 TURCOTTE, M., 703
 TURNER, C. E., 1087
 TURSKI, L., 715
 TYLER, C. B., 503

URETSKY, N. J., 1233
 URTTI, A., 367
 UYENO, E. T., 1001
 VACCARINO, F. J., 431
 VALLANO, M. L., 419
 VAN AKEN, J. H. M., 147
 VAN DER POEL, A. M., 147
 VANDERWENDE, C., 419
 VAUPEL, D. B., 539
 VÉCSEI, L., 15, 633
 VENTURA, D. F., 909
 VESTAL, T., 1313
 VETULANI, J., 967, 1115

WALLACE, M., 579
 WALLER, M. B., 763
 WALSH, J. W., 1271
 WASSERMAN, E. M., 783
 WASSERSUG, R. J., 363
 WATSON, P. J., 955
 WATSON, S. D., 863
 WAUQUIER, A., 1155
 WEINBERGER, S. B., 547
 WEINER, N., 569
 WEINGARTEN, H. P., 863
 WELDON, D. A., 1281
 WENNOGLE, L. P., 159
 WETTSTEIN, J. G., 733
 WHITE, M., 381
 WILLETTE, R. N., 19
 WILLIS, G. L., 1135
 WILLNER, P., 255
 WISE, R. A., 239
 WISE, R. W., 1037
 WITKIN, J. M., 223
 WOOD, W. G., 1037
 WOODSON, P. P., 915
 WOOL, R. S., 1281
 WORTH, T., 1257
 WRONSKI, A., 495
 WU, P. H., 749

YORK, J. L., 119
 YOUDIM, M. B. H., s43
 YOUNG, L., 703
 YOUNG, R., 603
 YUEN, H., 749
 ZACHARKO, R. M., 263, 1245
 ZADINA, J., 1193
 ZERBE, R. L., 699
 ZEUCHNER, J., 495
 ZITO, K. A., 665
 ZORNETZER, S. F., 313

